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ABSTRACT 
   
There are many biological questions that require single-cell analysis of gene 
sequences, including analysis of clonally distributed dimeric immunoreceptors on 
lymphocytes (T cells and B cells) and/or the accumulation of driver/accessory mutations 
in polyclonal tumors. Lysis of bulk cell populations results in mixing of gene sequences, 
making it impossible to know which pairs of gene sequences originated from any 
particular cell and obfuscating analysis of rare sequences within large populations. 
Although current single-cell sorting technologies can be used to address some of these 
questions, such approaches are expensive, require specialized equipment, and lack the 
necessary high-throughput capacity for comprehensive analysis. Water-in-oil emulsion 
approaches for single cell sorting have been developed but droplet-based single-cell lysis 
and analysis have proven inefficient and yield high rates of false pairings. Ideally, 
molecular approaches for linking gene sequences from individual cells could be coupled 
with next-generation high-throughput sequencing to overcome these obstacles, but 
conventional approaches for linking gene sequences, such as by transfection with 
bridging oligonucleotides, result in activation of cellular nucleases that destroy the 
template, precluding this strategy. Recent advances in the synthesis and fabrication of 
modular deoxyribonucleic acid (DNA) origami nanostructures have resulted in new 
possibilities for addressing many current and long-standing scientific and technical 
challenges in biology and medicine. One exciting application of DNA nanotechnology is 
the intracellular capture, barcode linkage, and subsequent sequence analysis of multiple 
messenger RNA (mRNA) targets from individual cells within heterogeneous cell 
 
ii 
populations. DNA nanostructures can be transfected into individual cells to capture and 
protect mRNA for specific expressed genes, and incorporation of origami-specific 
bowtie-barcodes into the origami nanostructure facilitates pairing and analysis of mRNA 
from individual cells by high-throughput next-generation sequencing. This approach is 
highly modular and can be adapted to virtually any two (and possibly more) gene target 
sequences, and therefore has a wide range of potential applications for analysis of diverse 
cell populations such as understanding the relationship between different immune cell 
populations, development of novel immunotherapeutic antibodies, or improving the 
diagnosis or treatment for a wide variety of cancers. 
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CHAPTER 1 
INTRODUCTION 
Historical review of T cell biology 
 Whether he realized it or not, Thucydides observed the phenomenon of immunity 
nearly 2500 years ago. Observing soldiers who survived disease during the 
Peloponnesian War, he discovered that these survivors rarely if ever succumbed to the 
same disease [1]. While the concept of vaccinations and immunological memory would 
not be defined for millennia, the seed was laid for the further analysis of how one’s body 
protects itself from disease. Advancements in the study and practice of what would be 
come known as the field of immunology progressed in China and India in the 11th century 
as these countries battled small pox epidemics. However, it wasn’t until the mid 19th 
century and the discovery that microorganisms were responsible for illness that the 
science of immunology was formally established. Furthermore, most of the initial 
experimental studies involved humoral immunity and the biochemical characterization of 
antibodies [2].  
  Some of the earliest pioneering work demonstrating CD8 T cell pathology came 
from James Murphy between 1911 and 1926 [3, 4]. Murphy suggested that it was a 
subset of cells (lymphocytes), rather than antibodies that were causing allograft rejection. 
Murphy demonstrated that injection of adult lymphoid tissue near implanted tumor cells 
in chick embryos led to a rapid destruction of the tumor graft. However, it would be 
decades before CD8 T cells were fully understood in terms of both immune protection  
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and graft rejection as leading immunologists of the day fully admitted that nothing of 
importance was known about lymphocytes [2].  
 In the mid 1950s, it was well known that while stable levels of lymphocytes 
remained in the blood, the thoracic duct drained nearly ten times that number back into 
the circulatory system each day. Numerous hypotheses tried to account for this 
discrepancy including that other cells degraded lymphocytes, or that they died in 
peripheral tissues. In 1964, James Gowans published a seminal paper illustrating how 
lymphocytes continually recirculate from the lymph system to the circulatory system via 
the thoracic duct and back [5]. Once lymphocyte migration patterns and kinetics were 
understood, studies outlining lymphocyte roles in graft rejection, differentiation into 
antibody producing cells, and immunological memory were rapidly performed [6-8]. 
 While the seminal work of Gowans et al. laid the foundation for our current 
understanding of T cell biology, during his work it was postulated that all small 
lymphocytes were homogenous in terms of their potential. In the early 1960s Jacques 
Miller began to identify the role of the Thymus in lymphocyte development. Performing 
thymectomies, Miller’s research demonstrated the existence of at least two major classes 
of lymphocytes: antibody-producing cells derived from the bone marrow, and a second 
class of cells derived from the thymus [9-12]. It was these pioneering studies from 
Gowans and Miller that began research into the cellular aspect of immunology. 
 By the early 1970s it had become widely accepted that lymphocytes derived from 
the thymus (T cells) were functionally distinct from their antibody-producing 
counterparts derived from the bone marrow (B cells). Initial experiments into T cell 
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function demonstrated the cytotoxicity of T cells; additionally, the removal of B cells 
from lymphocyte fractions did not alleviate cytotoxicity [13, 14]. The initial killing 
assays demonstrated a high level of specificity that would eventually manifest itself as 
the discovery of clonal antigen receptors on T cells. While the discovery of T cell 
receptor (TCR) clonality occurred in the late 1960s [15, 16], it would take more than a 
decade before an accurate understanding of T cell antigen recognition was established. 
 In1974, Peter Doherty and Rolf Zinkernagel accomplished the next major 
discovery in T cell antigen recognition by demonstrating that T cells obtained from 
Lymphocytic Choriomeningitis Virus (LCMV) infected mice would only kill target cells 
that expressed the same Major Histocompatibility Complex (MHC) proteins [17]. 
Differing opinions on how the MHC was involved with T cell antigen recognition 
revolved around two main hypotheses. The two-receptor model was based on the 
hypothesis that T cell antigen recognition involved two interactions, the first between the 
T cell and the viral antigen, and the second between the T cell and the MHC. This 
hypothesis was rejected however, when Zinkernagel and Doherty demonstrated that 
MHCs were complexed with viral antigens and therefore T cell antigen recognition 
occurred via a single T cell receptor (TCR) and an MHC:antigen complex [18].  
 Although somewhat similar in genetic organization, the B cell antigen receptor 
(BCR) was characterized well before a complete understanding of its counterpart in T 
cells was understood. Somatic rearrangement of BCR genes explained the phenomenon 
of how such a wide diversity of antigens could be recognized by receptors encoded by so 
few genes. However, characterization of the TCR eluded scientists due to the inability of 
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TCRs to bind free antigen and the fact that T cells did not secrete their receptors as B 
cells did. It wasn’t until the early 1980s when Allison et al. generated clonotypic 
antibodies against T cell clones permitting analysis of the TCR [19, 20]. The initial 
biochemical analysis of the TCR revealed it to be very similar to the B cell receptor; a 
heterodimeric receptor containing both constant and variable regions. 
 Characterization of the TCR complex led way to further studies to outline antigen 
processing and presentation for T cell recognition. Shortly after Allison and colleagues 
characterized the TCR, in 1983 Shimonkevitz, Marrack, Kappler and Grey revealed that 
antigen must first be fragmented into short peptides for TCR recognition [21] and two 
years later Townsend and Yewdell et al. demonstrated T cell recognition of intracellular 
influenza proteins and therefore the existence of a mechanism to transport and present 
antigenic peptides on the surface of cells [22, 23]. It was these pioneering studies that 
firmly established the one-receptor hypothesis of T cell antigen recognition.  
 Concurrently with the research on understanding antigen processing and MHC 
presentation, studies were being performed to understand the T cell receptor genetic 
locus. Numerous groups had begun identifying the composition of the TCR in that it 
consisted of a dimer covalently linked by disulfide bridges. Additionally, each of the two 
monomers contained both constant and variable regions [24-26]. These studies helped 
propel two separate groups to independently clone the TCR and allowed them to outline 
the genetic organization of the beta locus of the TCR [27-29]. Once the genes were 
characterized a more complete understanding of the basis for constant and variable  
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regions of the TCR was used to provide an initial explanation for the vast heterogeneity 
of an individual’s T cell repertoire. 
 Although a detailed structural and genetic picture of the TCR had been elucidated, 
how the T cell interacted with the antigen:MHC complex was still unclear. It wasn’t until 
1987 when Bjorkman and Wiley were able to crystallize Class I MHC and thus provide 
its structure [30] that the deep, negatively charged, MHC antigen-binding groove was 
visualized. Realization that antigenic peptide was presented to T cells bound to a groove 
on the surface of MHC molecules resolved any remaining questions about the one-
receptor hypothesis. Bjorkman and colleagues used the crystal structure of the MHC to 
propose that TCR engage both the antigenic peptide as well as surface residues of the 
MHC [31]. They also discovered that the majority of polymorphisms between different 
MHC corresponded to either the peptide-binding site or to TCR contact residues, further 
evaluation of which would eventually yield the mechanisms behind T cell MHC 
restriction and allele specificity [2].  
 With this new knowledge of MHC:antigen presentation, several groups began to 
outline the CD8 co-receptor’s role in antigen recognition. In the late 1980s, it was 
demonstrated in a number of different ways that CD8 increases the avidity of T cell 
antigen recognition through binding interactions with Class I MHC complexes [32-34]. It 
wouldn’t be until eight years later in 1996 that David Garboczi would finally crystalize 
and thus provide the first complete picture of the TCR:peptide:MHC complex [35]. 
 Once a clear picture of how T cells recognized and thus responded to antigen was 
determined, the next decade would see huge strides in a more complete understanding of 
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all aspects in T cell biology. Specifically, the roles of perforin/granzyme and the Fas 
ligand in T cell cytotoxicity, proteosome degradation of antigen and the numerous 
chaperone proteins involved with antigen processing, positive and negative selective 
processes delineated over stages of thymic development, classifying numerous types of 
memory T cells, and the impact of chronic infections on T cell function would all be 
elucidated [2]. Advancements in biochemical assays such as ELISPOT and intracellular 
cytokine staining allowed for the quantification of antigen-specific T cell subsets during 
various infections [36]. Additionally, in 1996 David Altman would develop MHC 
tetramers, capable of being loaded with various peptides that could be used to analyze 
and/or quantitate antigen-specific subsets of T cells from polyclonal populations [37].  
 The late 1990s and early 2000s would expound upon the discoveries of the early 
90s and utilizing the new technologies provided by Altman and others a more thorough 
understanding of memory T cells and T cell differentiation would elucidate differences in 
central and effector memory T cell subsets [38]. Additionally it was discovered that CD4 
T cells have a major role in CD8 T cell differentiation [39] as well as during chronic 
infections leading to T cell exhaustion and/or deletion [40]. These studies (and others) 
have laid the groundwork for current research into diagnostics and therapeutics for 
chronic diseases plaguing our world today. 
  While Murphy’s pioneering studies of what would later come to be identified as T 
cells began in the early 1900s, it has only been in the last 20 years that a complete 
understanding of how T cells recognize and thus respond to antigen has been elucidated. 
Furthermore, while the discovery of many of our successful vaccinations preceded our 
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understanding of the immune system, advancement in our understanding of T cell 
structure and function may be necessary before we are able to develop protective 
vaccines against the many deadly pathogens (HIV, HCV, malaria) that still plague our 
world. Future studies should also be directed towards a more thorough evaluation of the 
effects of and relationships between antigen density and persistence, CD4 T cell help via 
co-stimulation and cytokine secretion, and other factors involved in CD8 T cell activation 
[41]. Our knowledge of T cells has been slowly evolving over the last hundred years, 
however remarkable progress has been seen over the last few decades. It goes without 
saying that many of these recent advancements have coincided with the development of 
new and more precise biochemical tools and assays. We should strive to continue our 
development of new molecular tools, as future discoveries in T cell biology will 
undoubtedly depend on such advancements.  
 
The innate immune system is the first line of defense 
 All multicellular eukaryotic organisms have evolved highly complex and intricate 
systems of immunity. Innate immunity is the most universal aspect of these systems, as 
most living organisms survive solely based on the actions of an innate immune system. 
Only vertebrates have developed adaptive immune systems (discussed later). Regardless 
of which branches of the immune system an organism has, all types of immunity must be 
represented by three core elements: the ability to sense and thus respond to an ever 
increasing diversity of pathogens, neutralizing or eliminating these pathogens from the  
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host, and maintaining the ability to discern self from non-self and thus sparing host 
tissues from the detrimental effects of eliminating the pathogens [42]. 
 The innate immune system can be broken into two main branches, the afferent or 
“sensing” branch and the efferent or “effector” branch. While some cells specialize in one 
branch or the other, most innate immune cells will have roles in both. Additionally, there 
are both cellular and humoral components of the innate immune system and once again 
each component will have various roles in the two branches of the system [42].  
 The first major priority of the innate immune system is to sense the initial onset of 
an infection. While vastly different in both approach and specificity compared to the 
adaptive immune system, the innate immune system recognizes foreign substances using 
a series of receptors and soluble components that alert cells to an infection. Some of the 
earliest recorded understanding of this fact came in the late 1800s and early 1900s when 
scientists discovered the disease-causing toxin from gangrenous infections “Sepsin” [43, 
44]. Later renamed endotoxin and now commonly referred to as lipopolysaccharide 
(LPS), several decades would pass before LPS would be chemically characterized [45, 
46] and even longer before it was recognized as the major component to Gram-negative 
bacterial cell walls [46]. Concurrent with the discovery of LPS as an immune system 
activator, many other microbial components were discovered to trigger immune 
responses as well (i.e. peptidoglycan, lipoteichoic acid, double stranded RNA, etc) [42]. 
These “non-self” antigens act as triggers upon innate system recognition for the 
activation of the innate immune response. 
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 The innate immune system varies from the adaptive immune system in a number 
of ways, including pathogen recognition. While the adaptive immune system has evolved 
to develop repertoires of highly unique receptors for the recognition of virtually any 
invading pathogen, the innate immune system relies on a limited series of receptors, each 
dedicated to recognition of a class of broadly conserved Pathogen Associated Molecular 
Patterns (PAMPs).  These broadly recognizing receptors, referred to as pattern 
recognition receptors (PRRs), have evolved to distinguish ligands specific and 
indispensable to microbes while maintaining indifference to host tissue [47]. One of the 
first classes of these receptors to be recognized is the Toll Like Receptors (TLRs) [48]. 
Thirteen different TLRs have been discovered to date (eleven found in humans) [49-51], 
each of which is believed to confer the ability to recognize a different PAMP or class of 
PAMPs. Additionally, some TLRs form hetero- or homo-dimers with other TLRs (i.e. 
TLR2/TLR6) while others work as monomers for antigen recognition. Initial recognition 
of bacteria, fungi, protozoa and viruses can all be accomplished through various 
ligand:TLR interactions [52, 53]. Similar to TLRs, numerous other broadly recognizing 
innate immune receptors have evolved including RIG-I like receptors (RLRs), f-
methionyl-leucyl-phenylalanyl (fMLP) receptors, nucleotide-binding oligomerization 
domain-like (NOD-like) receptors, and others. Each of these receptor types sense 
microbial products and lead to effector responses via intracellular secondary messenger 
system signaling cascades. 
 While the ability of the innate immune system to sense an infection is paramount 
in the cascade of events leading to immune protection, its ability to kill microbes is 
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equally important. Although the adaptive immune response is the primary means by 
which vertebrates clear an infection, the innate immune response acts as our first line of 
defense, and must slow the progression of the infection down long enough for activation 
of the adaptive immune response to occur. For this purpose, innate immune cells have 
developed a number of chemical means by which to kill invading pathogens. 
 In vertebrates, innate immunity relies heavily on cells derived from the myeloid 
lineage. Macrophages and dendritic cells are two classes of mononuclear phagocytes 
highly efficient at T cell antigen presentation (discussed later), and are therefore excellent 
at phago- or pinocytosis of extracellular compounds and lysosomal degradation. While 
dendritic cells have virtually no anti-microbial capability, macrophages are capable of 
phagocytosing and killing whole microbes. Neutrophils, basophils and eosinophils are 
three classes of polymorphonuclear cells each with killing ability. Neutrophils are the 
most abundant innate cell type and can perform 4 main anti-microbial functions: 
phagocytosis, release of reactive oxygen species, degranulation of anti-microbial proteins 
and enzymes, and secretion of their DNA as a web of fibers trapping and killing microbes 
referred to as neutrophil extracellular traps (NETs) [54]. Eosinophils and basophils are 
more restricted and rely mainly on the secretion of different anti-microbial granules. 
Numerous other innate immune cell types exist, each of which may utilize one or many 
of the previously mentioned anti-microbial effector responses, however all innate 
immune cells perform an additional role over the course of the immune response, the 
release of cytokines to direct other innate immune cells or for the activation of adaptive 
immune cells. 
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Antigen processing by the innate immune system 
  Professional antigen presenting cells (APCs) such as dendritic cells and 
macrophages play a key role in T cell immunology. Unlike B cells, whose antigen 
receptors are capable of interacting with the intact native structure of antigens, T cells 
require proteolytic degradation of antigens into small peptides and then presentation of 
these antigens on the surface of cells via MHC complexes. A unique characteristic of 
MHC proteins is that they are both polygenic and polymorphic. Humans have three genes 
that express classical MHC class I proteins, HLA-A, HLA-B and HLA-C, and three 
genes that express classical MHC class II proteins, HLA-DR, HLA-DQ and HLA-DP 
[55]. Intracellular infections can lead to the buildup of foreign cytosolic proteins, 
proteosomal degradation of these proteins followed by MHC I presentation allows for 
activation of CD8 T cells. Additionally, APCs are constantly surveying our extracellular 
environment by sampling exogenous matter (including microbes) through phagocytosis, 
pinocytosis, and receptor-mediated endocytosis [56]. Following endosomal lysis of these 
ingested antigens, extracellular proteins are usually loaded onto MHC II complexes for 
activation of CD4 T cells. More recently discovered however, is the process of cross-
presentation by MHC I, which involves extracellular antigens from phagocytosed 
particles or proteins assembled with MHC I. While more restricted in the cell types 
capable of this process (specific classes of dendritic cells only), cross-presentation is an 
extremely important aspect of antigen presentation [57, 58]. 
 Originally discovered in 1908 by Elie Metchnikov [59], phagocytosis was 
originally thought to be solely a mechanism of microbial killing by the innate immune 
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system. The role of phagocytosis for MHC II presentation of extracellular antigens (and 
for cross presentation by MHC I) has since been well defined.  Phagocytosis is a process 
involving the remodeling of actin to form a bowl around the engulfed particle that will 
eventually close to form a phagosome [60, 61]. Following phagosome formation, the 
vesicles will interact with lysosomal vesicles from the endocytic system to form 
phagolysosomes. While the events leading up to formation and the specific properties of 
any given phagolysosomes may differ by phagocytic cell type [62], maturation of the 
phagolysosomes is highly regulated by innate signaling pathways initiated by the 
engulfment of exogenous particles [63]. Particles in the phagolysosome are rapidly 
degraded by a highly acidic environment (pH ≈ 4.5-5), reactive oxygen species (ROS), 
proteases, and many other antimicrobial proteins and peptides [60]. 
 The processing of intracellular pathogens from viral or intracellular bacterial 
infections involves the use of a specialized proteolytic machine called the 
immunoproteosome. Short peptides produced by immunoproteosomal cleavage will then 
be loaded onto MHC I complexes for activation of CD8 T cells. The immunoproteosome 
is derived from the ubiquitously expressed proteosome (26S proteosome) who functions 
to degrade ubiquitinated proteins [64]. Conversion of the proteosome to the 
immunoproteosome is triggered by inflammatory cytokines (IFNγ and TNFα) that may 
be released under inflammatory conditions such as during an infection, autoimmune 
disease, or allergy [65, 66]. The basic proteosome complex itself is a large barrel shaped 
protein complex composed of a catalytic 20S core and two 19S regulatory caps [67]. The 
inner subunits of the catalytic core confer caspase, trypsin, and chymotrypsin like 
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cleavage capability [68], and the 19S cap of the proteosome recognizes ubiquitinated 
proteins and transfers them into the core for degradation. However, upon inflammatory 
cytokine stimulation, five of the catalytic core subunits are replaced with 5 different more 
catalytically efficient subunits and the 19S regulatory cap is replaced with the 11S cap 
that lacks requirement for ubiquitination [69-71]. Upon these changes, the proteosome 
becomes the immunoproteosome and degrades intracellular proteins more much 
efficiently.  
 
MHC loading and antigen presentation by innate immune cells 
 MHC class I molecules are expressed on virtually all nucleated cells and are 
necessary for the presentation of peptides derived from intracellular proteins [72]. 
While presentation of degraded self-proteins such as old degraded proteins or defective 
ribosomal translation products is common [73, 74], the classical MHC class I antigen 
presentation pathway is also responsible for processing and presentation of viral peptides 
translated by the host ribosomes to CD8 T cells from infected cells. Upon recognition of 
peptide:MHC, virus-specific CD8 T cells will eliminate the virally infected cells.  
 MHC class one molecules are heterodimers composed of a 45000 MW type I 
integral membrane glycoprotein and a 12000 MW soluble β2-microglobulin (β2M) 
protein [75]. The dimeric protein is composed of four domains: three alpha domains (α1, 
α2, and α3) derived from the glycoprotein and the fourth domain deriving from β2M. The 
combination of the α1 and α2 domains form the antigen-binding groove (Figure 1.1A). 
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Figure 1.1: Crystal structures of major histocompatibility complex class 
I and II. [A] The crystal structure of the MHC class I molecule illustrates the 
interaction between the alpha chain composed of three subunits and the interlocked β2m 
peptide. Alpha helices of the α1 and α2 subunits form a groove for peptide binding. [B] 
The crystal structure of MHC class II molecule illustrating a heterodimer formed of both 
an alpha and beta chain, each composed of two subunits. Alpha helices on the α1 and β1 
subunits fold together, forming the MHC II peptide-binding site. MHC I crystal structure 
adapted from Zhang et al. 2012 [76] and MHC II crystal structure adapted from Painter et 
al. 2011 [77]. 
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This binding site is suitable for displaying peptides of 8-10 amino acids in length and is a 
required step in the synthesis of the MHC molecules. MHC class I molecules are 
assembled in the lumen of the rough endoplasmic reticulum (ER), and as loading of 
peptide is a required step of MHC synthesis, cytosolic peptides must be transported into 
the lumen of the ER. This peptide transport is carried out by the transporter associated 
with antigen processing (TAP) complex [78, 79]. In a complex with three other ER 
resident chaperone proteins, calreticulum, tapasin and ERP57, TAP associates with the 
nascent MHC class I complex and facilitates the loading of peptide [80, 81]. Following 
peptide loading, MHC class I complexes (with associated peptide) dissociate from the tap 
complex and are exported to the Golgi and sent on to integrate into the cell plasma 
membrane. 
 MHC class II molecules are more restricted in cell types expressing them 
(Dendritic cells, macrophages and B cells) [82] and are specifically responsible for the 
presentation of internalized exogenous antigens to CD4 T cells. The MHC class II 
molecule is also a dimeric protein complex, however it is composed of two integral 
membrane chains (α and β). Each chain constitutes two domains (α1, α2, β1, and β2) to 
the total MHC class II complex with the two distal domains α1 and β1 combining to 
form the antigen binding groove (Figure 1.1B).  
 MHC class II assembly again takes place in the ER however, unlike MHC class I 
assembly, construction of the MHC class II molecule is not dependent upon intra-ER 
loading of MHC with peptide. Instead, association of α chains with β chains is 
accomplished with the help of the invariant chain (Ii) [83]. Annealing of Ii to the antigen-
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binding groove prevents premature peptide binding and facilitates complete assembly of 
an MHC class II molecule and allows its exit from the ER. Additionally, Ii also facilitates 
transport of the MHC class II molecule to an endosome (then referred to as MIIC) at 
which point Ii will be degraded by endosomal proteases leaving behind a small fragment 
referred to as CLIP bound to the antigen-binding groove of the MHC II molecule [84-86]. 
Following Ii degradation, endosomally degraded exogenous proteins will be exchanged 
for the CLIP molecule to assess the MHC II peptide binding. Three MIIC-resident 
chaperone proteins HLA-DM, HLA-DR, and HLA-DO mediate CLIP/peptide exchange 
[87, 88]. Once an MHC II has successfully bound to peptide, the peptide:MHC complex 
will be delivered to the cell membrane for antigen presentation to CD4 T cells. 
 The previously mentioned pathway of degradation and presentation of 
intracellular antigens on MHC class I molecules is the mechanism behind most if not all 
cellular presentation of viral peptides. More recently discovered however is that the 
initiation of most immune responses (including extracellular infections) is mainly 
mediated by dendritic cells [89]. For viral infections, some viruses can infect dendritic 
cells directly and therefore provide the viral antigens for classical MHC I presentation. 
However, for extracellular infections such as some bacterial, parasitic, and fugal 
infections, the dendritic cells will not directly express the antigens. For these infection 
types, dendritic cells must phago- or pinocytose the antigens from the extracellular 
environment and then ‘cross present’ the peptides on their MHC I molecules. There are 
two main models, referred to as the “vacuolar” and “cytosolic” pathways, for how 
dendritic cells accomplish this cross presentation of extracellular antigens on MHC I 
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molecules [90]. The cytosolic pathway model proposes that partially degraded 
phagocytosed antigen is released into the cytosol where it is then processed by the 
proteosome and enters the classical MHC I pathway (Figure 1.2A), or re-enters the 
phagosome through TAP and is loaded onto MHC I that have been recycled from the 
membrane down into the phagosome (Figure 1.2A). The vacuolar pathway, similar to the 
second cytosolic pathway, involves the recycling of membrane-bound MHC I molecules 
into endosomes and/or phagosomes where they are then loaded with exogenous antigen 
(Figure 1.2B) [91]. Regardless of the mechanism, cross presentation allows dendritic 
cells to present extracellular antigen and antigen from intracellular infection of non-
dendritic cells on MHC I molecules to stimulate CD8 T cell responses [56]. 
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Figure 1.2: The two models of extracellular antigen cross presentation 
on MHC I. [A] The cytosolic pathway model proposes that peptides from 
phagocytosed antigens are exported to the cytosol where they will be ubiquitinated and 
targeted to the proteosome for degradation. Following degradation, the peptides will 
either be (1) translocated back into the phagosome through TAP and loaded onto MHC I 
that have been recycled from the cell membrane, or (2) fed into the classical MHC I 
loading pathway in the ER. [B] The vacuolar pathway proposes that cross presentation is 
independent of both the TAP and proteosome. For this pathway, peptides are generated 
from phagocytosed antigens by cathepsins and low pH in the phagosome, and are 
subsequently loaded on MHC I in the phagosome that have migrated from the cell 
membrane. Figure 1.A and 1.B have been adapted from Mantegazza et al. 2013 [56]. 
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The adaptive immune system is required for protection 
 While the term “immunity” refers to an encompassing ability of a host to resist 
being destroyed by infectious microbes [92], a great dichotomy exists between branches 
in the vertebrate immune system. Researchers of the innate immune system specialize 
mainly on how microbes are recognized via innate immune receptors, how innate cells 
kill invading microbes, and how innate cells alert the system of an infection via cytokine 
signaling. Adaptive immunologists have spent the last few decades seeking to understand 
the generation of B and T cell receptor diversity, immune self-tolerance, immunological 
memory, and the generation of protective antibody and T cell responses. 
 While the two branches of the immune system perform many different roles, they 
are both in many ways dependent upon one another. In the late 1960s it was discovered 
that mononuclear phagocytic cells were required for effective lymphoid cell responses to 
antigens [93, 94]. Now more thoroughly understood, the adaptive immune system is 
highly dependent on the innate system for antigen presentation and activation. Even more 
interesting was the discovery that different “types” of adaptive response can be triggered 
depending on the mechanism of innate cell activation. Specifically, intracellular 
pathogens such as viruses require a more robust T helper type 1 (TH1) response, while 
some extracellular pathogens such as helminths require a less intense T helper type 2 
(TH2) response [95]. It is now incredibly clear that the innate immune system, while less 
robust in its protective capability, is an integral part of the adaptive immune system’s 
protection. However, while the innate immune system may be involved with preventing  
 
 
20 
infection, once virulent infections occur, the adaptive immune system is required to clear 
them. 
 There are many differences between the innate and adaptive immune systems, 
including the means by which they recognize microorganisms. Innate cell antigen 
receptors are proteins encoded in the germ line that allow them to identify broad classes 
of compounds usually specific to various types of invading microbes. In contrast to this 
relatively inflexible system of innate receptors is the nearly infinitely diverse repertoire of 
adaptive cell antigen receptors. B and T cells acquire they’re diverse repertoires of 
antigen receptors by somatically rearranging large sets of genes to create an estimated 
pool of more than 1016 possible receptors per cell type [96]. These highly diverse 
repertoires of antigen receptors allow the adaptive immune system to cope with the 
immense genetic variability of microorganisms, but also lends to the possibility of 
innocuous antigen reactivity (allergies) or autoreactivity (autoimmunity). 
 A second key difference between the innate and adaptive systems is the ability of 
adaptive cells to proliferate and develop into effector and/or memory cells. Clones of B 
and T cells with receptors triggered by antigen will proliferate, creating a pool of millions 
of antigen-specific B cells and T cells [97]. The effector subset of these proliferated cells 
differ in numerous ways from the naïve cells from which they were derived, and the 
changes allow the effector cells to respond quickly and efficiently when they encounter 
antigen on target cells in the periphery. Upon clearance of the infection, the majority of 
the proliferated cell fraction will die off, leaving behind a small subset of antigen-specific 
cells, termed memory cells. While similar to naïve cells, memory cells are quiescent and 
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require activation by APCs and co-stimulation in order to become effector cells. 
However, memory cells do not require as rigorous of an activation step, and will 
therefore differentiate into effectors much faster than naïve cells. This fast activation 
ability of memory cells is the crux of some types of vaccinations. 
 
The successful activation of T cells requires multiple productive TCR peptide:MHC 
interactions 
 T cell activation is a highly crucial checkpoint in adaptive immunity and it is 
governed through a number of signaling interactions. In order for T cells to initiate and 
regulate the adaptive immune response, be it against infection, cancer, during 
autoimmunity or allergy, productive binding between the TCR and antigenic peptides 
bound to MHC must first occur [98]. Following activation signals, T cells may 
proliferate, differentiate, kill target cells (CD8 T cells), secrete cytokines (CD4 T cells), 
or carry out other effector functions [99].  
 Numerous experiments have evaluated different panels of TCR:peptide/MHC 
(TCR:pMHC) combinations to establish the relationship between TCR:pMHC 
stoichiometry required for T cell activation as measured by downstream cytokine 
secretion or killing ability [100-102]. Some studies have demonstrated that T cell 
activation is at an optimum when plotted over the TCR:pMHC dissociation time (τ) 
[103], which is the reciprocal of the off rate (koff = 1/τ) [99, 104]. More simply, high 
affinity antigens (antigens that bind with long dissociation times) lead to poor activation 
of T cells [105]. However, different experiments, utilizing intricate pMHC titrations have 
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shown that antigens with short dissociation times cant produce the same optimal 
responses as antigens with longer dissociation times [100, 106]. In these dose-response 
experiments optimal T cell activation was directly correlated to the TCR:pMHC 
dissociation constant (Kd), and inversely proportional to the off rate (koff). These differing 
opinions on the relationship between T cell activation parameters have led to the 
development of numerous models aimed at explaining TCR:pMHC binding kinetics 
[106-109]. While continued experimental analysis will be necessary for further 
explanation of TCR:pMHC binding kinetics vs T cell activation, a kinetic proofreading 
model described by Lever et al. in 2014 [99] is an elegant combination of what we 
currently understand.  
 In the analysis by Lever et al., they looked over all the various published models 
of TCR:pMHC binding kinetics with the aim to predict quantitative T cell responses to 
antigens over varying antigen:TCR affinity [99]. Their analysis revealed five distinct 
models: (1) The occupancy/affinity model states that T cell activation is directly 
proportional to the number of TCR:pMHC interactions, (2) the kinetic proofreading 
model posits that T cell activation is proportional to the fraction of TCR:pMHC 
interactions maintained for a sufficient time to achieve full signaling, (3) the kinetic 
proofreading with limited signaling model proposes that T cell activation requires 
continuous signaling that necessitates serial binding of TCRs to multiple pMHCs, (4) the 
kinetic proofreading with sustained signaling model states that there is an optimal 
dissociation time for all T cell activation at any pMHC concentration, and (5) the kinetic 
proofreading with negative feedback model predicts that T cell activation will exhibit an 
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optimum as a function of the pMHC dose [99]. In summary, they concluded that the 
phenotypic model most compatible with experimental data currently available [106, 110-
112]was the kinetic proofreading with limited signaling model. This model allows for 
reversible binding of TCR:pMHC and therefore serial TCR:pMHC interactions.  
 
CD4 T cells recognize antigenic peptides presented on MHC class II while CD8 T 
cells recognize peptide presented on MHC class I 
 The molecular details of antigen presentation by MHC class I and II molecules 
was described nearly fifteen years ago. While both similar in their antigen presentation 
function, MHC class I and II molecules typically only present peptide fragments to CD8 
or CD4 T cells respectively. A key difference between the two types of MHC antigen 
presentation is the source of the peptides they present. Peptides derived from intracellular 
antigens such as viral proteins are typically displayed on MHC class I molecules and thus 
recognized by CD8 T cells, while peptides derived from extracellular sources are 
commonly displayed on MHC class II and recognized by CD4 T cells [113]. As 
mentioned above, additional mechanism of antigen presentation have also been 
elucidated in which exogenous antigens are presented by MHC I (cross-presentation) 
[114], or endogenous antigens presented by MHC II (autophagy) [115]. A second key 
difference between the two types of MHC antigen presentation is the mechanisms of 
antigen degradation. The MHC I pathway commonly utilizes proteosomal degradation of 
intracellular peptides, while the classic MHC II pathway relies on phagolysosomal  
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proteolysis. These intrinsic differences between MHC I and II antigen presentation are 
fundamental in the different effector functions of CD8 and CD4 T cells. 
 Most likely owing to the fact that they originate from a common founder gene that 
has been duplicated [116], MHC I and II share several characteristics. Both classes have a 
similar structure, they express high levels of polymorphism, and serve the same goal of 
antigen presentation to the immune system. However, MHC class I and II molecules 
differ in a wide variety of properties. Beyond the differences discussed above, tissue 
expression for MHC I is found on nearly all cells while MHC II is reserved mainly for 
professional antigen presenting cells such as dendritic cells, macrophages and B cells. 
These intrinsic differences in MHC I and II are essential for the different effector 
functions of the CD8 and CD4 T cells by which they are recognized. CD8 T cells are our 
main protectors from viral infections, and as such CD8 T cells must be able to recognize 
viral peptide presented by virtually any cell. While CD4 T cells are more encompassing 
in their directing role of the immune response, they play a key role antibody production 
and are thus necessary for directing the immune response against extracellular pathogens 
that are mainly presented by the previously mentioned professional antigen presenting 
cells.  
 
The CD4 and CD8 co-receptors are involved with TCR:pMHC binding and 
intracellular signaling 
 In the late 1970s, T cells found in the peripheral blood or secondary lymphoid 
organs were distinguished using monoclonal antibodies (mAbs) by the exclusive 
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expression of either CD4 (previously known as T4, L3T4, Ly1, or Leu3) or CD8 
(previously known as T8, Leu2, or Ly2/Ly3) cell surface proteins [117]. Initial 
experiments linked T cell expression of CD4 with the ability to initiate B cell production 
of antibodies and CD8 expression with cytotoxic function [118, 119], however it was yet 
unknown whether these surface molecules possessed any inherent effector mediating 
function themselves. It wasn’t until the discovery that CD4 T cells only respond to 
antigen presented on MHC II molecules [120] and that CD8 T cells only respond to 
antigen presented on MHC I molecules [33] that studies into how the CD4/CD8 co-
receptors mediate TCR:pMHC recognition were undertaken.  
 A number of studies have identified the roles of the CD4 and CD8 co-receptors on 
stabilizing TCR:pMHC recognition and downstream signaling [102, 121-123]. 
Specifically it was shown that at the extremes, high-affinity TCR:pMHC interactions 
were sufficient for downstream activation without the need for CD4/CD8 co-stimulation, 
but TCR:pMHC interactions with low affinity (Kd > 3µM) necessitated CD4/CD8 co-
receptor recognition [102, 121]. Structural data has demonstrated a ternary complex 
formed between the TCR:pMHC:co-receptor interaction (Figure 1.3) [124, 125].  
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Figure 1.3: Ternary complexes of CD4 and CD8 co-receptors with 
respective TCR:MHC. [A] Crystal structure (left) and corresponding cartoon (right) 
of TCR:MHC with CD4 co-receptor oriented with CD4 T cell at the bottom and antigen 
presenting cell (APC) at the top. The domain 1 (D1) of the CD4 co-receptor contacts the 
β2 subunit of the MHCII complex. [B] Crystal structure (left) and corresponding cartoon 
(right) of TCR:MHC with CD8 co-receptor oriented with CD8 T cell at the bottom and 
antigen presenting cell (APC) at the top. The α domain (α) of the CD4 co-receptor 
contacts the α3 subunit of the MHCI complex. Crystal structure images adapted from Li 
et al. 2013 [125]. 
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These ternary complexes are formed by the MHC-dependent recruitment of CD4 or CD8 
co-receptors to the immunological synapse formed between the T cell and the antigen-
presenting cell [126]. In addition to enhancing TCR:pMHC binding kinetics, the CD4 and 
CD8 co-receptors are also believed to play a role in the kinetic proofreading model 
discussed above [99]. Surface plasmon resonance (SPR) studies have shown that the half-
lives of co-receptor:MHC interactions to be <35ms for both CD4 and CD8 [123, 127]. In 
contrast to this brief interaction, the TCR:pMHC interaction can last >10,000ms [128], 
therefore indicating the possibility of CD4/CD8 co-receptor disengagement 1000X per 
antigen recognition. Furthermore, it has been demonstrated that while CD8 has been 
found to stabilize TCR:pMHC binding [129], CD4 does not provide significant 
stabilization to the TCR with peptide presented on MHC II molecules [130]. It has 
therefore been proposed that the primary purpose of the CD4 and CD8 co-receptors is to 
enhance intracellular signaling rather than stabilize the TCR:pMHC interaction [131].  
 In addition to their role as binders to tighten the key interaction between TCR and 
pMHC, it has also been demonstrated that the CD4/CD8 co-receptors participate in signal 
transduction [132-134]. Seminal work by the groups of Schlossman [135] and Bolen 
[136] revealed that the CD4 and CD8 proteins were both associated with intracellular 
protein tyrosine kinase (PTK) signaling activity. Specifically, CD4 and CD8 co-receptors 
augment TCR signaling by increasing the efficiency by which recruitment of the proto-
oncogene tyrosine-protein (Src) kinase lymphocyte-specific protein tyrosine kinase (Lck) 
is brought to the intracellular TCR domains. The likelihood that free Lck will associate  
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with the TCR signaling complex is very small compared to the corresponding likelihood 
for Lck bound to the CD4/CD8 co-receptor [131].  
 
The T cell receptor complex includes a dimeric TCR and the CD3 signaling complex 
 In the early 1980s, monoclonal antibodies were generated against antigen-specific 
T cell clones in the hopes of identifying the antigen receptor on T cells [19, 137]. These 
antibodies not only were generated against the dimeric αβ TCR, but also against the 
nonpolymorphic CD3 proteins [138]. While determination of the antigen-binding 
function of the αβ TCR was obvious early on, the role of the CD3 proteins was less 
obvious. Initial studies went into analyzing the stoichiometry between the TCR proteins 
and the multiple CD3 γ, δ, ε, and ζ proteins. It was discovered that the CD3 proteins exist 
as a series of hetero- and homo-dimers consisting of γε, δε, and ζζ all in association with 
a single αβ TCR complex [138]. 
 
 
 
 
 
 
 
 
 
 
 
29 
 
Figure 1.4: The mature αβ  T cell receptor complex includes the TCR 
and the CD3 signaling complex. The αβ T cell receptor is a dimeric structure 
composed of two type-I glycoprotein chains linked together by disulfide bridges (dashed 
lines). Each chain is comprised of two extracellular domains (variable and constant), a 
hydrophobic transmembrane region and a very short intracytoplasmic region. Due to the 
short nature and lack of any intracellular protein docking sites or signaling motifs, a 
multimeric complex referred to as CD3 mediates signal transduction following antigen 
recognition. The three CD3 dimers (εγ, δε and ζζ) contain acidic transmembrane residues 
that interact with basic residues on the transmembrane portion of the TCR chains. Signal 
transduction is mediated by intracellular tyrosine activation motifs (ITAMs) contained on 
the intracellular portions of the CD3 subunits. The γ, δ and ε subunits each carry one 
ITAM, while the ζ subunits contain three. Once phosphorylated upon TCR activation, the 
ITAMs will recruit several tyrosine kinases such as ZAP70, triggering a signaling 
cascade leading to T cell activation and/or effector function. Image adapted from 
Schoettle et al. 2015 [139]. 
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 Several lines of evidence pointed towards the CD3 complex of proteins 
involvement in signal transduction: unlike the αβ TCR proteins that have extremely short 
intracellular domains the CD3 proteins had long cytoplasmic tails, anti-CD3 antibodies 
resulted in T cell activation, and experiments using cell lines expressing αβ without CD3 
or CD3 without αβ revealed the obligatory co-expression of the two protein complexes 
[140]. Further studies revealed that engagement of the TCR and/or CD3 led to increases 
in intracellular Ca2+ concentrations both released from intracellular pools released from 
the endoplasmic reticulum (ER) stores in response to inositol triphosphate (IP3) and from 
influx of Ca2+ from outside of the cell replenishing the ER stores [141]. Additional 
studies revealed that hydrolysis of the membrane lipid phosphatidyl inositol 4,5 
bisphosphate by the enzyme phospholipase C (PLC) generated both IP3 and 
diacylglycerol (DAG), an important regulator of protein kinase C (PKC) [142], leading 
the researchers to believe that the TCR functioned through regulation of PLC activity 
[98].  
 A key finding in the unraveling of TCR signal transduction was the knowledge 
that T cell activation required PTK function [143], which led researchers to discover TCR 
recruitment of cytosolic PTKs to activate a secondary messenger system. This finding 
was brought forth by the discovery that upon stimulation of the TCR, inducible 
phosphorylation of the ζ chain of the CD3 complex was observed leading to PLCγ 
function, and the same phosphorylation and PLCγ function could be induced by PTK 
[144]. Concurrent with these findings, the discovery that cytosolic PTKs lck and fyn  
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associated with both the TCR and CD4/CD8 co-receptors were being described [136, 
145], providing more evidence for the requirement of PTK function in TCR signaling.  
 The pathway of CD3 signal transduction is initiated by the phosphorylation of 
tyrosines within the cytoplasmic tails of the CD3 proteins. Designated immunoreceptor 
tyrosine-based activation motifs (ITAMs), each CD3 ε, δ, and γ tail contains a single 
tyrosine motif, and each ζ tail contains three [146]. Numerous experiments were 
conducted creating chimeric cell surface proteins expressing the intracellular ITAM 
domains that all revealed ITAM tyrosine phosphorylation upon receptor ligation [147], 
indicating tyrosine phosphorylation of ITAMs as a requirement for TCR signaling and T 
cell activation. Following phosphorylation, the ITAMs were then discovered to serve as a 
docking site for the 70 kDa syk kinase family protein ζ-association protein (ZAP-70) 
[148]. Once recruited, ZAP-70 functions as an active PTK, phosphorylating numerous 
downstream substrates leading to activation and proliferation of the T cell. 
 Following TCR:pMHC ligation and ITAM phosphorylation by the PTKs lck and 
fyn, recruitment of ZAP-70 leads to phosphorylation of two key targets: the 
transmembrane adapter protein linker for the activation of T cells (LAT), and the 76-kDa 
cytosolic adapter protein src homology 2 (SH2) domain-containing leukocyte 
phosphoprotein (SLP-76) [149, 150]. Knockout experiments demonstrated that the loss of 
either LAT or SLP-76 results in near complete loss of TCR signal transduction [151]. It 
was determined that these two chaperone proteins form a docking site complex, allowing 
for correct spatial arrangement and timing of multiple downstream signaling pathways.  
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 Upon engagement with the TCR complex, nine tyrosine residues on LAT will be 
phosphorylated. These tyrosines act as a docking site for PLCγ. Following PLCγ 
recruitment, SLP-76 is recruited to LAT via a mutual chaperone protein [152]. SLP-76 
contains three functional domains involved with the interaction between LAT and PLCγ 
and other downstream adapter proteins and kinases [153]. LAT, SLP-76, and the other 
effector proteins making up this initial signaling complex all work in conjunction to 
recruit each other to the complex, stabilize the complex upon recruitment, and enhance 
the guanine nucleotide exchange factor (GEF) Vav1 phosphorylation of SLP-76 [154, 
155]. The result of these multiple interactions in forming the proximal signaling complex 
is believed to be required for PLCγ stabilization and thus optimal activity of PLCγ-
dependent pathways including Ca2+ and DAG mediated responses [156]. 
 Once activated, PLCγ hydrolyzes the membrane lipid phosphatidylinositol 4,5 
bisphosphate (PIP2), releasing the secondary messengers DAG and IP3 [157]. The PLCγ 
production of DAG results in activation of two separate pathways, Ras and protein kinase 
C theta (PKCΘ). Activation of Ras, a guanine nucleotide-binding protein, activates the 
serine-threonine kinase Raf-1 that activates the mitogen-associated protein kinases 
(MAPKs) extracellular signal-regulated kinase 1 (Erk1) and Erk2. Following Erk 
activation, activation of signal transducer and activator of transcription 3 (STAT3) that 
promotes T cell survival [158]. Ras is additionally involved with activation of the 
activator protein-1 (AP-1) c-Jun/c-Fos transcription factor complex leading to 
upregulation of CD69 involved in proliferation [159]. In addition to the Ras pathway, 
DAG also mediates PKCθ induced activation of nuclear factor kappa-light-chain-
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enhancer of activated B cells (NFκB). Briefly, upon T cell activation, the inhibitor of 
NFκB (IκB) is phosphorylated, ubiquitinylated, and degraded, which allows NFκB to 
translocate to the nucleus and up regulate transcription of multiple genes involved in 
survival and effector function of the T cell [160].  
 The second PIP2 cleavage product IP3 activates Ca2+-permeable ion channel 
receptors (IP3R) on the ER membrane, resulting in the release of ER stores of Ca2+ into 
the cytosol. The loss of ER-Ca2+ leads to an influx of extracellular Ca2+ through plasma 
membrane Ca2+ release-activated Ca2+ (CRAC) channels via a process referred to as 
store-operated Ca2+ entry (SOCE) [161]. Ca2+ ions are somewhat ubiquitous secondary 
messengers in most eukaryotic cells, however TCR-induced increases in intracellular 
Ca2+ concentration result in the activation of Ca2+ and calmodulin-dependent 
transcription factors including myocyte-enhancing factor 2 (MEF2), downstream 
regulatory element antagonist modulator (DREAM), and the phosphatase calcineurin. 
Following activation, calcineurin dephosphorylates the transcription factor nuclear factor 
of activated T cells (NFAT) allowing it to translocate to the nucleus and increase 
transcription of the T cell growth factor interleukin-2 (IL-2)[162]. 
 In addition to the activation of transcription factors resulting in the up regulation 
of growth, proliferation, and survival factors, T cell activation also results in programmed 
actin cytoskeletal rearrangements [163]. Upon T cell activation, filamentous actin (f-
actin) will accumulate at the T cell:APC interaction surface, reorienting the T cell in a 
more conducible alignment for continued interaction with the activating APC [164]. 
Additionally, upon activation the T cell will become polarized, where the microtubular 
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organizing center (mTOC) will reorient towards the TCR:pMHC interaction, an essential 
step in creating the organized structure between the T cell and the APC known as the 
immunological synapse [165]. Finally, activation of T cells results in activation of 
integrins, αβ heterodimeric receptors that mediate cell-cell interactions. The two key 
integrins activated upon T cell activation are the leukocyte function-associated antigen-1 
(LFA-1) and very late antigen-4 (VLA-4). These two integrins will bind their respective 
ligands intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule 
(VCAM) on APCs, infected cells, endothelial cells and extracellular matrix proteins 
[166]. 
 
Co-stimulation of the T cell co-receptor CD28 provides additional signals required 
for T cell activation 
 When T cells are activated solely through the TCR:pMHC and CD3 complex, 
they often enter a state of anergy or non-responsiveness [97]. In order to avoid the 
anergic state and reach a productive activation, co-ligation of other cell surface receptors 
provides additional signaling input. While there are many other co-receptors that can 
enhance signaling, the most robust of these is CD28 [98].  
 CD28 signaling has been shown to enhance cell proliferation, cytokine 
production, cell survival, and increased cell metabolism [97]. The key signaling 
intermediate downstream of T cell CD28 ligation with its respective ligands CD80/CD86 
on APCs is phosphoinositide 3-kinase (PI3K). Following ligation, PI3K converts PIP2 to 
phosphatidylinositol (3,4,5) triphosphate (PIP3) at the cell membrane which then serves 
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as a docking site for the protein kinase Akt [167]. The downstream protein 
phosphorylation by Akt enhances numerous pathways including NFκB survival signaling 
[97], NFAT regulation of IL-2 production [168], and increased cell surface express of the 
insulin transporter Glut1 thus allowing for increased T cell metabolism [169].  
 
T cells are derived from bone marrow resident hematopoietic stem cells but migrate 
to the thymus for development 
 In adults, each class of blood cells is derived from bone marrow (BM) resident 
hematopoietic stem cells (HSCs). The different classes emerge as the result of 
progressive losses in differentiation potential for the other cell lineages [170]. Modern 
experimental techniques have made it relatively simple to isolate HSCs and create model 
systems both in vitro and in vivo for studying blood cell differentiation leading to cell fate 
and lineage commitment [171]. The first major bifurcation in the lineage commitment 
process of HSCs is into either the lymphoid or myeloid lineage. The lymphoid lineage 
gives rise to the adaptive T and B cells, as well as natural killer (NK) cells, and the 
myeloid lineage comprises platelet producing megakaryocytes, erythrocytes and innate 
cell types such as monocytes, macrophages, and granulocytes. Additionally, while also of 
hematopoietic origin and commonly associated with the myeloid lineage, dendritic cell 
lymphoid/myeloid lineage affiliation is somewhat controversial [172].  
 One of the first major changes HSCs undergo during lineage commitment is the 
loss of self-renewal capability [173] at which point the cells may be classified as 
multipotent progenitors (MPPs). Following progression to MPP status, the cells will then 
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diverge into either common lymphoid progenitor (CLP) cells or common myeloid 
progenitor (CMP) cells, with potential for restriction to all cell types within the respective 
common lineages [174, 175]. Cell surface expression of different proteins allows for the 
identification and isolation of either subset of common progenitor types; CLPs can be 
identified as IL-7Rα+Thy-1.1−Lin−Sca-1loc-Kitlo [174] and CMPs as 
CD34+FcγRIII−/loThy-1.1−IL-7Rα−Lin−Sca-1−c-Kit+ [175]. This initial discovery of a 
common lymphoid progenitor suggested a common origin for all lymphocytes (B and T 
cells), instead of separate pathways of development directly from the HSC stage.  
 There have been numerous laboratories elucidating the key signal/expression 
changes on MPP cells that direct cell differentiation to either the CMP or CLP restriction. 
A key finding was that MPPs could be separated based on Flt3 expression levels [176], 
and these MPP subsets could be further subdivided into three main subcategories: 
Flt3loVCAM-1+, Flt3hiVCAM-1+, and Flt3hiVCAM-1- [177]. in vivo characterization of 
these three subsets demonstrated that only the most primitive Flt3loVCAM-1+  subset of 
MPPs could give rise to CMPs (as well as CLPs), while the most developmentally 
advanced Flt3hiVCAM-1- subset were more restricted and preferentially give rise to CLPs 
only [178].  
 Upon becoming CLPs, commitment to the lymphoid lineage has been established 
as the cells have lost all ability to generate myeloid lineage cells. It was observed that 
injection of CLPs intrathymically resulted in CLP differentiation into T cells [179], 
however intravenous injection of CLPs resulted in B cell differentiation [174]. It was 
hypothesized that upon lineage specification, progenitors would preferentially migrate to 
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distinct loci either within the BM or the thymus that only support differentiation into B 
cells or T cells, respectively. Known as microenvironments, these anatomical niches are 
highly specialized structures where specific cellular components and stem/progenitor 
cells localize to aid in cell differentiation. HSCs utilize a similar model in the bone 
marrow where osteoblasts at the trebacular region of the bone cavity express the adhesion 
molecules N-cadherin and VCAM-1 to retain the HSCs in their niche [180]. T and B cell 
niches in the thymus and BM have also been investigated. As T cells undergo their 
consecutive stages of development they will migrate to different regions of the thymus 
[181] and developing B cells will traverse from niche to niche in the BM as they progress 
through their developmental stages as well [182]. The main homing signals directing 
cells to the various niches for each stage of their development are chemokines [183]; 
SDF1α, CCL19, CCL21 and CCL25 have all been shown to aid in the homing of T cells 
during their development in the thymus [181].  
 While BM resident HSCs retain the ability to divide, immature thymocytes have 
lost self-renewal capability and therefore must be constantly replenished by progenitors 
from the BM to sustain adequate numbers of developing T cells [184]. The deterministic 
cue dictating whether bi-potential CLPs will enter T cell or B cell lineage commitment is 
through the signaling molecule Notch. Inhibition of Notch 1 signaling in the earliest 
developmental stages of thymocytes results in B cell development [185]. Additionally, 
constitutive expression of Notch 1 can induce T cell development of BM resident MPPs 
[186]. These findings suggest that the replenishment of developing T cells in the thymus 
comes from the migration of bi-potential MPPs from the BM. 
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 The final step before T cell development involves the actual circulatory system 
migration of BM-derived progenitor cells to the thymus. In addition to the intrinsic 
signals dictating T cell lineage, lymphoid progenitors must be able to mobilize from their 
niches in the BM and home to specific regions of the thymus for continued lineage 
commitment and development.  A small population of T cell generating MPPs has been 
found to express increased levels of CD62L. These cells have enhanced ability for thymic 
homing [187]. Additionally, increased expression of the chemokine receptor 9 (CCR9) 
has been shown on thymic homing progenitor cells [188]. CCR9 is the receptor for 
chemokine ligand 25 (CCL25), also known as thymic expressed chemokine (TECK), 
which is expressed in the thymus but not the BM. Together with NOTCH expression, 
CD62L and CCR9 expression of BM derived progenitor cells leads to thymic migration 
and T cell lineage commitment. 
 
T cell development occurs throughout multiple stages in the thymus 
 Once progenitor cells reach the thymus, T cell development proceeds in a highly 
regulated, well-defined, sequential manner. As the developing cells progress through 
developmental stages, cell differentiation becomes more and more restricted [189].  
 Premature cells enter the thymus at the cortico-medullary junction and proceed to 
migrate to the outer cortex [190]. Developing cells at this stage express neither TCRs, 
CD3 signaling complexes, nor CD4/CD8 co-receptors and as such are commonly referred 
to as “Double negative” (DN) cells. Two of the first surface proteins to be expressed 
during this developmental stage are the CD44 molecule and the IL-2α receptor (IL-2Rα). 
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During this stage, increased transcription of the recombinase activating genes 1 and 2 
(RAG1 and RAG2) leads to somatic rearrangement of the TCR genes (discussed below). 
At the double negative stage, only the TCRβ chain genes are rearranged, and only 
functional rearrangements result in β chains capable of binding the surrogate α chain 
pTα, the prerequisite for progression to the next developmental stage [191]. Cells not 
expressing functional β chains will either attempt another round of β chain gene 
rearrangement or undergo apoptosis. Cells that are capable of expressing functional β 
chains will successfully join their β chain with the pTα chain to form the pre-TCR that 
will be expressed on the cell surface along with the CD3 signaling complex for testing of 
functionality. It should also be mentioned that during the double negative stage of 
development T cells would also rearrange the gene sets encoding the γδ TCR. This will 
be discussed in more depth below. Following a successful β chain rearrangement, the cell 
will proliferate, producing hundreds of clones and the process will repeat in the 
proliferated cells by rearranging the α chain genes as they attempt to form a mature TCR. 
The random rearrangement and selection of TCRα and β genes (along with the sloppy 
joining of the gene segments) is the main mechanism of TCR diversity development 
which will again be discussed in more depth below [192].  
 As the cell progresses in development, it will finish rearranging the TCRα genes 
and upregulate expression of both CD4 and CD8 co-receptors, creating “Double positive” 
(DP) T cells. The double positive developmental stage again takes place in the thymic 
cortex and accounts for over 70% of thymocytes [189]. Continued TCRα gene  
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rearrangement and eventual expression of the mature TCR defines this stage of T cell 
development. Upon successful α chain rearrangement, expression of the complete αβ 
TCR will be followed by a series of selective tests. In order to ensure that mature T cells 
can recognize self-MHC presentation of antigenic peptide, the interactions of the newly 
expressed TCR will be tested during “Positive selection”. Cortical thymic epithelial cells 
(cTECs) expressing numerous MHC will be utilized to assess TCR:MHC interaction, 
failure of which will result in the T cell entering an unresponsive state known as anergy, 
or the cell will die from neglect [193]. Our current understating of this positive selection 
process involves both the strength of the TCR:MHC interaction (affinity), as well as the 
number of actual TCR:MHC interactions occurring (avidity). This selection process 
ensures self-MHC restriction of T cells and will result in final CD4 vs CD8 lineage 
commitment. While the deciding factor on whether to become CD4 or CD8 ultimately 
depends on which MHC class (I or II) is recognized, the process of lineage commitment 
is much more intricate than simple selective kinetics. Initially, DP cells will down 
regulate expression of both CD4 and CD8 co-receptors and then re-express CD4 only. If 
these CD4hiCD8lo cells make a productive interaction with MHC II they will be 
committed to the CD4 lineage and completely down regulate expression of CD8. 
However, if no successful interaction is made with MHC II, the cells will down regulate 
expression of CD4 and up regulate expression of CD8. These CD4loCD8hi cells will then 
attempt interaction with MHC I molecules and should an interaction of sufficient affinity 
occur the cell will commit to the CD8 lineage and fully down regulate CD4 expression  
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[194]. Should no sufficient interactions occur between either MHC II or MHC I, the cell 
will die from neglect or enter a state of non-responsive anergy.  
 As the developing cells progress from the DP stage to the single positive (SP) 
stage, expressing either the CD4 or CD8 co-receptor, they will undergo a final selective 
process. “Negative selection” is the process by which self-reactive T cells are deleted 
from the developing repertoire. It involves the interaction between T cells and self-
peptide presented by medullary thymic epithelial cells (mTECs), and thus takes place in 
the thymic medulla [195]. Uniquely, mTECs are capable of expressing a majority of 
tissue-specific proteins in the thymic medulla, which allows them to present most of the 
body’s protein to developing T cells. To accomplish this feat, mTECs express the master 
transcriptional autoimmune regulator (AIRE) transcription factor. AIRE promotes the 
expression of tissue-specific proteins in the thymic medulla and thus allows for self-
reactive T cells whose TCR recognizes the body’s tissue-specific proteins to be deleted 
[196].  Depending on the strength of interaction, there are ultimately three potential fates 
for cells following negative selection. Should strong TCR recognition of self-
peptide:MHC occur, the developing T cell may be differentiated into a natural regulatory 
T cell (Treg) [197]. As these cells express a high affinity for self-peptide, they are 
excellent at ensuring that peripheral autoimmune responses by lower affinity 
conventional T cells are suppressed. If a moderate level of self-peptide:MHC recognition 
occurs the cell will undergo apoptosis and die. Only if relatively weak or a lack of 
recognition occurs will the developmental T cell survive to maturity and thus be allowed 
to exit to the periphery [197]. While the process of negative selection is formulated to 
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ensure a lack of autoreactive T cells in the immune repertoire, many autoreactive T cells 
will escape this selective process and exit the thymus. Peripheral tolerance mechanisms 
such as regulatory T cells and suppressive cytokines help to prevent autoimmunity from 
occurring (Figure 1.5) [198].  
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Figure 1.5: T cell development is a highly ordered process of events 
occurring in distinct stages and locations within the thymus. Common 
lymphoid progenitor cells travel to the thymus and enter through the high endothelial 
venule (HEV). Now double negative 1 (DN1) cells, these early progenitors begin β-, γ-, 
and δ-chain gene rearrangements. Reaching DN2, the cells migrate towards the cortex 
and complete β-, γ- and δ-chain rearrangements. Should successful γδ rearrangement 
occur before successful β-chain, the cells will express γδ TCRs and exit the thymus as 
mature γδ T cells, forgoing any further selective processes. If productive β-chain 
rearrangement occurs first, the β-chain will be paired with a surrogate α-chain (pTα) as 
the cell moves into the DN3. If a productive β- chain rearrangement occurred, the cell 
will enter DN4 stage and proliferate. In the early double positive (DP) stage, the cells will 
undergo α-chain rearrangement. Upon successful α-chain recombination, the cell will 
shuttle its αβ TCR to the cell surface, up regulate both CD4 and CD8 co-receptors and 
undergo positive selection mediated by the cortical epithelial cells. Following positive 
selection, the cell will become either a single positive (SP) CD8 or CD4 T cell. At the SP 
stage, the cell migrates back towards the cortico-medullary junction and undergoes the 
final process of negative selection carried out by medullary epithelial cells. Following 
negative selection, the newly matured naïve T cell will leave the thymus back through the 
HEV and exit to the periphery in search of its cognate antigen. Figure adapted from 
Schoettle et al. 2015 [139]. 
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 Overall, the positive and negative selective processes are extremely stringent and 
the vast majority of developing T cells will never reach maturity. It has been estimated 
that as low as 1-2% of progenitor cells that enter the thymus will ever reach complete T 
cell maturity [199]. Less dense than the cortex, the thymic medulla acts as a reservoir of 
newly matured T cells that will remain for roughly two weeks in the thymus before 
exiting to the peripheral circulation as they undergo approximately six rounds of cell 
division [200].  
 
Organization of the T cell receptor genetic loci 
 One of the hallmarks of adaptive immunity is the high degree of specificity of the 
antigen receptors found on B and T cells. In order to maintain sufficient diversity of 
receptors allowing for identification of a multitude of pathogens and transformed cells 
encountered in an organism’s lifetime, a repertoire of highly diverse TCRs (and BCRs) 
must be generated. The vast majority of T cells express heterodimeric antigen receptors 
composed of both an α and β chain (αβTCR) while a small subclass of T cells express a γ 
and δ chain (γδTCR). The ability of T cells to generate such a large diversity of antigen 
receptors is dependent upon recombination of variable (V), diversity (D), and joining (J) 
segments for TCRβ and δ chains, and V and J segments for TCRα and γ. The most 
variable parts of the TCR, commonly referred to as the complementarity determining 
regions (CDRs), make the major contact with the p:MHC complex and thus constitute 
TCR specificity [201] and will be discussed below.  
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 The human germline TCRβ locus on chromosome 7q34 contains 64 V, two D, 14 
J, and two constant gene segments; similarly the TCRα locus on chromosome 14q11 has 
44 V, 61 J, and one constant gene segment (relative numbers for the murine TCR gene 
locus are only slightly lower) [202]. Interestingly, while the loci for the α, β, and γ chain 
gene segments are located on different chromosomes or discreet from one another on the 
same chromosome (TCRγ is found discreet from TCRβ on chromosome 7q34), the δ 
chain locus is interspersed entirely within the α chain locus on chromosome 14q11 
(Figure 1.6) [202].   
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Figure 1.6: Somatic recombination of semi-randomly selected germline 
encoded TCR gene segments is required to form the variable regions of 
TCRs. The α- and γ-chains are composed of only V and J segments and therefore 
require only a single VàJ rearrangement. The β- and δ-chain variable regions are 
composed of V, D and J segments, the first rearrangement joins a DàJ, and the second 
rearrangement joins a VàDJ. While the β (middle) and γ (bottom) genes are located 
discreetly on chromosome 7, the δ segments are interspersed within the α locus (top) on 
chromosome 14. The multiplicity of V, D, and J gene segments allows successive 
rearrangement events to occur if an unproductive rearrangement leads to an inadequate 
receptor chain. This process may continue until either a productive rearrangement occurs 
of the supply of gene segments is exhausted. Figure adapted from Schoettle et al. 2015 
[139]. 
 
 
 
 
 
 
47 
During the lineage commitment process of T cell development, simultaneous 
reorganization of the TCRβ, γ, and δ loci will occur prior to TCRα reorganization. 
Signaling from the productive reorganization the TCRβ locus producing a TCRβ chain 
paired with the pre-TCRα chaperone protein will halt further reorganization and allelic 
exclusion of the γ and δ loci, and follow with TCRα gene rearrangement leading to αβ T 
cell lineage commitment [203]. Conversely, should productive rearrangement and 
signaling via the γδTCR occur prior to β chain rearrangement, allelic exclusion of the 
TCRβ and α loci will occur as the cells progress to γδ T cell commitment. The nature of 
this process may account for the quantitative bias towards commitment of T cells to the 
αβ lineage rather than γδ lineage as only successful rearrangement of a single loci  
(TCRβ) needs to be accomplished for αβ commitment whereas both the γ and δ chain 
loci need to be successfully rearranged for γδ commitment [204], however subsequent 
positive and negative selective processes αβ T cells are required to pass may negate 
overall numbers as γδ T cells are not subjected to these restrictions.  
 The key enzymes involved in the somatic recombination of the TCR gene loci are 
the recombination activation genes 1 and 2 (RAG1/2). The temporal control of 
expression of these genes determines the order by which the TCR alleles and loci are 
rearranged. The RAG1/2 complex is responsible for joining different gene segments 
together and mediating the splicing and rejoining events that lead to gene recombination 
[205]. It was recently demonstrated that RAG1/2 recruitment sites are most likely based 
on differential histone methylation of pairing TCR loci, ensuring the maintenance of tight  
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control of recombination only between loci on the same chromosome and also possibly 
for allelic exclusion [206], however it remains unclear what signals might mediate such 
differential methylation. Following recruitment, RAG1/2 recognition of specific 
palindromic recombination signal sequences (RSSs) ensures correct gene segment 
selection within each chromosome. These RSSs will employ either a 12mer or 23mer 
spacer region (corresponding to one and two turns of the DNA double helix, respectively) 
and will be flanked by semi-conserved heptamer and nonamer sequences preceding 
and/or following each V, D, and J gene segment [207].  The 12 and 23 nucleotide (nt) 
spacers may bind to the RAG1/2 complex differently which allows for pairing of 12mer 
RSSs with 23mer RSSs. Gene segments flanked by a 12mer RSS will only recombine 
with segments flanked by a 23mer RSS [208]. More importantly, for TCRα chain 
recombination this ‘12/23 rule’ ensures that V segments (flanked by 23mer RSSs on the 
3’ side) recombine to J segments (flanked by 12mer RSSs on the 5’ side) and not with 
other V segments, and for TCRβ chain recombination D segments (flanked by 23mer 
RSSs on the 3’ side) recombine with J segments (flanked by 12mer RSSs on the 5’ side) 
and V segments (flanked by 23mer RSSs on the 3’ side) recombine to D segments 
(flanked by 12mer RSSs on the 5’ side).  The temporal organization of these 
recombination events is coordinated to the developmental stage of the precursor T cell 
[208] and will be discussed in detail below (Figure 1.7).   
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Figure 1.7: Recombination signal sequences (RSSs) ensure correct 
V(D)J recombination. The recombination of V, D, and J gene segments is directed 
by sequences referred to as recombination signal sequences (RSS), which flank the 3’ 
side of V segments, both sides of D segments and the 5’ side of J segments. There are 
two types of RSSs, one containing a 12nt spacer and one with a 23nt spacer. 
Recombination of VDJ genes can only occur between genes flanked by different RSSs 
(“12/23 rule”). Both RSSs are comprised of their respective 12 or 23nt spacer flanked on 
either side by a 7nt heptamer and 9nt nonamer. In addition to their function of providing 
recognition sites for enzymes to cut and rejoin the DNA, RSSs also ensure that correct 
joining of gene segments occurs: VàJ for TCRα/γ (top), and DàJ followed by VàDJ 
for TCRβ/δ (bottom). Figure adapted from Schoettle et al. 2015 [139].  
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 One important consequence of this process relies on the inherent diploid 
organization of the human (and mouse) T cell genome. As diploid cells, T cells possess 
two alleles for each TCR loci. However, the majority of T cells in an individual express 
only a single TCRβ chain on each cell. While allelic exclusion of the alternate TCRγ/δ 
loci is most likely RAG1/2 expression mediated, it is currently unknown whether any 
additional signaling is required or if it is a stochastic process. Should an unproductive 
rearrangement at one TCRβ allele occur, there is an equal probability for the second 
allele to undergo rearrangement or for the first allele to rearrange again [209].  However, 
upon successful β chain rearrangement, pairing with the surrogate pTα chain, and 
intracellular signaling, down regulation of RAG1/2 expression will terminate 
rearrangement of the γ, δ, and other β allele [203].  While the vast majority of mature T 
cells express a single β chain, current estimates suggest that a significant fraction of T 
cells (30%) will express two distinct α chains [210, 211]. This is believed to be due to the 
fact that TCRα rearrangement may continue for some time after the first successful α 
chain rearrangement. Unlike the events following TCRβ rearrangement, where 
immediate signaling halts further loci rearrangements, upon successful TCRα 
rearrangement arrest of successive rearrangements depends on signaling during positive 
selection (MHC restriction) and CD4 vs CD8 lineage commitment which allows 
sufficient time for additional TCRα rearrangements on the other allele [210]. However, 
while many cells may express two distinct TCRα chains, only one of the two is likely to 
recognize antigen presented by self-MHC when paired with the TCRβ chain (thus  
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passing positive selection), and therefore even cells expressing two TCRα chains will be 
specific to a single antigenic epitope although it has been postulated that these cells may 
be responsible for some cases of allergy or autoimmunity [212]. Continued research into 
simultaneous quantification of both TCRα and TCRβ from individual cells will be 
required to rectify these potential discrepancies.  
 
Somatic rearrangement of TCR genes occurs in precise steps corresponding to 
consecutive stages of T cell development 
 Following NOTCH signaling from bone marrow stromal cells, precursor T cells 
will upregulate CCR9 and migrate from the bone marrow to the thymus to complete their 
development [213]. Entering as double negative (DN) cells, these cells will progress 
through multiple stages of development (i.e. DN I, DN II, DN III, DN IV, early DP, late 
DP, single positive) during which a highly organized and regulated series of events will 
lead to TCR recombination. These events are both spatially and temporally regulated 
throughout the thymus, ensuring that only T cells with productively rearranged TCR that 
are not self-reactive are permitted to leave the thymus to the peripheral circulation 
(Figure 1.5). 
 The process of somatic recombination occurs in both T cells and B cells creating 
TCRs and BCRs, respectively. These recombination events occur between semi-
randomly selected gene segments (V and J or V, D, and J) encoded in the T or B cell’s 
germline DNA. This highly regulated and intricate process involves the selection, 
splicing, and recombination of discreet gene segments from discrete sites on the same 
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chromosome. The variable domains of TCRα (and γ) result from the recombination of V 
and J segments, while the variable domains of TCRβ (and δ) result from the 
recombination of V, D and J segments. While only a single recombination event is 
necessary for alpha chain rearrangement (VàJ), two recombination events are required 
for beta chain rearrangement (DàJ proceeded by VàDJ). The recombination events 
between these gene segments are coordinated to the developmental stage of the precursor 
T cell. It is hypothesized that the specific sequences of the RSSs juxtaposed to each gene 
segment influence the order of the recombinations by differential binding to the RAG1/2 
complex [208]. Some form of hierarchical RAG1/2 binding preference may help to 
ensure DàJ recombination is always followed by VàDJ for the TCRβ chain, such that 
no VàJ recombination events occur.   
 Following RAG1/2-mediated synaptic complex formation between two gene 
segments, the RAG1/2 complex will cut the strands by generating double stranded breaks 
(DSBs) in the DNA between the RSS and the coding portion of the V/D/J segment [209]. 
Initial RAG1/2 cleavage occurs between the coding sequence 5’ end of the heptamer 
portion of the RSS and is followed by cleavage on the opposite strand, generating 
hairpins in the RAG-maintained coding strands and free ends for the noncoding strands 
containing the excised RSSs. For the recombination of two gene segments in the same 
5’à3’ orientation, the excised portion of DNA (referred to as an excision circle or signal 
sequence) will be bound by the Ku70/80 protein complex (also involved in 
nonhomologous end joining DNA repair mechanisms) and ligated together by DNA 
Ligase IV. For the joining of two sequences inverted to one another in reading frame, an 
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inversion of the DNA strand will occur, and the intervening non-coding sequence will be 
sequestered at a distal site in the genome [209].  
 Following RAG1/2 strand cleavage and hairpin formation the gene segments to be 
recombined will be held in close proximity to each other by the RAG complex, and the 
binding of Ku70/80 will then stabilize the hairpin structures. At this point junctional 
diversity is generated between the gene segments. Activation of the enzyme Artemis by 
the protein kinase DNA PKcs will allow Artemis to randomly cleave the coding sequence 
hairpins held by Ku70/80. This random cleavage creates palindromic (P-) nucleotide tails 
on the ends of the coding strands [214]. While discussed in further detail below, it should 
be mentioned that along with the random selection of each of the many possible gene 
segments to recombine, this represents one of the key steps in the generation of diversity 
in the TCR repertoire. After the random cleavage of the DNA strands by Artemis, the P-
nucleotide tails will be aligned by XRCC4 and the Cernunnos proteins allowing for the 
recruitment of the next key enzyme terminal deoxynucleotide transferase (TdT) [215]. 
TdT mediates the next key step in TCR diversity generation by adding non-templated (N-
) nucleotides to the 3’ ends of the palindromic tails. Short stretches of complementarity 
between the P- and N-nucleotides most likely facilitates brief pairing of the two strands 
which allows DNA exonucleases and polymerases (Polλ and/or Polµ) to remove unpaired 
nucleotides and fill in any remaining gaps in between the DNA strands. Once the junction 
between the two gene segments is aligned and all regions have been complimentarily 
paired, recombination will be completed by DNA Ligase IV that seals the final nick 
between the two strands (Figure 1.8) [207].
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Figure 1.8: Somatic recombination of TCR gene segments. T cell receptor 
gene rearrangement of variable (V), diversity (D) and joining (J) gene segments generates 
an enormous repertoire of antigen receptors with different specificities. (1) RAG1/2-
mediated synaptic complex formation occurs between semi-randomly selected gene 
segments (V and J depicted above) encoded in the T cell’s germline DNA. (2) Cutting the 
strands by inducing DSBs in the DNA between the RSS sequences and the coding portion 
of the V/D/J genes, the RAG1/2 complex then generates hairpin loops in both stands. The 
excised portion of DNA, referred to as the excision circle or signal sequence, will be 
bound together by Ku70/80 and ligated by DNA Ligase (not shown). (3) Binding of 
Ku70/80 will stabilize the hairpin structures as DNA PKcs activates Artemis who will 
randomly cleave the hairpins creating P-nucleotide tails. TdT and exonucleases will then 
add/remove N-nucleotides to the 3’ ends of the palindromic tails. (4) Following 
alignment and pairing of the two strands, DNA Ligase IV will seal the final nick. 
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 While the events that occur during somatic recombination are under high levels of 
enzymatic regulation, the order of the recombination events is also under high levels of 
regulation throughout T cell development. The entire process leading to expression of a 
membrane-bound αβ (or γδ) TCR is preceded by the progressive expression of specific 
enzymes and/or cell-surface proteins that mediate each consecutive genetic 
rearrangement or cell proliferative event. As previously mentioned, precursor cells 
entering the thymus do so without expression of either CD4 or CD8 co-receptors. The 
first portion of this DN stage (DN I) involves the initial expression of the RAG1/2 
proteins, resulting in initial Vβ and Vδ DàJ rearrangements as well as Vγ VàJ 
rearrangement. As the cells finish their initial TCRβ/γ/δ rearrangements the T cell 
precursors will advance to the DN II stage where they will complete TCRβ/δ 
recombination of VàDJ gene segments. During the DN III stage the cells will be 
analyzed for expression of either a γδ TCR or a pre-TCR consisting of a β chain paired 
with the surrogate pTα. Expression of a functional β:pTα pre-TCR results in pTα cross-
linking between pre-TCR on the same cells that leads to CD3 signaling-mediated down 
regulation of RAG1/2 expression through the ETS1 transcriptional regulator thus 
temporarily halting additional recombination events. Once this has occurred, termination 
of expression of pTα via the ID3 transcriptional regulator will release the inhibition on 
RAG1/2 expression for downstream recombination events [216]. However, should 
successful γδ rearrangement precede β chain rearrangement and pre-TCR signaling, the 
γδ T cells will exit the thymus with no apparent positive or negative selection events 
[217].  
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 Following successful DN III stage signaling through the β:pTα pre-TCR, the cells 
will begin to proliferate as they enter the DN IV stage. Sometimes referred to as ‘β 
selection’ [218], this event is a critical checkpoint during T cell development that allows 
for expansion of T cell precursors that have successfully rearranged their TCRβ chain 
[207]. This creates a pool of mono-clonal TCRβ expressing cells that may independently 
rearrange their TCRα chains creating unique TCRαβ combinations, giving rise to the 
final level of TCR diversity; αβ combinatorial diversity. 
 Following the proliferation of cells at the end of the DN IV stage, re-expression of 
the RAG1/2 proteins initiates TCRα VàJ rearrangements. While enhancer-/promoter-
dependent changes in chromatin structure are the mechanisms behind RAG accessibility 
to RSSs, it is still poorly understood how the delayed ‘opening’ of the TCRα locus until 
after TCRβ/γ/δ ‘opening’ and rearrangement [209]. Accompanying the completion of 
TCRα rearrangement, expression of both CD4 and CD8 co-receptors advances the 
precursor cells to the DP stage of T cell development. Upon reaching the early portion of 
the DP stage, the cells may express a complete αβ TCR and the process of positive 
selection ensuring self-MHC restriction ensues. Once a threshold TCR:MHC interaction 
has occurred, the cells will progress to the late DP stage and CD4/CD8 lineage selection 
will cause down regulation of one of the two co-receptors creating single positive (SP) 
cells. Upon reaching the SP stage, cells will undergo the final process of negative 
selection where autoreactive cells will be deleted from the developing repertoire. As 
mentioned previously, due to the rigorousness of the multiple genetic rearrangements,  
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positive selection, and negative selection, the vast majority of developing cells will not 
survive development, with only 1-2% ultimately exiting to the periphery [199].  
 
Complementarity determining regions and the structural basis for T cell antigen 
recognition 
 The process of somatic recombination of V, D, and J gene segments produces 
variable regions on the distal portions of the TCRα and TCRβ chains and thus constitute 
the repertoire of T cell antigen receptors. These variable regions recognize antigenic 
peptide fragments presented on MHC molecules by infected, cancerous, or antigen 
presenting cells. Following somatic recombination, each protein variable region will 
contain three highly diverse loops, termed complementarity-determining regions (CDRs) 
1, 2, and 3 that make direct contact with the peptide and/or MHC molecule [219]. The 
CDR1 and 2 loops are directly encoded within the randomly selected V gene segment 
portion of the TCRα or TCRβ chain, however the CDR3 loops are encoded by a region 
spanning the 3’ end of the V gene segment, the D gene segment (β chain only), the 5’ end 
of the J gene segment, and the random P- and N- nucleotide junctions between them 
[220]. Therefore, compared to the CDR1 and 2 loops, CDR3 loops are significantly more 
diverse due to the nucleotide additions and losses between the junctions of the V-J (α 
chain), and V-D-J (β chain) gene segments. Furthermore, in addition to the diversity in 
amino acid sequence, CDR3 loops may also differ in loop length [221]. While CDR3 
loop lengths between paired BCR/antibody heavy and light chains (and γδ TCR chains) 
are relatively broad and unmatched [219], the loop lengths between paired TCR α and β 
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chains are narrow and closely matched, suggesting the possibility that functional αβ 
chain pairing may be determined by CDR3 loop length [219, 222]. 
 Similar to antibodies that recognize protein ligands [223], the site of pMHC 
antigen recognition on the TCR is relatively flat, which is consistent with similarly flat 
nature of the pMHC complex [224, 225]. Using x-ray crystallography, it has been 
determined that most TCRs have a cleft between the α and β chain CDR3s possibly for 
accommodation of a central upward facing side chain from the antigenic peptide [226]. 
This property has led to the speculation that the majority of peptide discrimination is 
contingent on CDR3 interaction, consistent with the higher level of diversity observed in 
CDR3s than their counterpart CDR1 and 2s. While the majority of antigenic peptide 
contact occurs via the CDR3 loops, CDR1 and 2 make major contacts with the conserved 
structural elements of the MHC molecule (Figure 1.9) [205].  
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Figure 1.9: Complementarity determining regions (CDRs) 1 and 2 
mainly contact the self-MHC protein while the highly diverse CDR3 
region makes major antigenic peptide contact. [A] The coding sequences for 
the CDR regions correspond to three hypervariable regions (HVRs) of DNA for each 
TCR chain. While HVR 1 and 2 (corresponding to CDR1 and 2) are germline encoded 
within each given V gene, HVR3 (corresponding to CDR3) is encoded by the imprecise 
junction of the V, D, and J gene segments for TCRβ or V and J gene segments for TCRα. 
[B] Crystal structure solutions of TCR:pMHC complexes have repeatedly shown that 
although all three CDR can contact both MHC and bound peptide epitopes, CDR1 and 2 
(pink and blue, respectively) make contact primarily with the MHC protein (green) while 
CDR3 (red) is typically centered over the bound peptide (yellow). [C] Crystal structure of 
complete TCR:pMHC complex. Crystal structures adapted from Garcia et al. 2012 [227]. 
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An overview of TCR diversity 
 In order for the immune system to combat the ever increasingly diverse number of 
pathogens it may encounter in an individual’s life time it has developed an immensely 
large repertoire of T cells with unique TCRs where only a few clones will be specific for 
any given antigen. Estimations for the number of different possible TCRs encoded in the 
genome (the potential repertoire) and methods for quantifying the number of TCRs 
present in an individual (the realized repertoire) have both been attempted numerous 
times over the past 16 years and as technology improves the values for both estimates 
continue to rise [192, 228-232].  
 A functional immune system must possess both vigorous reactivity against 
pathogens and a lack of overt self-reactivity [228]. These defining features are inherently 
postulated by the clonal selection theory [233], which states that lymphocytes express a 
highly diverse, clonally distributed set of antigen-specific receptors, and upon antigen 
recognition, expansion of antigen-reactive cells provides sufficient protection from the 
infection. As the immune system cannot predict which pathogens it may encounter in a 
given lifetime, it relies on maintenance of a highly diverse TCR repertoire. Following the 
elucidation of the process of somatic recombination [220], the puzzle of how such 
diversity is generated was discovered.  
 As discussed above, diversity in reference to the TCR repertoire is mainly 
confined to the CDRs that make contact with the pMHC. Specifically, the diversity of 
generated CDR3 regions is due to 4 main contributors: (1) the stochastic selection of one 
from a number of possible V, D, and J gene segments, (2) semi-random DNA cleavage 
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by the enzyme Artemis leaving P-nucleotide hairpins, (3) N-nucleotide addition and 
subtraction by TdT and exonucleases at the junctions of the V, D, and J genes, and (4) the 
pairing different α and β chains to generate the functional receptors [205]. The seminal 
paper by Arstilla et al. published in 1999 [192] estimated diversity generated by this 
process to be capable of producing 106 unique TCRβ chains per person and similar 
estimates for TCRα, yielding a possible 1012 unique TCRαβ pairs (should completely 
random pairing of α and β chains be possible). However, more recent investigations have 
increased this estimate to 1016-1020 unique pairs [96, 230]! Interesting to note, adult 
humans have roughly1012 T cells [192] (mice have roughly 108 [234]) and it is known 
that some T cells will express the same TCR [228], so while the theoretical diversity may 
be as high as 1016-1020 possible receptors, a given human will actually express fewer than 
1012 at any given time.  
 Estimates of the actual αβ T cell diversity expressed in humans were first 
obtained by extrapolation from small sub-samples of molecular measurements of TCR 
diversity using the ‘specratype’ or ‘immunoscope’ technique [222, 235]. Calculations 
from such methods produced an estimate of approximately 2.5x107 unique naïve αβ T 
cells per person; with 100 fold fewer unique antigen-exposed memory T cells. 
Interestingly, although four orders of magnitude smaller in cell number (1012 T cells in 
humans vs 108 T cells in mice), the actualized mouse αβ TCR repertoire was estimated to 
be near 2x106, only 10x less diverse than estimates for humans [236]. These early human 
estimates were most likely skewed however, as the methodology relied heavily on 
exhaustive capillary-based sequencing of rearranged TCR genes expressed in small, well-
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defined subsets of the repertoire, and then extrapolation of these subsets was applied to 
the entire repertoire [96]. The biases inherent in extrapolation severely limited these early 
estimates and recent advancements in technology have demonstrated that the actual 
number of unique αβ T cells may be 2-4 times as large [232, 236]. While all these 
estimates are thought to be somewhat minimalistic, given the limits in the total number of 
circulating cells they have been widely held to most likely convey realistic values [228]. 
 As previously mentioned, the diversity of the theoretically achievable TCR 
repertoire may be as high as four orders of magnitude greater than the actual repertoire 
(due to the limited number of T cells in an individual). This discrepancy may account for 
the differences in TCR repertoires between any two given individuals. In fact, it was 
found that even between genetically identical inbred mice, only 20-25% of TCRβ 
sequences were shared [236]. Additionally, alymphoid animals receiving spleen cells 
from the same donor were analyzed for TCR sequence homology, however 80% of 
discovered TCR sequences were unique [237]. Even genetically identical animals 
infected with the same strains of lymphocytic choriomeningitis virus (LCMV) responded 
with proliferation of different TCR sequences [238]. Therefore, while relatively high 
levels of diversity exist across the TCR repertoire, most clones will be found at a very 
limited copy number, and the constraints in the total number of cells found in a single 
individual only allows for a fraction of the potential diversity to be expressed at any 
given time.  
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Current approaches for analyzing TCR diversity 
 In the original experiments assessing the diversity of immune receptor repertoires 
a technique known as spectratyping/immunoscoping was utilized. Spectratype analysis 
utilizes polymerase chain reaction (PCR) technology to amplify cDNA reverse 
transcribed (RT) from immune receptor mRNAs [239]. The rearranged mRNA transcripts 
maintain different CDR3 lengths from specific TCR (or BCR) variable region genes due 
to the random VDJ gene selection and insertion/deletion of nucleotides at the gene 
segment junctions. Extrapolation from a small subset of these samples to account for the 
entire repertoire is then performed to estimate total TCR diversity. 
 A seminal review by Nikolich-Zugich outlines the four main steps to the 
spectratyping procedure [228]. First, the CDR3 of a selected Vβ-Jβ rearrangement (i.e. 
VB1-Jβ1) from a population of T cells is amplified by PCR following RT of purified T 
cell mRNA. Products from the PCR reaction will be separated by polyacrylamide gel 
electrophoresis (PAGE) based on CDR3 length (commonly referred to as CDR3 length 
polymorphism analysis [222, 235]). All the products of a given CDR3 length (N-
nucleotides) will migrate as a single band; typically 6-10 bands will be visible for any 
given Vβ-Jβ rearrangement, distributed in a Gaussian profile [192, 235, 236]. Second, 
quantification of the relative abundance of each band corresponding to CDR3 length is 
performed (i.e. a 10 amino acid CDR3 corresponding to a 30 nt band may constitute 11% 
of all amplified sequences). The band from the chosen Vβ-Jβ rearrangement of specific 
CDR3 length is excised from the gel for downstream analysis. Third, once the DNA from 
the excised band has been purified, the PCR products belonging to said band are 
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exhaustively sequenced until no new sequences are detected. The resulting number of 
sequences (X) corresponds to the diversity of TCRVβ sequences belonging to the 
selected Vβ-Jβ combination (i.e. Vβ1-Jβ1) with CDR3 length corresponding to the 
selected band excised from the gel (i.e. 30 nt). Finally, extrapolation to all TCRVβ 
sequences belonging to the selected Vβ-Jβ rearrangement (i.e. Vβ1-Jβ1) regardless of 
CDR3 length (for the previous example, the 30 nt band constituted 11% of all Vβ1-Jβ1 
rearrangements: X x 0.11 = % of total combination). The summary of this statistic 
represents the total β chain diversity. The number of different α chains found to pair to 
the given β chain (originally estimated to have a lower limit of ≥25 α chains per β chain 
[192]) is then used to calculate the total diversity of the repertoire. Using this method, it 
was determined that the human repertoire contained 2.5x107 different TCR clonotypes 
and the mouse repertoire was an order of magnitude smaller at 2x106 different clonotypes 
[192, 236]. 
 While highly novel and groundbreaking at the time, these previous assessments of 
diversity relied on massive extrapolation from extremely limited subsamples applied to 
the entire repertoire. As previously stated, due to the necessity of such extrapolations, 
accuracy and precision of this method was severely limited, and researches sought to 
improve upon methodologies for estimation of actual immune receptor repertoire 
diversity analysis.  
 The recent developments in high throughput sequencing technology has provided 
us with a much more powerful tool than the capillary-based sequencing technology that 
was afforded researchers when the analysis of TCR diversity began nearly 20 years ago. 
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Specifically, the illumina-based platforms allow for parallel sequencing of millions of 
short reads simultaneously in a few hours [240]. This has both increased the accuracy and 
precision by which diversity estimates can be made.  
 Harlan Robins and a team of researchers in Seattle have pioneered current modern 
immune receptor repertoire diversity analysis by adapting standard next generation 
sequencing technology specifically tailoring it for the analysis of large polyclonal 
immune receptor samples. Using unique sets of multiplex primer systems, ‘ImmunoSEQ’ 
technology allows for the simultaneous sequencing from genomic DNA of the differently 
rearranged TCRβ CDR3 regions expressed by millions of T cells. What became the 
standard of immune repertoire analysis, ImmunoSEQ enables the direct sequencing of a 
much larger (significant) fraction of CDR3 sequences than spectratyping, and due to the 
massively parallel nature of next gen sequencing, the samples may contain diversity far 
exceeding the capability of capillary-based DNA sequencing instruments. Finally, the use 
of high throughput sequencers also allows for estimation of the relative frequency for 
each CDR3 sequence discovered in a given population [232].  
 Generation of the library of human TCRβ CDR3 encoding sequencing amplicons 
using the ImmunoSEQ technology requires the use of multiple comprehensive multiplex 
primer sets. Equimolar pools of 45 Vβ forward primers (Vβ F primers) and 13 Jβ reverse 
primers (Jβ R primers), each specific to the known functional human TCRβ V and J gene 
segments were generated. Additionally, each primer contains at the 5’ end the universal 
forward and reverse primer sequences compatible with the base Illumina sequencing 
technology. While the entire amplicon generated by this method is roughly 200bp, the 
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average length of any given CDR3 region is 35 ± 3 base pairs [241], so all sequencing 
reads progressing from the J gene segment primers should capture the entire CDR3 
regions [239]. Using the ImmunoSEQ technology, the number of unique TCRβ 
sequences in healthy male adults was estimated to be between 3-4x106 [232], roughly 4x 
greater than estimates using the spectratyping method (Figure 1.10).  
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Figure 1.10: ImmunoSEQ strategy for TCRβ  chain deep sequencing. Equimolar 
pools of 45 Vβ forward primers and 13 Jβ reverse primers, each specific to the known 
functional human (or mouse - not shown) TCRβ V and J gene segments are combined in 
a dual multiplex PCR reaction to amplify all recovered TCRβ DNA. Proprietary software 
offered by Adaptive Biotechnologies allows customers to analyze millions of individual 
TCRβ chain V, D, and J gene frequencies, amino acid sequences, or even CDR3 
nucleotide sequences at a massively parallel level. Image adapted from Adaptive 
Biotechnology’s home web site [242]. 
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Chapter 2 outlines initial data from single chain (TCRβ) analyses that led to the finding 
of a lack of a ‘publicly’ distributed TCR repertoire. 
 
Limitations of currently available technology for the analysis of immune repertoires 
 The technological advancements in high throughput massively parallel 
sequencing have allowed for a much more comprehensive subsampling of the full 
immune repertoire. However, even with our improved sequencing capability, accurate 
estimation of the diversity of TCRβ CDR3 sequences in an entire αβ T cell repertoire 
requires measuring diversity in a finite number of sampled T cells followed by estimation 
of the number of CDR3 sequences not present in the sample. Statisticians have long since 
dealt with this issue in numerous fields of science, especially in population ecology. 
Commonly referred to as the ‘unseen species problem’ [243], estimation of species 
diversity in large populations from measurements in random, finite samples can be 
applied to the estimation of TCRβ CDR3 diversity [232, 244]. 
 TCR diversity can be defined using the Venturi strategy for measuring the 
diversity of species [245, 246]. Here, a species refers to a unique TCRα/TCRβ pair. The 
simplest measure of diversity used by ecologists, species richness, equals the total 
number of species, but ignores the relative abundance of different species. To provide a 
more accurate assessment of species diversity, we will use the Simpson Diversity Index 
(D = 1- ΣΦf2) where Φf is the frequency of BCR clones with abundance f in the 
population [247, 248]. Although diversity indices that encapsulate diversity in terms of a 
single number can be easily estimated by determining the frequency of sampling the 
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same species repeatedly, the data collected allows researchers to generate a much more 
comprehensive measure of species diversity: the frequency spectrum, sometimes called a 
Preston plot in ecology [249, 250]. The frequency spectrum will give us both the number 
of unique species (TCRαβ pairs) as well as their relative frequencies in the population. 
This approach was also used in the pioneering studies by Kourilsky et al. (among many 
others),when they measured the sequence diversity of TCR α and β chains [192, 232, 
236]. 
 The use of two multiplex primer systems (V gene segment multiplex and J gene 
segment multiplex) is required for amplification prior to sequencing. Inherent differences 
in primer-kinetics may potentially generate systematic bias in the inferred relative 
abundances of CDR3 sequences [232]. Furthermore, errors introduced by the 
polymerases used in the amplification and sequencing may artificially create ‘new’ 
CDR3 sequences. This will produce a Luria-Delbrück distribution of final CDR3 error 
frequencies, and as these errors will likely occur at random and be present at low copy 
numbers, the raw counts of rare CDR3 clones may be artificially inflated [251]. Both of 
these issues can be accounted for using unique algorithms that take into account both 
individual primer-kinetics and base polymerase fidelity error rates, respectively.  
 To estimate the magnitude of bias introduced due to primer-kinetics differences, 
samples of roughly 30,000 unique T cells were amplified for 25 PCR cycles, samples 
were split in half, and one half was amplified for an additional 15 cycles (40 cycles total). 
Both samples were then sequenced independently, and compared to one another for 
discrepancies. A linear correlation was observed after plotting the number of observations 
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of the 30,000 sequences from each sample. Attributing the mean variation about the line 
of correlation (1.5 fold) entirely to PCR bias, it was determined that each cycle of PCR 
amplification potentially induces bias on average of 1.51/15 = 1.027 [232]. Use of the 
immunoSEQ strategy, which employs 25 rounds of dual-multiplexed CDR3 amplification 
before sequencing, would thus potentially introduce biases of average magnitude 1.02725 
= 1.95 in the inferred relative abundance of distinct TCRβ CDR3 sequences.  
 Similarly, if n number of CDR3 regions is sequenced, each of length L, and the 
empirically defined per-base error rate is ε, one should expect nLε sequences to contain 
errors. The chance of the same error occurring multiple times, m, to the same sequence is: 
 
where c is the true copy number of the CDR3 clone and fc is the probability of a clone 
being present in c copies. Thus, the chance of multiple coincident errors decreases 
exponentially. Correcting for these sequencing errors is analogous to challenges faced 
during statistical inference from high coverage, pooled, or metagenomic sequencing 
projects in which the observed data are modeled as a convolution of the true data and the 
error probabilities [252].  
 While the above-mentioned problems due to PCR bias and enzyme fidelity can be 
accounted for both empirically and systematically, there is an additional area of concern that has 
yet to be addressed. As heterodimeric receptors, αβ TCRs are composed of two chains generated 
by independent rearrangements of both the TCRα loci and the TCRβ loci. The theoretical 
diversity that can therefore be generated is thus greatly increased due to combinatorial efforts by 
pairing any one of the numerous TCRα chains with any one of the numerous TCRβ chains. And 
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while it has been estimated that any given unique TCRβ chain will pair with on average 25 
different TCRα chains [192], determining the actualized number of unique TCRαβ pairs in an 
entire TCR repertoire will require technological advancements that can somehow covalently link 
the α and β chain CDR3 sequences from individual T cells into a single ‘amplicon’ suitable for 
downstream sequencing. It then goes with out saying that pursuit of such innovation has been the 
gold standard of modern immune receptor repertoire research.  
 
Current technological advancements in single cell sorting and additional approaches 
for pairing TCR mRNA sequences 
 Numerous strategies have been attempted to accomplish high-throughput single-
cell sequence analysis of polyclonal cell populations. There are many biological 
questions that require single-cell analysis of gene sequences, including analysis of 
clonally distributed dimeric immunoreceptors on lymphocytes [192, 211, 253, 254] and 
the accumulation of driver/accessory mutations in polyclonal tumors [255-258]. Lysis of 
bulk cell populations results in mixing of gene sequences, making it impossible to know 
which pairs of gene sequences originated from any particular cell and obfuscating 
analysis of rare sequences within large populations. Although current single-cell sorting 
technologies can be used to address some of these questions, such approaches are 
expensive, require specialized equipment, and lack the necessary high-throughput 
capacity for comprehensive analysis [259-261]. Water-in-oil emulsion approaches for 
single cell sorting have been developed [262] but droplet-based single-cell lysis and 
analysis have proven inefficient and yield high rates of false pairings. Ideally, molecular  
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approaches for linking gene sequences from individual cells could be coupled with next-
generation high-throughput sequencing to overcome these obstacles, but conventional 
approaches for linking gene sequences, such as by transfection with bridging 
oligonucleotides, result in activation of cellular nucleases that destroy the template, 
precluding this strategy as well [263-265]. Finally, combinatorics based methodology 
utilizing discreet high copy number sequences have been validated [266], but such 
combinatorics-based approaches are not capable of pairing low copy number sequences 
that constitute the majority of the TCR repertoire and more importantly may give rise to  
rare clones with high-anti-tumor/anti-pathogen activity.  
 Recent advances in the synthesis and fabrication of modular DNA origami 
nanostructures have resulted in new possibilities for addressing these and many other 
current and long-standing scientific and technical challenges in biology and medicine 
[267-270]. One exciting application of DNA nanotechnology in reference to immune 
repertoire profiling is the capability of the nanostructures with regards to intracellular 
capture and subsequent sequence analysis of mRNA from individual cells within 
heterogeneous cell populations [263, 271]. DNA nanostructures can be transfected into 
individual cells to capture and protect mRNA for specific expressed genes, and 
incorporation of a set of unique matching barcodes into the origami nanostructure may 
facilitate pairing and analysis of mRNA from individual cells by high-throughput next-
generation sequencing. This approach is highly modular and can be adapted to virtually 
any two (or possibly more) gene target sequences, and therefore has a wide range of 
potential applications for analysis of diverse cell populations such as understanding the 
 
73 
relationship between different immune cell populations, development of novel 
immunotherapeutic antibodies, or improving the diagnosis or treatment for a wide variety 
of cancers. 
Objectives 
 The following chapters outline a proposal to develop a novel DNA origami 
nanotechnology approach to analyze T cell receptor genes expressed in single cells 
within polyclonal populations, without the need for single-cell sorting. Specifically, it will 
be outlined how to use DNA origami nanostructures to capture and protect both TCRα 
and β chain mRNA in transfected T cells as a means of both quantifying actual TCR 
diversity (including that of αβ chain pairing) and making predictions about the payoff 
between diversity and protection. It will be shown that DNA origami nanostructures can 
be transfected into lymphocytes by electroporation with high efficiency, thus avoiding the 
endosomal/lysosomal degradation pathway, and are able to selectively bind and preserve 
lymphocyte immunoreceptor mRNA for subsequent analysis. Integral fluorescent labels 
on the DNA origami facilitate identification of transfected cells, and reisolation of the 
nanostructures with bound mRNA is achieved using integral biotin labels and avidin 
column purification. An important design feature of the DNA origami is that the mRNA 
capture sequences on any given nanostructure are linked to one another by a unique 5’-
5’ ‘bowtie’ linkage that includes matching complimentary barcodes; the recovered 
mRNA are reverse transcribed utilizing the origami capture probes as gene-specific RT 
primers thereby linking the cDNA to the bowtie-barcodes. Furthermore, as the DNA 
origami capture probes are required for priming the RT reaction, any unbound mRNAs 
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will not be amplified, improving selectivity and avoiding false pairing. Thus, the 
following chapters will be used to outline and validate this approach for obtaining paired 
TCRα and TCRβ sequences from single cells in large oligo- or polyclonal T cell 
populations (>106 cells/run), without the need for single-cell sorting. This approach will 
reveal potentially important rare T cell receptor sequences that are not identifiable in 
conventional approaches and avoid the high costs associated with single-cell sorting.
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CHAPTER 2 
ANALYSIS OF THE PUBLIC VERSUS PRIVATE NATURE OF THE CD8 T CELL 
TCRB CHAIN CDR3 REPERTOIRE AT THE V/J GENE SEGMENT AND AMINO 
ACID LEVEL 
ABSTRACT 
 The complex mechanism of somatic recombination of V, D, and J gene segments 
gives rise to the TCR and in doing so generates the diverse repertoire of lymphocyte 
receptors that is necessary for defense against infection. Modern deep-sequencing 
approaches enabled us to probe the ‘public’ versus ‘private’ nature of the TCRβ CDR3 
repertoire. We found that naïve TCR repertoires in any given individual are not “flat”, but 
rather display a gradient of TCR diversity with some precursors present at low numbers 
and others present in relatively high frequency. When comparing V and J gene usage 
between individuals, repertoires were very consistent and recombination frequencies 
between V and J gene segments were conserved as well. However, when comparing 
repertoires from different individuals at the amino acid level, major differences were 
observed, with only ~11.5% of sequences shared between any two individuals. As would 
be expected, the shared (public) fraction of CDR3 sequences correlates to the few 
sequences that are highly expressed in any given individual. These differences in TCR 
repertoires have many novel implications, such as why individuals display differing 
competencies in immune protection, for analysis of individuals post vaccination, or for 
analysis of immune reconstitution (such as after chemoablation). 
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IMPORTANCE 
 Thus far, TCR diversity has been described in terms of simple summary statistics, 
such as the number of distinct TCR (based solely on analysis of TCRβ chain sequences), 
which is analogous to species richness or the Simpsons diversity index in ecology that 
provides a single number to describe the relative abundance of different species [245-
247]. However, through the use of TCRβ multiplex sequencing, our findings suggests 
that simple summary statistics are inadequate to describe total diversity as these fail to 
include the frequency of each individual TCR species in the population, which can vary 
over 10,000-fold [272, 273]. Furthermore, previous studies (again based solely on TCRβ 
sequence data) have also roughly described individual TCR in absolute terms as either 
public (occurring in many individuals) or private (occurring rarely in individuals) [274, 
275]. By comparison of TCR repertoires between multiple genetically identical 
individuals we have determined that the naïve T cell receptor repertoire is very consistent 
among different individuals at the V and J gene level. Furthermore, when analyzing 
different subsets of V gene expression, the J gene recombination frequencies are 
conserved as well. However, analysis of these individual’s repertoires at the amino acid 
level revealed that major differences arise among even genetically identical individuals. 
Finally, as one might expect, the small shared (public) fraction of TCR gene sequences 
correlates to the few TCR gene sequences that are highly expressed in most individuals. 
These vast differences in “public” TCR gene sequences may help to explain the 
immunological variance in self-protective ability among different individuals.    
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INTRODUCTION 
 The adaptive immune system relies on a highly diverse repertoire of antigen 
receptors (TCRs and BCRs) with the goal enabling the host to mount highly specific 
immune responses tailored to virtually any encountered pathogen. The immune system’s 
response to pathogenic infection involves activation of highly biased profiles of antigen-
specific T cells, selected from a highly diverse naïve cell repertoire [233]. In the vast 
majority of T cell responses, the specific repertoire of T cells activated during a given 
immune response will be distinct between any two given individuals [276]. This ‘private’ 
T cell response constitutes the distinct T cells activated in immune responses to specific 
epitopes bearing TCRs that are rarely observed between any two individuals. 
Contrastingly, on some occasions antigen-specific TCR repertoires may be observed in 
multiple individuals, constituting a ‘public’ TCR repertoire. Interestingly, such public 
immune responses have been reported in a variety of immune responses, not only to 
pathogenic infections but also in malignancy and autoimmunity (Table 2.1) [229]. 
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Table 2.1: Examples of public TCRs in humans. Table adapted from Li et 
al. 2012 [276]. 
Disease Antigen TCRβV TCRβJ TCRαV TCRαJ Ref. 
Infectious Diseases       
EBV EBNA 3A339-347 7-6 2-7 26-2 52 [277] 
Cytomegalovirus IE1316-324 5-1 1-3 Unknown Unknown [278] 
Cytomegalovirus pp65103-114 28 2-7 8-6 30 [279] 
Parvovirus B19 NS1572-580 5-1 2-1 Unknown Unknown [280] 
Clostridium tetani Tetanus toxin 5-4 2-3 41 Unknown [281] 
HSV Virion P2249-57 10 2-1 8-1 27 [282] 
HIV Gag162-172 19 1-2 5 13 [283] 
Malignancy       
Melanoma Melanin-A26-35 27 2-1 12 34/45 [284] 
Cancer (multiple) NY-ESO1157-165 12-3 2-1 17 31 [285] 
Autoimmunity       
MS MBP83-99 6-5 2-7 23 10 [286] 
Reactive Arthritis Unknown 5 2-3 Unknown Unknown [287] 
Aplastic Anemia Unknown 9 2-1 Unknown Unknown [288] 
Psoriasis vulgaris Unknown 3 2-7 Unknown Unknown [289] 
Systemic sclerosis DNA Topo I 30 1-1 Unknown Unknown [290] 
Sarcoidosis Unknown Unknown Unknown 12-1 15 [291] 
Rheumatoid 
Arthritis 
Unknown 27 2-7 22 1 [292] 
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 In some instances, the observed public TCRs were shown to correlate with 
favorable outcomes, including SIV [293]. Additionally, studies of HIV-infected 
individuals demonstrating long-term non-progressive disease revealed a repertoire of 
shared TCRs displaying effective cross-reactivity of epitope variants [290, 294-296]. 
However, the effects observed from antigen-specific publicly shared TCR repertoires are 
not always favorable. It has also been observed that public TCR usage in SIV studies 
facilitated viral immune evasion [297]. The relative cost vs benefit of publicly distributed 
antigen-specific TCR repertoires will most likely be antigen-specific and require further 
research [276]. 
 While a publicly distributed T cell response to a given antigen between different 
individuals may seem obvious due to the fact that any given invading antigen (or self-
protein in terms of cancer or autoimmunity) will only provide a limited number of 
activating epitopes (and thus possible TCRs capable of recognizing and responding), the 
inherent prerequisite for such public T cell responses is the sharing of discreet TCRs in 
the naïve T cell repertoire between individuals. Therefore, in order for any public T cell 
response to occur to a given antigen, there must exist some amount of overlap of the 
naïve TCR repertoire [298]. The factors contributing to such overlap have been 
previously hypothesized [299-301]. 
 In order for public T cell responses to occur, there must be mature naïve T cells in 
different individuals with identical TCRs. In fact, previous studies have demonstrated 
that on average, any two individuals share 10.5% (±1.8%) of their expressed CDR3 
amino acid sequences [302]. These public subsets of T cells could arise from favorable 
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positive selection during T cell development or be due to a stochastic communal 
production during recombination events across individuals (or both) [276]. Mechanisms 
involving biases of thymic selective events during T cell development have been 
proposed [299, 300], however repertoires in DP thymocytes and mature naïve T cells 
have been demonstrated to show high levels of similarity [276], indicating thymic 
selective biases to play a relatively minor role in the public distribution of naïve TCR 
repertoires. Therefore, the majority of any commonality among naïve TCR repertoires 
between individuals must rely mainly on selective biases in VDJ recombination.  
 Pioneering studies by Venturi and colleagues [301, 303-305] outline the 
phenomenon of ‘convergent recombination’, and demonstrated that biases during VDJ 
combinatorial events are the major contributors of public TCR repertoires. Described as: 
“…the process whereby multiple recombination events converge to produce the 
same nucleotide sequence, and multiple nucleotide sequences converge to encode 
the same amino acid sequence, resulting in different TCR sequences generated 
with differential frequencies during recombination.” 
Venturi and others outlined biased V/D/J gene usage and further combinatorial biases 
(including not only biases between selected V, D, and J genes, but also biases in the 
number of nucleotide insertions/deletions at the coding ends of the VDJ junctions) [301, 
303-309]. With its inherent prediction that different TCR sequences have different 
expression frequencies, convergent recombination outlines why specific clonotypic 
frequencies of different TCRs display high levels of public distribution variation [276].  
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This theory was evaluated by the demonstration that TCRβ sequences with convergent 
features are present at higher copy numbers within individuals and are also shared 
between individuals at a statistically higher than average level [310], however it was 
determined that random convergent recombination processes are an insufficient cause of 
the relatively significant overlap observed in DP thymocytes, indicating involvement in 
other mechanisms as well [276].  
 While Venturi’s theory of convergent recombination demonstrates statistically 
significant predictions about the extent to which naïve TCR repertoires are shared 
between individuals, it accounts for less than half of the TCRβ sequence overlap 
observed in actualized TCR repertoires from separate individuals [276]. Furthermore, 
multiple groups have demonstrated that there are multiple TCR combinatorial sequences 
that should be preferentially produced due to convergent recombination that are present at 
lower clonotype frequency in any given individual, and therefore makeup a smaller 
proportion of the public TCR repertoire than would be predicted [274, 276, 303-305]. To 
account for this discrepancy, VDJ recombinatorial biases have been proposed as 
contributors to naïve TCR repertoire overlap that is not accounted for by convergent 
recombination [309, 311-313].  
 Extensive preferences have been observed in the usage frequencies and pairing 
frequencies of different VDJ gene segments during TCR recombination [309, 311]. 
Skewed usage patterns of individual Vβ, Dβ, and Jβ gene segments have been observed 
in human lymphocytes [311], as well as well as non-random usage of Jβ gene segments  
  
 
82 
in human Vβ17 gene segment repertoires [309]. Furthermore, statistically preferential 
pairing between specific Vβ genes with specific Dβ and Jβ genes has also been shown 
[208, 312]. Additionally, there are statistically significant differences between the various 
Vβ and Jβ gene segments in terms of the numbers of ‘random’ exonuclease-removed 
nucleotides from the 3’ end of V gene segments and the 5’ end of J gene segments [314]. 
Should a given exonuclease cleavage of a gene segment preferentially result in a multiple 
of 3 nucleotides in its junction it may be expressed (due to functionality) at a higher level 
than a gene segment resulting in random numbers of remaining nucleotides. Furthermore, 
the specific base usage frequencies during TdT N-nucleotide addition for given VDJ 
junctions is also not random [276, 308, 309].  
 While the aforementioned convergent recombination and recombinatorial biases 
during TCR repertoire development may account for the ~10.5% TCRβ CDR3 homology 
between individuals, it should be mentioned that these biases were demonstrated in the 
pre-selected DP thymocyte population, and therefore losses due to positive and negative 
selective events may reduce the actualized intrinsic convergent/recombinatorial biases 
inducing public repertoire formation in the actual circulating repertoire [276, 315]. 
Overall however, it is clear that the development of TCR repertoires is not as random as 
once proposed, and the selective pressures due to convergent recombination and 
recombinatorial bias may contribute to the small level of a ‘publicly’ distributed naïve 
TCR repertoire [229, 276]. 
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 In chapter two we utilize single chain (TCRβ) sequence analysis of mouse naïve  
CD8+ T cells to provide key insight into the public vs private nature of somatic 
recombination of naïve CDR3 sequences. Specifically, we demonstrate homology 
between individuals at the Vβ and Jβ gene usage level consistent with the previous 
studies mentioned above. However, at the amino acid level, differences begin to arise 
among even genetically identical individuals when analyzing the supposedly ‘public’ 
distribution of naïve TCRβ CDR3 sequences. 
 
MATERIALS AND METHODS 
 Mice: 6-8 week old C57BL/6 mice were purchased from Jackson laboratories 
(Bar Harbor, ME) maintained in our ASU animal facilities. All mice were maintained 
under specific-pathogen free conditions at The Biodesign Institute and experiments were 
performed in compliance with institutional guidelines as approved by Institutional 
Animal Care and Use Committee of Arizona State University. 
 Cell sorting:  CD8+ T cells were purified by positive immunomagnetic cell 
sorting (>95% CD8+; Miltenyi Biotec) as previously described [316] from spleens of 6-
week-old donor C57BL/6 mice.  
 Cell surface antibody staining: Single cell suspensions were prepared from 
splenocytes as previously described [36]. Erythrocytes were lysed with ammonium 
chloride lysis (ACK) buffer purchased from Lonza (Allendale, NJ) and FACS staining  
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was done as previously described [37] in 96 well plates with flurochrome-labeled 
monoclonal antibodies: anti-CD8 (clone 53-6.7), anti-CD44 (clone IM7), anti-CD4 (clone 
GK1.5). Samples were then fixed in 1% paraformaldehyde solution and immediately 
acquired on a BD LSR II Fortessa flow cytometer (San Jose, CA) and analyzed using 
FlowJo Software (Tree-Star, Ashland, OR). All monoclonal antibodies were purchased 
from BD Pharmigen (San Diego, CA) or eBiosciences (San Diego, CA). 
 TCRβ  CDR3 sequencing and bioinformatic analysis: Three samples consisting 
of between 1.16 x 106 – 1.48 x 106 CD8+ sorted cells from C57BL/6 mouse spleens were 
shipped to Adaptive Biotechnologies (Seattle, WA) for standard ImmunoSEQ TCRβ 
profiling [232]. All data and statistics were generated from the proprietary ImmunoSEQ 
analyzer software using a previously described VDJ gene-calling algorithm [317]. 
 
RESULTS 
 The naïve TCRβ  repertoire is very consistent among different individuals at 
the V and J gene expression level.  By utilizing the ImmunoSEQ high-throughput 
sequencing approach [232] on genomic DNA extracted from purified CD8+ T cells, we 
were able to analyze the CDR3 sequence repertoire from >1 x 106 T cells from each of 
the spleens of three C57BL/6 mice. Samples consisted of 1.16 x 106, 1.34 x 106, and 1.48 
x 106 CD8+ sorted T cells from each of the respective mice. Each of the three samples 
yielded roughly 105 CDR3 sequence reads (Table 2.2) with an average CDR3 length of  
 
 
85 
around 42 nucleotides for both total reads (Figure 2.1A) and productive reads (Figure 
2.1B).  
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Table 2.2: Sample cell counts and respective TCRβ  CDR3 sequences 
and CDR3 lengths obtained from ImmunoSEQ analysis. 
Sample Total number of cells 
sampled 
Productive 
rearrangements  
Average CDR3 
length 
Spleen 1 1.16 x 106 9.5624 x 104 42.25 nt 
Spleen 2 1.34 x 106 1.10998 x 105 42.29	nt	
Spleen 3 1.48 x 106 1.27103 x 105 42.36 nt 
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Figure 2.1: TCRβ  CDR3 length distributions. CDR3 length distribution 
patterns (peak profile representation) reflect a typical Gaussian-like profile. An average 
CDR3 length of 42 nucleotides was observed from CD8+ T cells sorted from splenocytes 
from all three mice for both the total [A] read profile as well as the subset of productive 
reads only [B]. 
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 The mouse TCRβ chain is composed of one each V region, D region, and J 
region. Previous studies have reported that public TCR repertoires across these regions 
are due to convergent recombination and selective bias during VDJ recombination [274, 
276, 301]. Utilizing the ImmunoSEQ technology, we were able to determine that the 
frequency with which specific V and J genes were used was highly variable (>10,000 
fold in some cases) within an individual, however these V and J gene usage frequencies 
are conserved between the three individuals analyzed. Analysis of the frequency of 
expression of each individual V gene shows that there was no significant difference 
between the three mice (Figure 2.2A). Additionally, all three mice had virtually identical 
J gene expression frequencies as well (Figure 2.2B). Analysis of the Vβ gene segment 
utilization frequency demonstrates that ten of the thirty-two Vβ gene segments account 
for >90% of the sequences collectively observed in the three donors, again providing 
support for selective biases in VDJ gene selection during somatic recombination.  
 
 
 
 
 
 
 
 
 
89 
 
Fig 2.2: Public distribution of TCRβ  V gene and J gene expression 
frequencies between three inbred individuals. [A] All three mice display 
virtually identical V gene expression frequencies for all 31 of the functional mouse V 
genes. [B] Similarly, the 14 J genes were observed to show no significant differences 
among the three mice analyzed.  
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 CDR3 sequencing reveals V-J gene segment recombination frequencies are 
conserved between individuals. Consistent with previous data [306], the frequency with 
which specific VβàJβ recombinations were observed in an individual was highly 
variable. Remarkably however, while the majority of possible VàJ recombinations were 
observed to be highly variable within an individual, specific VβàJβ recombination 
frequencies were highly conserved between the three different individuals, especially for 
the more rare VβàJβ recombinations (Figure 2.3-2.10). VβàJβ recombination 
frequency graphs were not generated for Vβ genes that were not sampled at least once by 
all three mice (Vβ6, 7, 8, and 9).  It has previously been reported that a small fraction of 
the TCRβ CDR3 sequences observed from genomic DNA extracted from naïve CD8+ T 
cells would generate out-of-frame transcripts, not encoding functional TCRβ chains 
[306]. Consistent with our data from in-frame transcripts, the VβàJβ recombination 
frequencies of the out-of-frame CDR3 sequences also displayed high levels of non-
uniformity. As these out-of-frame transcripts would be selected against during thymic 
selection, the variability in VβàJβ recombination must attributable, at least in part, to 
VDJ gene segment selection biases (occurring prior to the thymic selection events).  
 Analysis of the individual VβàJβ recombination frequencies demonstrates that 
high levels of non-conformity exist for each individual V gene segment in terms of the 
relative frequencies to which J gene segments it pairs. Again however, while non-
conformity exists in VβàJβ gene pairing within an individual for each specific V gene 
segment, homology in VβàJβ gene selection is observed between the three individuals.  
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Figure 2.3: TCRβV1-3 gene segments display public recombination 
frequencies between individuals. Analysis of TCRβV1-3 gene segment 
recombination frequencies reveals conservation in J gene segment pairing between three 
individuals. 
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Figure 2.4: TCRβV4, 5, and 10 gene segments display public 
recombination frequencies between individuals. Analysis of TCRβV4, 5, and 
10 gene segment recombination frequencies reveals conservation in J gene segment 
pairing between three individuals. 
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Figure 2.5: TCRβV12-1, 12-2, and 13-1 gene segments display public 
recombination frequencies between individuals. Analysis of TCRβV12-1, 12-
2, and 13-1 gene segment recombination frequencies reveals conservation in J gene 
segment pairing between three individuals.  
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Figure 2.6: TCRβV13-2, 13-3, and 14 gene segments display public 
recombination frequencies between individuals. Analysis of TCRβV13-2, 13-
3, and 14-0 gene segment recombination frequencies reveals conservation in J gene 
segment pairing between three individuals. 
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Figure 2.7: TCRβV16, 17, and 19 gene segments display public 
recombination frequencies between individuals. Analysis of TCRβV16, 17, 
and 19 gene segment recombination frequencies reveals conservation in J gene segment 
pairing between three individuals. 
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Figure 2.8: TCRβV20-22 gene segments display public recombination 
frequencies between individuals. Analysis of TCRβV20-22 gene segment 
recombination frequencies reveals conservation in J gene segment pairing between three 
individuals. 
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Figure 2.9: TCRβV23, 24, and 26 gene segments display public 
recombination frequencies between individuals. Analysis of TCRβV23, 24, 
and 26 gene segment recombination frequencies reveals conservation in J gene segment 
pairing between three individuals. 
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Figure 2.10: TCRβV29-31 gene segments display public recombination 
frequencies between individuals. Analysis of TCRβV29-31 gene segment 
recombination frequencies reveals conservation in J gene segment pairing between three 
individuals.  
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 The majority of TCRβ  CDR3 sequences are present at low frequencies while 
significantly fewer sequences occur at relatively higher frequencies. Previous 
estimates of diversity have borrowed an approach from ecology, specifically population 
diversity studies, in which TCR diversity was described by enumerating the number of 
distinct clones (species) in a given repertoire (population) as well as their respective 
frequencies. Commonly referred to as the Simpson diversity index [318], these summary 
approaches compress all the diversity information into a single number.  In order to 
develop a more accurate and comprehensive model to assess a quantitative description of 
TCR diversity, the frequency distribution of different clone sizes must also be included in 
the metrics used [230]. By plotting the frequency distribution of TCRβ chain sequences 
from the mouse naïve CD8+ T cell repertoire we found that a majority of sequences are 
present at relatively low frequencies, and that a much smaller fraction of sequences occur 
at relatively higher frequencies (Figure 2.11). It should be mentioned however, that this 
data only represents TCRβ chain information, and that without paired TCRα information 
the discrepancy in our estimates of clone size frequencies were most likely even further 
underestimated.  
 Specifically, we found that while several clones have very high frequencies 
(~10%), possibly due to the biased selection of V/D/J gene segments and/or due to 
convergent selective events, the majority of clones (~90%) are found fewer than 100 
times in a given individual.  
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Figure 2.11: Plot of the frequency distribution in the TCRβ  CDR3 
sequences of naïve CD8+ T cells. CD8+ T cells from C57Bl/6 mice were isolated 
by magnetic beads and >98% purity confirmed by flow cytometry. Genomic DNA was 
subjected to TCRβ V-J multiplex DNA sequencing and the distribution of unique in-
frame CDR3 sequences is plotted. While few sequences occur at relatively high 
frequencies, the majority of CDR3 sequences are present at low frequencies (>100 
copies). Figure adapted from Schoettle and Blattman’s data in Zarnitsyna, 2013 [230]. 
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 At the amino acid level and even more pronounced nucleotide level, major 
differences arise among individuals when analyzing the public vs private TCRβ  
CDR3 sequence repertoire. While high levels of homology are observed between 
individuals at the V/J gene segment usage level, this public distribution is drastically 
diminished when analyzing CDR3 sequences at the amino acid level and even further 
disparaging at the nucleotide sequence level. Furthermore, while it has been suggested 
that an adequate sampling of individual TCR repertoires would demonstrate the true 
prevalence of public TCR sequences [298, 303, 305], our deep sequencing approach to 
investigate the relative ‘publicness’ of the TCR repertoire of three genetically identical 
mice reveal very little true sharing of CDR3 repertoires between individuals.  
 We found that on average, any two mice in our data set share ~11.5% of the 
CDR3 amino acid sequences expressed between the two individuals (Figure 2.12A-C). 
Even more revealing, samples between two individuals share only ~2% of nucleotide 
sequence homology (Figure 2.13A-C). On average, comparison of amino acid sequences 
between samples 1, 2, and 3 yielded 15,608 shared sequences out of 135,489 total 
sequences (11.5%) (Table 2.3). From the analysis of nucleotide sequences we observed 
12,980 shared sequences from 653,470 total sequences (2.0%) (Table 2.4). Alignment of 
CDR3 regions was defined by the CASS consensus amino acid sequence. Frame shift and 
non-productive sequences were excluded. All comparison analysis was performed with 
ImmunoSEQ data analysis software and standard spreadsheet programs. 
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Figure 2.12: A decrease in public TCRβ CDR3 sequence repertoire is 
observed at the amino acid level. Although relatively conserved at the gene 
frequency level, only ~11.5% of amino acid sequence homology (blue dots) was 
observed between three genetically identical C56BL/6 mice. Comparing splenocytes 
from mouse 1 vs 2 [A], 1 vs 3 [B], and 2 vs 3 [C], the majority of discovered CDR3 
amino acid sequences (~88.5%) were private to any given mouse (green and red dots). 
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Figure 2.13: A further decrease in public TCRβ CDR3 sequence 
repertoire is observed at the nucleotide level. While ~11.5% of TCRβ CDR3 
amino acid sequence homology was observed between the three individuals, only 2% 
sequence homology (blue dots) was observed at the nucleotide level. Comparing 
splenocytes from mouse 1 vs 2 [A], 1 vs 3 [B], and 2 vs 3 [C], the majority of discovered 
CDR3 nucleotide sequences (98%) were private to any given mouse (green and red 
dots).. 
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Table 2.3: Comparing public vs private CD8+ T cell CDR3 amino acid 
sequences between three C57BL/6 mice. Public fraction percentages between 
compared mice are highlighted in yellow. 
 1 vs 2 1 vs 3 2 vs 3 
Total # Seq 127,027 - - 
1 only 52,666 - - 
2 only 60,022 - - 
Shared (#) 14,339 - - 
Shared (%) 11.3 - - 
Total # Seq - 136,635 - 
1 only - 51,354 - 
3 only - 69,630 - 
Shared (#) - 15,651 - 
Shared (%) - 11.5 - 
Total # Seq - - 142,806 
2 only - - 57,525 
3 only - - 68,445 
Shared (#) - - 16,836 
Shared (%) - - 11.8 
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 Table 2.4: Comparing public vs private CD8+ T cell CDR3 
nucleotide sequences between three C57BL/6 mice. Public fraction 
percentages between compared mice are highlighted in yellow. 
 1 vs 2 1 vs 3 2 vs 3 
Total # Seq 202,880 - - 
1 only 91,882 - - 
2 only 107,256 - - 
Shared (#) 3,742 - - 
Shared (%) 1.8 - - 
Total # Seq - 218,438 - 
1 only - 91,335 - 
3 only - 122,814 - 
Shared (#) - 4,289 - 
Shared (%) - 2.0 - 
Total # Seq - - 233,152 
2 only - - 106,049 
3 only - - 122,154 
Shared (#) - - 4,949 
Shared (%) - - 2.1 
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 Public TCRβ  CDR3 sequences are found in relatively higher frequencies 
than private CDR3 sequences. Previous studies have reported that public TCRs display 
a higher level of convergent recombination than private sequences [274, 276, 303, 310]. 
Additionally it has been shown that public TCR sequences differ from private sequences 
in their gene segment usage and CDR3 lengths [302]. On average, the more public CDR3 
amino acid sequences tend to be roughly one amino acid shorter than those expressed 
privately in individuals. Additionally, public CDR3 amino acid sequences showed 
significantly fewer nucleotide insertions and deletions in the V-D and D-J junctions of 
the TCRβ chain. All of the aforementioned findings indicate that public CDR3 sequences 
tend to be closer to germ-line DNA configurations [302, 306].  
 Previous findings have shown that public CDR3 sequences demonstrate a biased 
and restricted V and J gene segment usage compared to the more inclusive private 
sequence repertoire, and furthermore that the public V and J gene usage frequencies do 
not mirror the private gene usage frequencies [302]. To further assess these findings, we 
next analyzed the frequency of each TCRβ CDR3 amino acid sequence with respect to its 
degree of sharing between individuals, and we found that public TCR sequences tend to 
be more abundant than private TCR sequences (Figure 2.14).  
 
  
 
 
 
107 
 
Figure 2.14: The majority of public TCR sequences are found in 
relatively high frequencies. Comparing frequency (y-axis) to the number (x-axis) 
of unique TCRβ CDR3 sequences of both public (blue) and private (red) sequences we 
find that the shared or public fraction of TCR gene sequences correlates with the few 
TCR gene sequences that are found in high numbers across individuals. 
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Figure 2.15: Sequences found at higher frequencies tend to have a 
higher ratio of public:private distribution. As the frequency for specific CDR3 
sequences increase (x-axis), the ratio of the number of public:private sequences (y-axis) 
increases as well. More clearly stated, the more frequently a CDR3 sequence is 
expressed, the more likely it is to be a public CDR3 sequence shared between individuals. 
However, CDR3 sequences expressed at relatively low frequencies (<10 copies) tend to 
be privately expressed by a single individual. 
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DISCUSSION 
 Using ImmunoSEQ TCRβ CDR3 sequencing we were able to compare the naïve 
CD8+ T cell receptor repertoires of three genetically identical mice. We discovered that 
most sequences are present at very low frequencies (<10 copies/individual) and only a 
few sequences are present at high frequencies. Furthermore, we compared the relative 
distributions of V and J gene segment usage between the mice and found that at the 
whole gene level, V and J expression is conserved between individuals. We also 
determined that average CDR3 length (12 amino acids) was conserved between the mice 
both for total reads as well as productive in-frame reads. Additionally, when analyzing 
VàJ recombination frequencies between individuals we also found that the specific 
VàJ recombination frequencies were conserved as well.  
 However, when analyzing the CDR3 sequences at the amino acid level, 
divergence between individuals began to emerge. While there was definitely a conserved 
public fraction of CDR3 sequences shared between individuals (~11.5%), the majority of 
CDR3 sequences in any individual are private, specific to that individual only. Even more 
revealing, when analyzing the public CDR3 sequences shared between individuals at the 
nucleotide level only ~2% of sequence homology was observed. This lack of a true 
publicly distributed TCR repertoire can most likely be attributed to the fact that the 
potential repertoire of  >1010 possible TCRβ CDR3 sequences is much greater than the 
actual number of cells found in a given individual (mice).  
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 Closer examination of the public vs private fractions of TCRβ CDR3 sequences  
revealed many additional insights into the attributes of shared CDR3 sequences. The 
majority of public TCR sequences are found in relatively high frequencies. Comparing 
frequency to the number of unique TCRβ CDR3 sequences of both public and private 
sequences we found that the shared or public fraction of TCR gene sequences correlates 
with the few TCR gene sequences that are found in high numbers across individuals. 
Furthermore, sequences found at higher frequencies tend to have a higher ratio of 
public:private distribution. The more frequently a CDR3 sequence is expressed, the more 
likely it is to be a public CDR3 sequence shared between individuals. However, CDR3 
sequences expressed at relatively low frequencies (and thus the majority of CDR3 
sequences) tend to be privately expressed by a single individual. These findings bring up 
additional questions about population dynamics of public vs private immune repertoires. 
 Our findings, as well as numerous studies to date, highly suggest that the 
observed sharing of TCR CDR3 sequences between individuals is determined by two key 
processes: (1) convergent recombination [274, 303], and (2) recombinatorial biases 
during VDJ gene segment selection [229, 312, 319]. Even though a relatively small 
fraction of the total repertoire, it is still intriguing that VDJ recombination is not a totally 
random process, which has the potential to generate a much more diverse repertoire 
within an individual and also set of repertoires across a population [276]. It has been 
proposed that the discrepancy between the massively diverse repertoires VDJ 
recombination is capable of producing and although small, shared fraction of immune 
repertoire actually found in populations may benefit the species as a whole [276]. 
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Additionally, recombinatorial biases during VDJ selection have also been proposed as a 
form of natural selection, a co-evolutionary event, to maintain population-wide immunity 
to the ever evolving smorgasbord of pathogens we are exposed to as a species [320]. 
Comparing phylogeny of immune repertoire diversity vs pathogen evolution over 
thousands of years may shed insight into these questions.  
 Defining the biological utility of public recombinatorial biases may play an 
additional role in the realm of prophylactics, diagnostics, or even therapeutics. If 
manipulation of recombinatorial biases were achievable, one could theoretically skew an 
individual’s immunity to specific pathogens. The regulation of VDJ recombination has 
been analyzed in depth with respect to recombination signal sequences, enhancers, and 
promoters in the TCR genetic loci [314, 321-323]. Additionally studies have revealed the 
role of epigenetic factors in the regulation of somatic recombination by altering the 
chromatin accessibility [324-326]. Additional studies and investigations into how these 
upstream signals regulate VDJ recombination may potentially provide insight into how 
TCR repertoires can be manipulated, although the ethics of such manipulation will be a 
topic of future debate.  
 As previously mentioned, the analysis of public vs private distributions of TCR 
repertoires brings up a fundamental question of immunology. Is VDJ recombination 
somehow pre-determined by genetically programmed processes that are ‘immune’ to 
peripheral stressors, or is the development of immune repertoires a responsive evolution 
to the ever changing immune stressors encountered by the host? As proposed by Li et al. 
[276] and reviewed by many others, could the immune system be utilizing ‘adaptive 
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mutation’, the process by which organisms change their genetic information to adapt to 
encountering different pathogens [327-331]? On one hand, evolution of the immune 
repertoires over time to specifically combat the pathogens of that era would allow for an 
evolutionary benefit to populations. However, retention of public fractions of the TCR 
repertoire would limit diversity, and thus make populations more vulnerable to rare 
pathogens [276].  
 It is clear that a large repertoire is required to generate an effective immune 
response to the highly diverse array of pathogens one may encounter in a lifetime. 
Studies by our group [230] and others [332, 333] have investigated the relationship 
between repertoire diversity and protection. To provide reliable protection against a given 
pathogen there must exist some number of T cell clones present in the naïve repertoire 
that are specific for the pathogen [230]. The existence of diverse private repertoires 
across a population plays an important role in defense against new pathogens, but 
increasing diversity of the private repertoire renders many in the population susceptible to 
these pathogens. The delicate balance between public vs private immune repertoires 
ensures that at although many will be susceptible to newly encountered pathogens, at 
least some individuals in the population will be able to mount an effective immune 
response and thus survive. Natural selection and the proceeding evolution would then 
suggest that the once private TCRs would then become part of the public repertoire 
fraction.  
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 Through the use of TCRβ CDR3 repertoire next generation sequencing, we have 
demonstrated that there exists VDJ gene usage homology between individuals in the 
naïve CD8+ TCR repertoire. Furthermore, recombination frequencies between specific 
VàJ genes are also conserved among individuals. However, analysis of the amino acid 
and nucleotide sequences of TCRβ CDR3 sequences reveals a much smaller public 
fraction of CDR3 sequences shared between individuals, although this fraction is much 
larger than would be predicted by stochastic VDJ rearrangement. Finally, analysis of the 
publicly distributed fraction of sequences reveals these sequences to be present in 
relatively higher frequency than those found privately. It must be pointed out however, 
that T cell receptors are heterodimers whose two constituent chains are generated by 
independent rearrangement events of the TCRα and TCRβ loci. The theoretical diversity 
of the TCR repertoire is thus significantly increased by the potential pairing of any of the 
possible α chains with any of the possible β chains. And although it has been estimated 
that each unique TCRβ chain is on average paired with 25 different TCRα chains [192], 
this estimate was taken from an extremely small subset of the TCR repertoire and 
extrapolation of such may include extreme bias. Understanding the balance between 
immune diversity and immune protection has been limited by a lack of methods for 
accurately estimating total TCR diversity as this is a function of both sequence diversity 
within each somatically recombined TCR loci as well as pairing diversity due to 
combination of different TCRα and TCRβ chains. Single cell sorting and sequencing of 
both TCR chains for the pre-immune repertoire remains unfeasible while molecular 
strategies for linking TCR sequences within individual cells have not been adequately 
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developed. Determining the number of unique TCRαβ combinations in the entire TCR 
repertoire will require new techniques for linking TCRα and TCRβ sequence 
information. In chapter three we outline a template molecule for such an approach. 
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CHAPTER 3 
DESIGN AND DEVELOPMENT OF DNA NANOSTRUCTURES FOR CAPTURE 
AND REISOLATION OF TCRA AND TCRB MRNA FROM INDIVIDUAL CELLS 
ABSTRACT 
 DNA origami nanostructures have the potential to become dynamic biomolecular 
tools. Applications of these nanostructures include use as smart therapeutics, drug 
delivery systems, and intricate molecular machines. One immediate application is as 
nanoscale gene chips at the single cell level for interrogating gene expression or 
sequences. Current tools for single-cell analyses such as single-cell sorting or oil-in-water 
emulsion droplet sorting are limited by cell throughput, while high-throughput molecular 
methods for single cell analysis of more than a single gene remain inadequately 
developed. Here, we demonstrate the use of DNA origami nanostructures as a novel 
strategy to capture and protect TCRα and β mRNAs from individual cells within large 
polyclonal cell populations without the need for single-cell sorting. We demonstrate that 
these nanostructures are highly transfectable, are inherently resistant against intracellular 
degradation, and due to their modular design can capture mRNA from virtually any gene 
pair facilitating high-throughput sequence analysis of paired genes from individual cells. 
While applied here for the capture of TCR mRNAs, this tool has the potential for a wide 
range of applications including the rapid advancement of immunotherapy for cancer by 
providing both immune receptor genes from individual T cells, rapid development of 
monoclonal antibodies, or enhancing personalized approaches to cancer by analysis of 
progressive mutations to maximize therapeutic efficacy. 
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IMPORTANCE 
 Heterogeneity is becoming recognized as a major problem in complex biological 
systems including immunology and cancer. In particular, advances in single cell analyses 
have led to the realization that both immune responses and cancer are diverse populations 
of cells based on either somatic recombination/hypermutation or progressive mutations. 
Single cell sorting of antigen-reactive lymphocytes can be used for identification of novel 
immunotherapeutic or experimental antibodies, but this approach remains prohibitively 
expensive and time-consuming for large cell populations.  
 One limiting factor in the analysis of cellular gene sequence heterogeneity is that 
cells must be individually sorted in order to maintain integrity of gene pairing. To our 
knowledge, the ability to constrain multiple mRNA species from individual cells from 
large cell populations without first pre-sorting has yet to be demonstrated. We show here 
the use of DNA origami nanostructures for capture and recovery of mRNA from 
individual cells without pre-sorting these cell populations. These nanostructures are 
highly transfectable in primary cell lines using electroporation and are robust against 
intracellular degradation during the time periods required for mRNA capture. Moreover, 
the highly modular nature of the DNA origami nanostructures make them easily 
adaptable to capture virtually any mRNA pairs, and modifications to the nanostructures 
allows for identification of transfected cells and for purification and reisolation of the 
nanostructures with bound mRNAs from cell lysate. These nanostructures represent an 
ideal balance between development of new technological approaches and application of 
to fundamental biological questions.  
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INTRODUCTION 
 The burgeoning field of DNA origami seeks to create molecular structures, tools, 
or molecular machines out of nucleic acids using predictable Watson-Crick base pairing. 
Originally, this field was constrained exclusively to the in vitro design and construction 
of these structures. However, recent advancements and successes in the nanotechnology 
field have led to an expansion in the potential applications for DNA origami 
nanostructures both in vivo and ex vivo [267-270].   
 One major area of interest for application of DNA nanotechnology is for sensing 
the intracellular environment [334-336] and/or capturing and sequencing mRNAs from 
individual cells [263, 271]. Such investigations are essential for assessing clonally 
distributed T cell or B cell dimeric receptor genes in highly diverse immune repertoires or 
for defining the diversification of cancer cells during disease progression. Previous 
studies by our group and others have shown the stability of DNA nanostructures in cell 
lysates [337] as well as serum [338], and Mao et al. showed that origami structures were 
conducive to cellular uptake [269]. The ease of engineering and adaptability of DNA 
nanostructures, combined with their intracellular stability provides a unique approach for 
capture, protection and reisolation of multiple mRNA species from individual cells from 
large heterogeneous cell populations without the need for single cell sorting. This 
approach has several advantages over current methods, such as single cell sorting 
followed by deep sequence analysis, for identification and/or analysis of multiple gene 
sequences from individual cells [259-261] including reduced cost, higher throughput, and 
the lack of need for specialized equipment. In contrast, conventional molecular 
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approaches for linking gene sequences, such as by transfection with bridging 
oligonucleotides, typically result in activation of cellular nucleases that destroy target 
mRNA and preclude downstream analysis [339]. More recently developed 
combinatorics-based approaches are useful for high copy number sequences from high 
frequency clones but provide little to no information on rare sequence variations [340].  
 DNA origami nanostructures offer an ideal and somewhat hybrid solution to these 
problems as they can be transfected into individual cells to capture and protect mRNA for 
specific genes, and using a novel system of barcoding the origami mRNA capture probes 
the mRNA bound to the DNA nanostructures can be bioinformatically linked following 
next-generation sequencing. The main innovation of our technology is the development 
of a highly novel strategy for capture and downstream analysis of multiple gene 
sequences from single cells within heterogeneous cell populations of massive sample size 
without the need for single-cell sorting. While this discussion focuses on applying the 
approach to the rapid identification of murine CD8 T cell receptor sequences, as 
mentioned above there are potentially a tremendous number of additional applications for 
this technology. Due to the highly modular nature of the origami molecules, the 
developed techniques can be (and currently are being) adapted by relatively simple 
modifications to the DNA origami nanostructure sequences, for the analysis of cells 
expressing other immunoreceptors (e.g. B cell receptors and novel antibodies, γδ T cell 
receptors), immune cells from other species, or specific mutations in cancer cells or 
cancer stem cells. In chapter 3, we describe the development of a robust method for the 
capture of sequence information from multiple genes from single cells without the need 
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for single-cell sorting or specialized equipment that is not only cost-effective and has the 
capacity for analysis of large cell populations, but is also easily adaptable for probing 
sequence diversity of multiple genes from other heterogeneous cell populations. 
 
MATERIALS AND METHODS 
 DNA origami design: DNA is an excellent nano-construction material. The 
development of “scaffolded DNA origami” represented a breakthrough in the field of 
DNA nanotechnology [341]. In this technique, single-stranded, M13mp18 genomic DNA 
(~7 kilobases) acts as a scaffold strand that is folded into a target shape (~60x90 nm in 
scale) as directed by 200+ short, ssDNA “staple” strands. A one-pot nanomolar-scale 
synthesis produces over 1014 origami nanostructures with a folding yield approaching 
100%. DNA origami nanostructures are fully addressable molecular pegboards, with 
more than 200 six-nanometer pixel positions resulting from the unique sequences of each 
of the staple strands, providing capability for addressable functionalization. Specific 
staple strands can be substituted to include extended single-stranded “probe” sequences 
that protrude from the DNA origami structure and are complementary to the selected 
conserved regions of either the TCRα or TCRβ mRNA coding sequences. 
 For initial development and validation of this approach, we used the P14 TCR 
transgenic mouse line that expresses a TCR specific for the glycoprotein 33 (GP33) 
peptide from the lymphocytic choriomeningitis virus (LCMV) (discussed below). Thus, 
selected staple strands were extended with complementary sequences to the CDR3- 
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proximal conserved regions of TCRα and TCRβ. Site-directed attachment of fluorescent 
tags (FITC) facilitated gel analysis and detection of successfully transfected cells by flow 
cytometry. Biotin tags were included on some staple strands for subsequent isolation and 
purification of transfected DNA origami nanostructures from cell lysates with bound 
TCR mRNA. It is important to note that more than one hundred trillion probe tiles can be 
fabricated in a one-pot annealing step (within 12 hours), which renders this method 
suitable for high-throughput applications such as next generation sequencing. 
Additionally, our group previously demonstrated that DNA origami structures retain their 
structure and are resistant to nuclease digestion in cell lysate [337]. Thus, it is possible to 
use these structures for mRNA capture and analysis due to their inherent intracellular 
stability. 
 DNA origami synthesis: The single-stranded M13mp18 bacteriophage genome 
(7.4 kb) was purchased from a commercial vendor (Affymetrix). All oligonucleotide 
staples were synthesized by and procured from a commercial vendor (IDT) and mixed in 
equimolar amounts resulting in a master pool. While standard staples are mixed in 
excess, the TCRα/β  mRNA capture probe strands and biotin-tagged staples were PAGE-
purified and quantified (by measuring absorbance at 260 nm) prior to being included in 
the origami folding reaction. Scaffold M13 ssDNA, staple DNA, and functionalized 
staples were then mixed in a fixed 1:5:3 ratio (50 nM scaffold, 250 nM staples, 150 nM 
mRNA probes/biotinylated tags/fluorophore tags) in aqueous buffer (1x TAE with 12 
mM Mg2+), followed by thermal denaturation (90°C) and gradual annealing (to 20°C) 
over 12 hours. Folded DNA origami was purified from non-folded products and excess 
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staples by centrifugation through 100K nominal molecular weight limit (NMWL) 
Amicon filters. Such purification typically results in a solution of 20-50 nM of target 
DNA origami nanostructures; the final concentration can be measured by A260/A280 
absorbance and standardized to either 20 or 50nM depending on the downstream 
application. The DNA origami nanostructures were also visualized by atomic force 
microscopy (AFM) to verify proper folding of the designed structures.  
 Mice: 6-8 week old C57BL/6 mice were purchased from Jackson laboratories 
(Bar Harbor, ME) and bred in our ASU animal facilities. P14 transgenic mice, in which 
CD8 T cells express TCR specific for the DbGP33- 41 epitope of LCMV, were obtained 
initially from Dr. Rafi Ahmed and bred in our animal facilities. All mice were maintained 
under specific-pathogen free conditions at The Biodesign Institute and experiments were 
performed in compliance with institutional guidelines as approved by the Institutional 
Animal Care and Use Committee of Arizona State University.  
 in vitro Transcription of P14 TCRα  and β  mRNA: DNA origami 
nanostructures were first optimized for binding to TCRα and β mRNA sequences using 
in vitro transcribed mRNA. Spleens from 4-6 week old P14 TCR-transgenic mice were 
prepared by mechanical disruption followed by red blood cell lysis in 0.83% NH4Cl 
buffer. CD8+ T cells were separated from total splenocyte cell suspensions by magnetic 
cell separation (MACS, Miltenyi Biotec) and >95% purity of sorted populations 
confirmed by flow cytometry. Total RNA was isolated using standard endotoxin free 
RNA extraction kits (Qiagen) and quality assessed by measuring A260/A280 absorbance  
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ratios (optimally between 1.8-2.0). To generate plasmids for production of large amounts 
of in vitro transcribed TCR mRNA, P14 TCRα and β cDNA was prepared using a 
Qiagen OneStep RT-PCR kit with P14 TCRα or TCRβ specific primers. RT-PCR 
products were sequenced and confirmed to be P14 TCR cDNA and then further amplified 
with AmpliTaq Gold PCR kits to create 3’-A overhangs necessary for cloning into pCR4-
TOPO plasmids (Invitrogen). Resulting plasmids were sequenced to confirm correct 
insertion of the PCR product. TCRα and TCRβ mRNA was then synthesized from EcoRI 
linearized plasmids by in vitro transcription using the T7 phage polymerase priming site 
and the Invitrogen MEGAscript T7 kit. Transcribed mRNA was purified with Invitrogen 
MEGAclear kits followed by assessment of concentration and purity (A260/A280=1.8-2.0).  
 DNA origami binding to immunoreceptor mRNA: P14 TCRα and TCRβ 
mRNA (0.5 µg/µL) was denatured for 5 minutes at 65°C and incubated with purified 
origami (20nM) in 1X TAE-Mg2+ so hybridization could occur (37°C, 1 hour). Negative 
controls included: 1) DNA origami without TCR-specific staples mixed with in vitro 
transcribed P14 TCRα and TCRβ mRNA and 2) DNA origami with TCR-specific staples 
mixed with anti-sense P14 TCRα and TCRβ mRNA generated using T3 polymerase from 
the opposite orientation on the pCR4 plasmid. To directly visualize mRNA binding, 
hybridized product was analyzed by AFM. Furthermore, analysis of gel migration shifts 
due to mRNA binding was assessed by agarose gel electrophoresis of incubation 
products. 
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 DNA origami transfection into primary T cells: Previous studies have utilized 
receptor-mediated endocytosis of DNA nanostructures via the caveolin-dependent 
pathway leading to microtubule transport to lysosomes and therefore breakdown of the 
nanostructure. The obvious problem with this strategy is that for mRNA capture and 
subsequent reisolation, our nanostructures must bypass the endocytosis pathway, and 
instead cross the membrane directly to the cytoplasm. Electroporation is the simplest 
method for cytoplasmic entry and thus avoidance of the deleterious effects of endosomal 
degradation. However high cell mortality rates have commonly been associated with this 
methodology. Recent advancements in microporation technology (the use of µL volume 
electroporations) have shown high transfection efficiencies (>93%) as well as high cell 
viabilities (>86%). For our T cell transfection experiments we used P14 TCRα/β 
transgenic mice. Splenocytes from 4- to 6-week-old P14 TCRα/β transgenic mice were 
prepared by mechanical disruption and red blood cell lysis in 0.83% NH4Cl. CD8+ T cells 
were purified by magnetic cell sorting and >95% purity of sorted populations were 
confirmed by flow cytometry. Cells were pelleted by centrifugation (1,200 rpm, 5 
minutes, 4°C), washed with MACS media (Miltenyi Biotec), and resuspended in MACS 
media at 1x107 cells/mL. For electroporation, a both the BTX Cuvette electroporation 
system (Harvard Apparatus) and the Neon syringe transfection system (Thermo 
Scientific) were used. Settings for the BTX cuvette system consisted of 2 mm gap 
cuvettes, 300 V, 10 ms, and one pulse. Settings for the Neon system consisted of 100 µL 
syringe tips, 2,000 V, 10 ms, 1 pulse. Samples consisted of 100µL cell suspensions and 
either 25 µL (50 nM) DNA origami suspension (in 1X TAE-Mg2+) or a mock transfection 
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control of 25 µL 1X TAE-Mg2+ buffer. Immediately following electroporation, cells were 
transferred to 100 µL fresh RPMI-1640 culture medium with 10% fetal calf serum and 
incubated at 37°C for 2-24 hours in individual wells of a 96 well plate. To assess 
transfection efficiency, cells were visualized on a LSR Fortessa flow cytometer after 
successive incubation periods; the fluorescein isothiocyanate  (FITC; 488 nm excitation, 
518 nm emission) tag incorporated into each nanostructure allowed for successfully 
transfected cells to be identified by flow cytometry. To verify that the DNA origami 
nanostructures had actually entered transfected cells, rather than binding non-specifically 
to the cell surface, we also included DNase pre-treatment (Turbo DNase, Ambion, Life 
Technologies) of transfected cells followed by FACS analysis. Furthermore, we verified 
that DNase resulted in destruction of DNA origami by incubating refolded origami in 1X 
Turbo DNase (37˚C, 30 min) followed by electrophoresis on a 1% agarose gel. It should 
be noted that Turbo DNase is a proprietarily engineered version of DNaseI and has a 
markedly higher affinity for DNA than wild type DNaseI, which we found to be much 
less effective at degradation of origami nanostructures.  
 Intracellular TCR mRNA binding, cell lysis, and origami purification: DNA 
origami with extended mRNA capture probes specific for TCRα and TCRβ conserved 
regions was purified from transfected P14 transgenic T cells by utilization of the four 
biotinylated origami staple strands. At 12 hours post-transfection, cells were lysed in 
100µL 1% NP-40 buffer including 2µL Ribolock RNase inhibitor for 30 minutes on ice. 
DNA origami with bound TCR mRNA was then isolated from cellular debris and any 
unbound mRNA by filtration through a streptavidin resin column (Pierce Streptavidin 
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UltraLink Resin, Sigma Prep Columns, 7-20µM pore size). Unbound cellular debris and 
mRNA was washed through the column using 3x350µL 1X TAE-Mg2+ rinses followed 
by centrifugation at 2,000 rpm for 30s. Specific capture of TCRα and TCRβ mRNA by 
DNA origami with probe staples was confirmed by Sanger sequencing of RT-PCR 
products and comparison to known P14 CDR3 sequences (discussed below).  
 Reverse transcription and P14-specific TCR chain CDR3 amplicon 
generation: Once mRNA-bound origami was purified from cell lysate in the streptavidin 
columns, reverse transcription (RT) was performed directly in the columns. Using the 
5’à3’ TCRα and TCRβ mRNA capture probes as RT primers, elongation was achieved 
by simply adding 40µL of the RT mastermix (Omniscript, Qiagen) directly into the 
purification column, and incubating for 1 hr in a 37°C heat block. The RNA was then 
removed by addition of an RNaseH cocktail (NEB), and TCRα/β cDNA was then eluted 
by heating the column to 95°C via heat block for 5 min, and centrifuging at 10,000 rpm 
for 5min. Finally, a standard polymerase chain reaction (PCR) using a single primer for 
each of the conserved priming sequences on either end of the mRNA capture probes, and 
additional single primers for the known P14 TCRα and β V-families (P14 TCR-Vα2 and 
TCR-Vβ8.1 genes) was performed to generate a pool of amplicons with corresponding 
P14 CDR3 regions within the resulting PCR product. Confirmation of the correct P14 
TCRα and TCRβ genes was confirmed by standard dye termination sequencing analysis 
of gel-isolated products. 
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RESULTS 
 AFM imaging confirms successful synthesis of DNA origami nanostructures. 
The nanostructure template chosen for our studies was the well-studied 2D rectangle first 
published by Rothemund in 2006 and was assembled and purified following previously 
described methods [341]. As the first application of our technology and what is presented 
here is for immune repertoire analysis, we designed our structures for capture of clonally 
distributed T cell receptor α and β chain mRNAs. For mRNA capture, each DNA 
origami molecule was refolded with selected staple strands extended to include a 3’ 
region complimentary to the constant region of either TCRα or TCRβ mRNA allowing 
for capture of up to 6 copies of each mRNA (Figure 3.1A). Additionally, four staple 
strands were conjugated to biotin for downstream purification and one/two strands were 
conjugated with fluorescein isothiocyanate (FITC) and/or 5-
carboxytetramethylrhodamine (TAMRA) for identification of successfully transfected 
cells (Table 3.1). Successful folding of DNA origami was verified by atomic force 
microscopy (Figure 3.1B). 
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Figure 3.1: DNA origami design and synthesis. [A] Basic DNA origami design 
showing circular M13 ssDNA (red) folded into a rectangular shape by annealing with 
“staple” primers (green), complementary to the M13 ssDNA. Selected staples are 
extended with complementary sequences to TCRα and TCRβ conserved regions (pink 
and blue, respectively) for binding mRNA. Other staples are biotinylated (black) for 
purification, or have fluorescent probes (green dot, red star) attached for transfection 
analysis. [B] Validation of properly folded DNA origami molecules was visualized by 
AFM, demonstrating the anticipated rectangular shape of the nanostructure. Each 
nanostructure is roughly 60 x 90 nM is size. 
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Table 3.1: Origami nanostructure staple modifications. Original sequences 
from [341], modifications include additions of gene-specific capture probes (A or B), 
biotin tags (/3Bio/), and fluorescent markers (/3Fitc/ or /3Tamra/). 
Staple ID Modification Original Sequence Modified Sequence 
73 Alpha probe GCCACGCTATACGTGGCA
CAGACAACGCTCAT 
A’-73-1   
GCCACGCTATACGTGGTTTGAAGATATCTTG 
A’-73-2                
GGTGGCGTTGGTCTCCACAGACAACGCTCAT 
69 Alpha probe GCGCAGAGATATCAAAAT
TATTTGACATTATC 
A’-69-1              
GCGCAGAGATATCAAATTTGAAGATATCTTG 
A’-69-2                
GGTGGCGTTGGTCTCATTATTTGACATTATC 
65 Alpha probe CATATTTAGAAATACCGA
CCGTGTTACCTTTT 
A’-65-1              
CATATTTAGAAATACCTTTGAAGATATCTTG 
A’-65-2                
GGTGGCGTTGGTCTCGACCGTGTTACCTTTT 
61 Alpha probe TTTTGTTTAAGCCTTAAAT
CAAGAATCGAGAA 
A’-61-1              
TTTTGTTTAAGCCTTATTTGAAGATATCTTG 
A’-61-2                
GGTGGCGTTGGTCTCAATCAAGAATCGAGAA 
57 Alpha probe AATCACCAAATAGAAAAT
TCATATATAACGGA 
A’-57-1              
AATCACCAAATAGAAATTTGAAGATATCTTG 
A’-57-2                
GGTGGCGTTGGTCTCATTCATATATAACGGA 
53 Alpha probe CCTCAAGAATACATGGCT
TTTGATAGAACCAC 
A’-53-1              
CCTCAAGAATACATGGTTTGAAGATATCTTG 
A’-53-2                
GGTGGCGTTGGTCTCCTTTTGATAGAACCAC 
158 Beta probe AGTTTGGAGCCCTTCACC
GCCTGGTTGCGCTC 
B’-158-1            
AGTTTGGAGCCCTTCAGTGTGACAGGTTTGG 
B’-158-2              
CTGCACTGATGTTCTCCGCCTGGTTGCGCTC 
162 Beta probe CAGCTGGCGGACGACGAC
AGTATCGTAGCCAG 
B’-162-1            
CAGCTGGCGGACGACGGTGTGACAGGTTTGG 
B’-162-2              
CTGCACTGATGTTCTACAGTATCGTAGCCAG 
166 Beta probe GGTAGCTAGGATAAAAAT
TTTTAGTTAACATC 
B’-166-1            
GGTAGCTAGGATAAAAGTGTGACAGGTTTGG 
B’-166-2              
CTGCACTGATGTTCTATTTTTAGTTAACATC 
170 Beta probe TACCTTTAAGGTCTTTACC
CTGACAAAGAAGT 
B’-170-1            
TACCTTTAAGGTCTTTGTGTGACAGGTTTGG 
B’-170-2              
CTGCACTGATGTTCTACCCTGACAAAGAAGT 
174 Beta probe TTTCAACTATAGGCTGGC
TGACCTTGTATCAT   
B’-174-1            
TTTCAACTATAGGCTGGTGTGACAGGTTTGG 
B’-174-2              
CTGCACTGATGTTCTGCTGACCTTGTATCAT 
178 Beta probe ATATATTCTTTTTTCACGT
TGAAAATAGTTAG 
B’-178-1            
ATATATTCTTTTTTCAGTGTGACAGGTTTGG 
B’-178-2 CTGCACTGATGTTCTCGTTGAAAATAGTTAG 
77 Biotinylation TGCTCAGTCAGTCTCTGA
ATTTACCAGGAGGT 
TGCTCAGTCAGTCTCTGAATTTACCAGGAGGTTTTTT/3
Bio/ 
78 Biotinylation GGAAAGCGACCAGGCGG
ATAAGTGAATAGGTG 
GGAAAGCGACCAGGCGGATAAGTGAATAGGTGTTTTT
/3Bio/ 
79 Biotinylation TGAGGCAGGCGTCAGACT
GTAGCGTAGCAAGG 
TGAGGCAGGCGTCAGACTGTAGCGTAGCAAGGTTTTT/
3Bio/ 
80 Biotinylation TGCCTTTAGTCAGACGAT
TGGCCTGCCAGAAT 
TGCCTTTAGTCAGACGATTGGCCTGCCAGAATTTTTT/3
Bio/ 
89 FITC AGAGGCATAATTTCATCT
TCTGACTATAACTA 
AGAGGCATAATTTCATCTTCTGACTATAACTA/3Fitc/ 
91 TAMRA TATGTAAACCTTTTTTAAT
GGAAAAATTACCT 
TATGTAAACCTTTTTTAATGGAAAAATTACCT/3Tamra/ 
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 Successful cloning and in vitro transcription of the TCR transgenic P14 
TCRα  and β  mRNA was confirmed by sequencing. The P14 transgenic mouse 
generates CD8+ T cells that express only TCR specific for the DbGP33-41 co-dominant 
epitope of LCMV. The P14 animal is widely used and gene sequencing of its TCRα and 
β chains has been well documented [342]. Specifically, the P14 animal is a TCRα 
knockout that is homozygous for a transgene encoding a Vα2/Vβ8.1 TCR specific for the 
LCMV peptide mentioned above. As such, it is deficient in the TCRα gene and therefore 
does not develop endogenous mature αβ T cells. Virtually all of the peripheral T cells are 
CD8+ and will express the transgenic TCR (Figure 3.2A). The mice are commonly used 
for in vitro studies of CD8+ T cell activation and differentiation, as well as a source for 
adoptive transfer of LCMV-specific T cells into wild type C57BL/6 mice. For our 
studies, the use of this model is especially valuable in order for proof-of-principle 
experiments to be conducted without the additional challenges of heterogeneity in 
captured sequences. Once plasmid vectors were constructed and in vitro transcription of 
large pools of both TCRα and TCRβ mRNA was conducted and confirmed by standard 
Sanger sequencing for homology to the known Vα2/Vβ8.1 P14 TCR sequences (Figure 
3.2B). 
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Figure 3.2: Sequencing confirms successful in vitro transcription of 
transgenic P14 TCR mRNAs. [A] Flow cytometry of sorted CD8+ T cells from 
spleens from P14 mice demonstrate >99% of CD8+ T cells to express the transgenic 
Vα2/Vβ8.1 TCR. [B] Sequencing traces of both TCRα (top) and TCRβ (bottom) CDR3 
regions from RT-PCR products in vitro transcribed P14 mRNAs. 100% homology was 
observed between reported P14 sequences and traces generated from in vitro transcribed 
mRNA RT-PCR products. 
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 DNA origami with TCR mRNA-specific probes can specifically hybridize 
with in vitro transcribed TCR mRNA. In order to optimize origami:mRNA binding, 
and for in vitro validation, P14 TCR transgenes encoding either TCRα or TCRβ genes 
were cloned into expression vectors and mRNA was in vitro transcribed. Secondary 
structures of the conserved C-domain of both TCRα and TCRβ mRNA were predicted 
using available software (mfold) to identify accessible regions within the first C-region 
exon for origami-probe annealing. Origami-probe sequences were designed to be 
complimentary to these sites located 3’ to the CDR3 sequence of interest (Figure 3.3A-B 
and Table 3.1). Specific binding of both TCRα and TCRβ mRNA by origami 
constructed with both TCR mRNA-specific probes was observed by atomic force 
microscopy (Figure 3.4A). No binding of mRNA was observed for DNA origami 
refolded without TCR-specific capture staples mixed with TCRα and TCRβ mRNA 
(Figure 3.4B) nor was binding observed for DNA origami with TCR specific staples 
mixed with “reverse sequence” TCRα + TCRβ mRNA. Furthermore, incubation of either 
TCRα or TCRβ mRNA alone with origami constructed with both TCRα and β probes 
yielded origami with binding of mRNA to only one side of the nanostructure, 
demonstrating mRNA-specific binding of both probes (Figure 3.4C-D). Additionally, 
under these saturating conditions, we observed specific binding of origami nanostructure 
to TCR mRNA by changes in mobility during electrophoresis of 20µL of each sample on 
a 1% non-denaturing agarose gel (Figure 3.5A). 
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Figure 3.3: Extended mRNA capture probes on DNA origami scaffold 
are designed to hybridize to conserved regions of either TCRα  or TCRβ  
mRNA. [A] Organization of TCRβ (left) and TCRα (right) genes including a 5’ 
variable region containing the heterogeneous CDR3 sequences of interest followed by a 
3’ conserved region serving as the origami probe hybridization loci. [B] Graphic 
representation of both TCRα and TCRβ mRNA transcripts hybridized to origami probes. 
5’à3’ orientation of both mRNA transcripts as well as both sets of origami probes is 
indicated. As mentioned above, each DNA origami molecule was designed to include 6 
sets of mRNA capture probes on each side for each gene allowing for capture of up to 6 
mRNAs of each species, however to simplify the illustration the origami molecule is 
depicted binding to a single TCRα and TCRβ mRNA. 
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Figure 3.4: DNA origami binding to TCRα/β mRNA visualized by 
atomic force microscopy. TCRα and β mRNAs were in vitro transcribed and 
incubated with DNA origami constructed with or without TCR probes. [A] Wide view 
AFM image of origami constructed with both TCRα/β probes incubated with both TCRα 
and β mRNAs. Visual binding of RNAs to both sides of numerous origami 
nanostructures demonstrates the ability of the nanostructures to bind both TCRα and 
TCRβ mRNAs simultaneously. [B] Wide view AFM image of origami constructed 
without mRNA probes incubated with both TCRα and β mRNAs illustrates no detectable 
non-specific binding of mRNA by the origami nanostructures. [C] Wide view AFM 
image of origami constructed with both TCRα and TCRβ probes incubated with TCRα 
mRNA only. [D] Wide view AFM image of origami constructed with both TCRα and 
TCRβ probes incubated with TCRβ mRNA only. Binding of mRNA to only one side of 
each nanostructure in C-D indicates that the alpha and beta probes are specific for 
binding to only alpha or beta mRNA respectively. 
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Figure 3.5: Gel electrophoresis of products from origami incubated with various in 
vitro transcribed mRNA combinations. TCRα and β mRNAs were in vitro transcribed 
and incubated with origami at 37°C. [A] Products of various mRNA:origami 
combinations were analyzed by agarose gel electrophoresis; Lane 1 - Origami only, Lane 
2 - Origami with alpha mRNA only, Lane 3 - Origami with beta mRNA only, Lane 4 - 
Origami with both alpha and beta mRNA. [B] Selected AFM images were captured of 
incubation products from origami alone (left), binding to individual alpha or beta mRNA 
(center two, respectively), or both mRNAs (right) with corresponding graphic 
illustrations below. 
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 Electroporation of DNA origami nanostructures routinely yields high 
transfection efficiencies. While the majority of the previously mentioned DNA 
nanostructure studies relied on simple cellular uptake of the nanostructures either with or 
without the aid of lipid-based transfection reagents, we found that electroporation of cell 
suspensions with DNA origami nanostructures yields robust transfection efficiencies 
while maintaining high cell viability. To assess transfection efficiency, cells were stained 
with anti-CD8-APC antibody (1:200 dilution, BD Biosciences) and after washing twice 
in FACS buffer, immediately acquired on an LSR Fortessa flow cytometer utilizing the 
origami FITC tag as a readout for successfully transfected cells. After establishing 
optimal voltages and pulse lengths for electroporations to maintain cell viabilities, routine 
transfection efficiency of >85% was observed for both systems after 20-24 hr incubation 
times (Figure 3.6A-B).  
 Additionally, to verify that the DNA origami nanostructures had actually entered 
transfected cells, as opposed to binding non-specifically to the cell surface and giving 
false positive signal, transfection samples were incubated with a concentrated DNase 
pretreatment (Turbo DNase, Ambion, Life Technologies) and then followed by flow 
cytometry analysis. No loss in transfection was observed following DNase treatment 
compared to samples without DNase treatment, indicating the nanostructures were in fact 
entering the cell membranes (Figure 3.7A). To ensure the origami nanostructures were 
sensitive to the DNase treatment resulting in their destruction should they be unprotected 
on the outside of the cell membranes 10 µL of origami (50 nM) incubated in 1 µL DNase  
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(30 min, 37°C) on a 1% agarose gel revealed no detectable nanostructure present 
following DNase treatment (Figure 3.7B).  
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Figure 3.6: High transfection efficiencies achieved by both BTX cuvette 
and NEON syringe transfection systems. [A] Flow cytometry analysis of 
electroporation samples of sorted CD8+ T cells with DNA origami (right) using the BTX 
cuvette system demonstrates transection efficiency of >85% after 24hr incubation 
(bottom) when compared to mock transfection controls (left). [B] Flow cytometry 
analysis of electroporation samples of sorted CD8+ T cells with DNA origami (right) 
using the Neon Syringe electroporation system demonstrates transfection efficiency of 
>90% after 24 hr incubation (bottom) when compared to mock transfection controls 
(left). Samples consisted of 1x106 cells in 75 µL MACS buffer and 25 µL DNA Origami 
(50nM) in 1X TAE-Mg2+ and were compared to negative control mock transfections of 
1x106 cells in 75µL MACS buffer and 25 µL 1X TAE-Mg2+.  
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Figure 3.7: DNase treatment of transfected cells reveals DNA enters cell 
membranes rather than binding non-specifically to cell surfaces. [A] To 
ensure that origami structures were entering cell membranes, rather than binding to the 
cell surface, cells were treated with a DNase cocktail after transfection prior to flow 
cytometry analysis. No significant loss in transfection efficiency was observed from 
samples treated with DNase (right) when compared to samples not treated with DNase 
(middle) relative to mock-transfected controls (left). [B] DNAse digestion destroys DNA 
origami nanostructures: Lane 1- MW marker, Lane 2: DNA origami (upper band), Lane 
3- DNA origami incubated with DNAse. 
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 Biotinylated origami nanostructures can be successfully purified from 
unbound mRNA using avidin column filtration. The incorporation of four biotinylated 
staples into the DNA origami nanostructure design allowed for relatively simple isolation 
of nanostructures from unbound in vitro transcribed mRNA via streptavidin column 
filtration (Figure 3.8A). After one hour of incubation with in vitro transcribed mRNA, 
samples containing origami with (or without) bound mRNA was then isolated from 
unbound mRNA by filtering the lysate through a primed streptavidin resin column. 
Purified origami was then eluted from the streptavidin columns by a solution of excess 
(2mM) biotin. Successful reisolation of mRNA bound origami was observed by gel 
electrophoresis (Figure 3.8B). To determine relative efficiency of origami elution and 
unbound mRNA purification successive elutions were analyzed by gel electrophoresis 
and compared to unpurified origami incubated with in vitro transcribed mRNA. While 
difficult to directly quantify, it was determined that pooling of 3 successive elutions may 
be necessary for high efficiency reisolation of the nanostructures from the purification 
columns. Additionally, the absence of a band corresponding to unbound mRNA 
corroborates RT-PCR data (discussed below) demonstrating undetectable levels of 
unbound mRNA in origami elution fractions. 
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Figure 3.8: Purification of DNA origami nanostructures from in vitro 
transcribed mRNA and cell lysate with bound mRNA using avidin 
filtration columns. [A] Following transfections or incubations with in vitro 
transcribed mRNA, nanostructures with bound mRNAs can be reisolated using avidin 
resin column purification. Following 1 hr incubation of cell lysate in avidin columns, 
three rinses with 350 µL 1X TAE-Mg2+ can be performed to remove any unbound mRNA 
and cellular debris. Origami with bound mRNA can then be eluted from the avidin 
columns with 100 µL 2mM biotin. [B] in vitro Transcribed TCRα/β mRNA was 
incubated with origami nanostructures and samples were purified via avidin column 
filtration and visualized by agarose gel electrophoresis; Lane 1: ladder, Lane 2: 
unpurified origami incubated with mRNA, Lane 3: 1st biotin elution of purified origami 
product, Lane 4: 2nd biotin elution of purified origami product, Lane 5: 3rd biotin elution 
of purified origami product. Subsequent rounds of biotin elutions can be pooled to 
increase efficiency of nanostructure reisolation. 
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 DNA origami mRNA-capture probes function as gene specific primers in 
reverse transcription reactions of captured mRNAs. To covalently link captured 
sequences to the DNA origami, the mRNA capture probes were used as primers for 
reverse transcription. Optimization reactions of reverse transcription were conducted on 
the surface of the DNA origami scaffold using in vitro transcribed TCRα and TCRβ 
mRNA. Briefly, origami with TCR mRNA-specific probes were incubated with in vitro 
transcribed TCR mRNA at 37°C for 20 minutes. The reaction mixture was purified via 
streptavidin columns to isolate origami with bound mRNA from any unbound mRNA. 
Origami with bound mRNA was then either eluted from the columns with 2mM biotin in 
1X TAE-Mg2+ (for AFM post-analysis) or retained in the column to perform the reverse 
transcription reactions directly in the purification column. 
 Four basic steps were identified and analyzed for sequence capture by the origami 
nanostructures (Fig. 4a): 1) The origami nanostructures were synthesized with gene-
specific mRNA capture probes 2) mRNAs were then successfully captured by the 
complimentary probes and thus annealed to the origami templates, 3) successful reverse 
transcription of the mRNA validated as elongation of the probes during a 1 hr 37°C 
incubation resulting in the sequence of interest being tethered into the origami molecule 
as an elongated cDNA strand and 4) an RNase cocktail was administered to the sample 
resulting in the degradation of any bound mRNA. Aliquots of product for validation of 
each step were analyzed by gel electrophoresis (Figure 3-9A) and steps 1, 2, and 4 by 
AFM (Figure 3-9B). 
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Figure 3.9: DNA origami capture probes successfully function as mRNA 
reverse transcription primers to create cDNA extended from the 
origami molecules.  [A] Agarose gel electrophoresis of products from the four stages 
of the amplicon generation process show migration shifts due to binding of mRNA and/or 
cDNA. Lane 1: DNA origami only. Lane 2: DNA origami incubated with in vitro 
transcribed mRNA. Lane 3: DNA origami incubated with in vitro transcribed mRNA 
after a reverse transcription reaction (origami has both cDNA elongation with mRNA still 
bound). Lane 4: DNA origami incubated with in vitro transcribed mRNA after a reverse 
transcription reaction and incubated in an RNase cocktail to remove the bound mRNA. 
[B] Selected AFM images demonstrate products from stages 1 (origami only), 2 (origami 
with bound mRNA), and 4 (origami with extended cDNA only) of the cDNA synthesis 
(stage 3 not imaged). 
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 Sequencing confirms successful transfection of DNA origami nanostructures, 
intracellular capture of mRNA, reisolation of purified nanostructures with bound 
mRNA, use of origami probes as RT primers, and amplification of P14 CD8+ T cell 
TCRα  and TCRβ  genes.  One major advantage of electroporation is that the delivery of 
DNA nanostructures is relatively quick; the time-dependent factor relies on the 
incubation length necessary for origami to come into contact and thus bind cytoplasmic 
mRNA. The stability of the rectangular DNA origami nanostructure used for our 
experiments in cell lysate has been previously evaluated by our group and found to be 
highly stable at 12-24 hr post-incubation [337]. Compared to our previous studies, the 
number of cells used for the transfections described here was increased by 3 orders of 
magnitude (1x106 cells/transfection), therefore sufficient purification of cellular debris 
and biotin from the elution buffer required for clear AFM visualization was not 
attainable. However, we were able to confirm specific mRNA capture and isolation after 
12-24 hr post-transfection incubations by gene-specific RT-PCR amplicon generation and 
sequencing.  
 To confirm capture of TCRα/β mRNA, P14 TCRα and β PCR reactions were 
performed using the RT product from purified origami with bound mRNA from 
transfected cells as input material. The probes on the origami nanostructures acted as 
suitable reverse transcription primers eliminating the need for [primer:template] 
optimization. Furthermore, as binding of mRNA to origami is required for reverse 
transcription, any unbound mRNA remaining in the purification columns were not 
transcribed, as the mRNAs would lack a primer for the RT reaction. Positive controls for 
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the RT-PCR reactions consisted of PCR reactions performed using the eluted RT product 
from origami incubated with in vitro transcribed mRNA for both TCRα and TCRβ genes. 
 Elution of RT product from transfection of origami constructed with TCRα/β 
probes yielded identical results as in vitro transcribed mRNA positive controls (Figure 
3.10A). In contrast, negative control samples consisting of elution of RT product from 
transfection of origami without TCRα/β probes did not yield a PCR product (Figure 
3.10A), indicating undetectable levels of nonspecific mRNA binding or amplification of 
unbound mRNA. Sequence confirmation of purified PCR products from transfected cells 
was obtained by comparison to known P14 TCRα/β sequences [202] confirming the 
ability of DNA origami nanostructures to capture, protect, and reisolate cytoplasmic 
mRNAs following post-transfection purification, and be used in downstream 
amplification and sequencing analysis (Figure 3.10B). 
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Figure 3.10: RT-PCR and sequencing confirm ability of DNA origami 
nanostructures to be transfected and capture both TCRα  and TCRβ  
mRNA from individual P14 CD8+ T cells. [A] Agarose gel electrophoresis of 
TCRα and TCRβ RT-PCR products amplified from mRNA captured by origami purified 
from post-transfected cell lysate. Using in vitro transcribed TCRα/β mRNA as positive 
controls, origami with TCRα/β probes transfected into P14 CD8+ T cells were able to 
bind, protect, and be reisolated with TCRα/β mRNA that was then reverse transcribed 
and amplified yielding identical bands as controls (lanes 2 vs 3 and lanes 5 vs 6). 
However, origami synthesized without TCRα/β probes did not yield RT-PCR products 
(lanes 4 and 7), indicating a lack of detectable non-specific mRNA capture by the 
nanostructures. [B] Sequencing traces of both TCRα (top) and TCRβ (bottom) from RT-
PCR products from transgenic P14 mice with reported TCRα and TCRβ gene sequences 
listed above. 100% homology was observed between reported P14 sequences and traces 
generated from post-transfected RT-PCR products. 
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DISCUSSION 
  In order to recognize and combat a diverse array of pathogens, T cells express a 
large repertoire of clonotypic αβ dimeric T cell receptors, resulting in an enormous 
number of specificities at the population level [228, 343]. TCR diversity is due to two 
processes. First, somatic recombination of V, D (for the TCRβ chain), and J gene 
segments, together with junctional diversity, results in diverse TCRa and TCRb 
sequences [205]. The CDR3 diversity of TCRα and β chains generated by recombination 
of gene segments has been directly estimated for each chain separately to be ~106 unique 
sequences in humans and only a slightly lower estimate of ~8x105 unique sequences in 
mice [192, 236]. Second, pairing between different TCRα and TCRβ chains results in 
potentially a one million-fold increase in TCR diversity: completely non-random pairing 
of each TCRα with a single TCRβ would result in a total diversity of ~106 unique TCR 
while completely random pairing of any TCRα with any TCRβ would yield a maximum 
combinatorial diversity of ~1012 (or greater) unique TCR. This diversity due to pairing of 
TCRα and TCRβ chains has not been systematically examined. The brute force method 
of sequencing both TCR chains at the single cell level is financially unfeasible for large 
naïve T cell populations; each sequencing reaction costs ~$2 so for a single naïve mouse 
with ~107 total T cells this would be a $20,000,000 experiment [260]! Molecular 
strategies for linking TCRα and TCRβ mRNA have not been adequately developed to 
generate suitable input material for standard multiplex deep sequencing of TCR CDR3 
regions that would provide information on both TCR chains from a single cell. One major  
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limitation to such approaches is that hybrid structures, generated by transfection with 
oligonucleotides complementary to the constant regions of TCRα or TCRβ mRNA 
results in activation of nucleases that destroy the template and therefore, preclude TCR 
sequence analysis [344, 345]. Our novel strategy to determine the contribution of pairing 
of different TCRα and TCRβ chains to total T cell receptor repertoire diversity utilizes 
DNA origami nanostructures to specifically bind the constant region of TCRα and TCRβ 
mRNA and protect these hybrid structures from destruction.  
 The fundamental properties of DNA origami nanostructures make them highly 
programmable, low-cost molecules that many labs can synthesize. These qualities have 
pushed researchers to identify the capabilities of using DNA nanostructures as 
therapeutic delivery systems, intracellular machines, and a wide bevy of technologies in 
the molecular biology toolbox. The use of DNA origami described here is the first 
assessment of how these ever evolving nanostructures can be manipulated and used as a 
“single-cell gene chip” for analysis of multiple mRNAs from individual cells without the 
need for single cell sorting. Additionally, the infancy of the field of DNA origami 
suggests that increasingly more complex structures and devices may soon be established, 
adding to the capability of projects such as ours in that new structures may lend to the 
ability to capture even more copies of mRNA and/or withstand intracellular degradation 
for longer periods of time which may be required for capture of rare mRNA species. 
 A central problem in immunology is that the immune system must balance 
diversity in immune populations with maintenance of sufficient precursor cells specific  
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for any given pathogen in order to mount effective responses. Quantitatively defining this 
balance between diversity and protection has been problematic, in large part due to the 
lack of methods for quantitating total TCR diversity; despite the quantitation of sequence 
diversity independently for TCRα and TCRβ chains in the naïve T cell repertoire for both 
humans and mice, a systematic accurate measurement of TCR combinatorial diversity, 
due to pairing of different TCRα and β chains, has not been attempted [192, 236]. Single 
cell sequencing of both TCR chains remains unfeasible while molecular strategies for 
linking TCR sequences have not been adequately developed [260]. We have developed 
novel DNA origami nanostructures that can be transfected into T cells to capture and 
protect both TCRα and TCRβ mRNA, and after re-isolation, can be used as a template 
for reverse transcription reactions, and following with PCR amplification, can provide 
input material for sequencing to obtain CDR3 sequence information for both TCR chains 
from individual cells within polyclonal T cell populations. 
 Due to the highly adaptable nature of the origami molecules, simple changes to 
the sequence of the mRNA capture probes allow this technology to be used in a wide 
variety of cell types in a wide variety of species (including humans). In summary, by 
providing a novel method for obtaining genetic information from individual cells within 
mixed cell populations without the need for single cell sorting, DNA origami 
nanostructures have created a biochemical tool that may be applied by immunologists and 
many other scientists, creating a unique collaboration between synthetic chemists and 
biologists that has been all too rare in the past. 
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 In chapter 4, together with Illumina paired end deep sequencing technology, 
discussion of an approach to link sequences captured by individual origami molecules 
will be discussed. 
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CHAPTER 4 
DEVELOPMENT OF MOLECULAR BOWTIE BARCODES FOR LINKING 
ORIGAMI-CAPTURED TCRA AND TCRB SEQUENCE INFORMATION FROM 
INDIVIDUAL CELLS 
ABSTRACT 
 The immune system must be able to recognize virtually any pathogen (providing 
immunological diversity) while maintaining enough cells specific for each pathogen in 
order to mount an effective response (ensuring sufficient protection). T cells generate 
diversity by imprecise joining of gene segments to generate alpha/beta heterodimeric T 
cell receptors (TCR) during a process called somatic recombination. Current methods do 
not allow for the simultaneous quantitation of both TCRα and TCRβ chain diversity 
from the same cells, which may result in virtually no sharing of clonotypes between 
individuals. Linking sequence information for TCRα and TCRβ chains from individual 
cells has been problematic due to the cost of single cell sorting and inadequate molecular 
approaches for linking the mRNAs encoding these proteins. To address this problem, we 
have developed novel DNA origami nanostructures to capture and protect both TCRα 
and TCRβ mRNAs from individual cells, which can then be physically and 
bioinformatically linked via a unique “bowtie-barcode” capture strand, sufficient to 
generate individual amplicons containing sequence information from both TCR from 
individual cells that can then be paired bioinformatically via next generation sequencing. 
This approach is directly amenable to single cell analysis of virtually any heterogeneous 
cell population for which sequence information on any two genes is required. 
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IMPORTANCE 
 The antigen receptors of mature CD8+ αβ T cells are heterodimers composed of 
two constituent chains generated by the process of somatic recombination of V, D, and J 
genes. The rearrangements for the α and β chains are generally thought to be independent 
processes [192, 236], culminating in the pairing of a single α chain to its complimentary 
β chain. While vast diversity can be generated for each chain by the somatic 
reorganization of TCR genes (including the random N- and P-nucleotide additions at the 
junctions), the theoretical diversity of an individual’s complete TCR repertoire is 
significantly increased by combinatorial diversity; the potential of constructing the 
heterodimeric receptor. Completely random pairing of any one of the numerous possible 
α chains with any of the possible β chains could yield >106 fold increase in theoretical 
diversity, while on the other hand completely non-random pairing where every α chain 
can only pair with a single β chain would mean there is no increase in diversity due to 
combinatorics.  
 Original estimates concluded that each unique TCRβ chain expressed in the naïve 
CD8+ TCR repertoire is on average paired with 25 different TCRα chains (however in the 
effector fraction of the repertoire each TCRβ chain was estimated to pair with only a 
single TCRα chain) [192]. However these estimates were extrapolated from an extremely 
small subset of the repertoire, and may not be universally distributed across the many 
possible TCRβ chain rearrangements. Determining an accurate estimate for the number 
of unique TCRαβ combinations in the entire TCR repertoire requires the development of 
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a technique capable of covalently/bioinformatically linking the α and β chain mRNAs 
from individual cells for subsequent sequencing. 
 
INTRODUCTION 
 One of the key tenants of the adaptive immune system is specificity. This 
specificity is driven by a repertoire of hypervariable antigen receptors (as well as 
antibodies) on both B cells and T cells. The process utilized to create the vast repertoire 
of antigen receptors involves genomic recombination events, enabling the cells and/or 
antibodies to recognize a multitude of potential pathogens that the host may encounter in 
a given lifetime. While the receptors on B cells (BCRs) are necessary to bind antigens 
and produce effective humoral immune responses, the crux of this study focuses on the 
critical nature of the T cell antigen receptor (TCR) for peptide:MHC recognition, and 
cellular immunity. 
 While two classes of T cells exist in animals (γδ and αβ), 90% of circulating T 
cells in humans express an αβ TCR [205] and was the focus of this study. It should be 
mentioned however, that relatively simple modifications to the capture probes (discussed 
below) would allow for analysis of γδ TCR genes, or even BCR/antibody heavy-light 
chain genes. Diversity within the TCR repertoire is generated in a number of ways, and 
similar to the BCR genetic loci, the TCR genetic loci contains many different variable 
(V), diversity (D), and joining (J) gene segments. These gene segments are subjected to a 
rearrangement process for both the α and β TCR chains during the early lymphoid 
differentiation of T cells in the thymus [205, 220]. In addition to the stochastic selection 
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and recombination of the V, (D), and J gene segments, addition and deletion of non-
templated nucleotides at the junctions between the V(D)J genes further increases the 
diversity of the TCR repertoire [222, 346]. With respect to the TCRα locus in humans, 47 
V genes, 57 J genes, and a single constant (C) gene allows for the 105 genes to rearrange 
into 2679 unique α chain VJC gene combinations. The TCRβ chain contains 54 V genes, 
2 D genes, 13 J genes, and 2 C genes, allowing these 71 gene segments to form a possible 
2808 unique β chain VDJC rearrangements. Combinatorial diversity (due to the pairing 
of α chains with β chains) creates an astonishing 7,522,632 possible unique αβ chain 
combinations [347]. What’s even more astounding is the fact that this value does not take 
into account the random insertions and deletions of non-templated nucleotides at the gene 
segment junctions, which result in predicted theoretical repertoires of 1015-20 different 
TCR combinations [229, 230].  
 Described by some as “infinite” [347], the theoretical diversity of the TCR 
repertoire far exceeds the actual size of the repertoire, as restriction by deletion of both 
over- and under-reactive cells occurs during negative and positive thymic selective 
processes, respectively. Furthermore, every given individual’s repertoire is dynamic in 
the sense that the clones (and their relative frequencies) are constantly being molded by 
clonal expansion of cells responding to antigen during said individual’s lifetime [228, 
348]. Original estimates for the human adult TCR repertoire predicted roughly 2.5 x 107 
unique αβ T cell clones [192]. However, advancements in technology have allowed for 
improvement upon estimates such as that by Arstilla et. al. to be considerably 
conservative, with the actual upper bound of TCR diversity in an individual being 
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potentially 4 orders of magnitude higher (1011) [343]. It should be mentioned that the B 
cell antigen receptor (BCR) diversity might be even more pronounced as the process of 
somatic hypermutation (a process of stepwise single nucleotide substitutions into the V 
gene segments and assessment for enhanced antigen binding) increases the diversity of 
expressed V gene segments [307, 349]. For all of the adaptive immune system antigen 
receptors (TCRs, BCRs, and antibodies), the majority of diversity arises in the third 
complementarity-determining region (CDR3) that makes major contact with the antigenic 
peptide [350], and as such, the diversity of the TCR repertoire is directly proportional to 
(and can mainly be attributed to) the diversity of the CDR3 repertoire [347]. 
 Over the last twenty years many different strategies have been employed to 
attempt to investigate the actual size and diversity of the TCR repertoire. Fluorescence 
activated cell sorting (FACS) analysis of subsets of T cells has been commonplace in 
standard immunology labs, however inherent restrictions from this approach lend to 
inaccuracies of predicted evaluations of the repertoire. Specifically, the availability of 
monoclonal antibodies for each of the TCR Vα and/or TCR Vβ gene segments restricts 
the number of analyzed clones per sample. Additionally, no sequence information can be 
garnered from such approaches [351]. Once the disadvantages of FACS were realized, 
methods utilizing TCR gene-specific PCR such as multiplex V-gene segment PCR and 
rapid amplification of cDNA ends (RACE) PCR began to emerge. Additional problems 
however, were immediately identified as not all of the V gene segments had been 
sequenced and thus primer sets did not include an encompassing repertoire of V-gene 
complimentary primers. Furthermore, the introduction of large sets of multiplex primer 
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systems may induce amplification biases in PCR products, and cross-reactivity between 
V-gene subfamilies have required multiplex primer system optimization experiments to 
ensure precise V-gene specific amplification [352] that is still undergoing. The 
immunoscope or CDR3 spectratyping technique to analyze CDR3 polymorphisms was 
the next advent to immune repertoire analysis. The drawbacks to this method however, 
are inherent in the necessity to extrapolate large portions of the repertoire from a very 
small subsample of actual sequence data [353].  As mentioned, spectratyping does not 
give an actual statistically significant portion of sequence data from a full repertoire 
sample. More importantly, the extrapolation necessary for analysis does not allow for a 
quantitative comparison of the clonal aberrations across the repertoire from different 
CDR3 arrangements. Finally, the low input of sequences used for extrapolation may 
induce false positives for sequences [347]. While introduction of Sanger sequencing into 
TCR repertoire analysis allowed for resolution of sequences at the single-cell level, the 
laborious and limiting nature of Sanger sequencing only allows for hundreds to possibly 
thousands of sequences to be assessed for any given investigation [354].  
 The recent advancements in next generation sequencing (NGS) technologies 
allow for the possible sequencing of tens of millions of short DNA sequence reads (i.e. 
TCR receptor CDR3 region sequences) to be both sequenced and analyzed using novel 
pipeline algorithms for both data conversion and read calling in routinely basic 
experiments [240]. Numerous groups have been evaluating methods (using multiplex 
primer systems, RACE amplification, or both) to harness the power of NGS capability for 
the use of immune repertoire sequencing at a massively high-throughput level, however 
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each approach relies on utilization of one of three commercially available sequencing 
platforms, and each comes with both advantageous attributes as well as inherent 
limitations [Table 4.1].   
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Table 4.1: Advantages and disadvantages of NGS methods for analysis 
of immune repertoire diversity. Data adapted from Bolotin et al. [355] and Hou et 
al. [347]. 
 
Method Advantages Disadvantages 
Roche 454 Sequencing Longest read lengths Lowest number of reads, 
bottlenecks in read calling, 
and frame shift errors 
Illumina Sequencing Greatest read numbers Highest error rate, shortest 
read length 
Ion Torrent Sequencing  Frame shift errors, 
moderately short read 
lengths, largest 
amplification biases 
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 While advancements in NGS technology have undoubtedly sent immune 
repertoire sequencing into a field all its own, most of the methodologies yield data from 
only one of the two receptor chains (i.e. either TCRα chain or TCRβ chain CDR3 
sequence data) and therefore are incapable of providing sequence information from a 
complete dimeric receptor pair of mRNAs [356]. The “holy grail” of immune receptor 
repertoire analysis is the capture, sequencing, and analysis of paired TCR (or 
BCR/Antibody) chain sequences to identify complete antigen receptor antigen binding 
sequences that can then be evaluated for introduction into genetically engineered 
chimeric antigen receptor (CAR) T cells, or for the production of broadly neutralizing 
antibody production.  To this end, recently developed systems seeking to acquire paired 
immune receptor gene sequences have been developed. A high throughput VH-VL gene 
sequence oil-emulsion pairing technique has been proposed by De Kosky et al. [261] for 
the evaluation of BCR/Antibody heavy and light chain pairings, single-celled sorting and 
subsequent sequencing methods have been adapted for both TCRs and BCRs [357], and 
combinatorics based approaches allow for the pairing of high copy number sequencing 
via bioinformatics [266].  
 While advancements in sequencing technology have allowed researchers to 
develop platforms for paired immune receptor sequencing from individual cells, each 
comes with its own crippling limitations. Any single-cell sorting-based approach requires 
isolation of single cells into either 96- or 384-well plates, limiting sample sizes necessary 
for complete repertoire analysis [357]. Oil-emulsion systems, such as that proposed by 
De Kosky and colleagues have proven inefficient and result in error-prone pairings due to 
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multiple cells per oil-emulsion droplet, and finally pairSEQ technology, developed by 
Adaptive Biotechnologies can only resolve clones present at ≥1/200,00 frequency, 
meaning that rare clones (which may include the rare, highly effective tumor infiltrating 
lymphocytes) may not be included in final sample analysis [266].  
 In summary, advanced high throughput sequencing technologies (specifically 
those tailored for the pairing of immune receptor gene sequences) are powerful tools for 
analysis of immune repertoires at an extremely high resolution. The inherent limitations 
of currently available techniques however, has prompted our investigation into the 
development of a novel system single-cell paired gene sequencing, with the hopes of 
eliminating both the need for single-cell or oil-emulsion-based sequencing, and any 
combinatorics-based resolution techniques.  
 To this end, in chapter 4 we propose a novel strategy for paired analysis of TCR 
sequences from single cells within heterogeneous cell populations of massive sample size 
without the need for single cell sorting. A key design feature different from what was 
outlined in chapter 3, is that the DNA origami utilized for pairing of immunoreceptor 
genes contain mRNA capture probes on any given nanostructure that are 
bioinformatically linked to one another by a unique 5’-5’ bowtie barcoded capture strand 
that includes ‘matching’ (complimentary) barcodes; the recovered mRNAs are reverse 
transcribed utilizing said capture probes as gene-specific RT primers thereby allowing 
for the bioinformatical linking of the TCRα and TCRβ CDR3 cDNAs back to one another 
during sequencing. 
 
 
160 
MATERIALS AND METHODS 
 DNA Origami Design for both mRNA capture and pairing: As mentioned in 
chapter 3, DNA is an excellent nano-construction material. Our design for the DNA 
scaffold used to not only capture multiple mRNAs from individual cells but to also pair 
said captured mRNAs is very similar to the design discussed in chapter 3 with one major 
exception. As the backbone for our nanostructures we again used the single-stranded, 
M13mp18 genomic ssDNA (~7 kilobases) and fold this strand into the target rectangular 
shape (~60 x 90 nm in scale) using the same cohort of 200+ short, ssDNA “staple” 
strands. While the biotinylated and/or fluorescent tag conjugated staples remain 
consistent with the previously described nanostructure from chapter 3, the mRNA capture 
probes from the nanostructure have been replaced with their basic staple strand 
counterparts. Our design for this nanostructure for capture and pairing of mRNAs 
includes only a single mRNA capture strand integrated into the M13mp18 ssDNA 
backbone with an internal 5’-5’ “bowtie” linkage, allowing for 5’à3’ strand 
directionality on both ends that can be used for dual mRNA capture. Additionally, the 
two ends of each “bowtie strand” synthesized (discussed below) has a unique but 
complimentary set of barcodes (12 nt-mers) that allow for captured mRNA to be 
bioinformatically linked back to one another following sequencing (Figure 4.1). 
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Figure 4.1: DNA origami design for bowtie strand barcoding of 
captured mRNA sequences. Organization of 5’-5’ bowtie mRNA capture probe 
includes a region complimentary to the M13mp18 phage ssDNA that includes a 5’-5’ 
phosphodiester or “bowtie” linkage, resulting in both ends of the bowtie strand to have 
5’à3’ directionality. These two ends are designed to be complimentary to the constant 
regions of either the TCRα or TCRβ mRNAs and therefore serve as our Cα and Cβ 
capture probes and downstream RT primers. Additionally, each capture probe includes a 
12-mer “barcode” upstream from the capture sequence that retains sequence 
complementarity to one another. These barcodes can be used to bioinformatically link 
captured TCRα and TCRβ gene information from the same cell during downstream 
sequencing. The locations of the four biotinylated strands used for purification and FITC 
conjugated strand used for FACS assessment of transfection are included as well. 
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 Design of 5’-5’ “bowtie barcode” mRNA capture strand: The Illumina 2x250 
paired-end sequencing platform is ideal for analysis of DNA origami-captured gene 
sequences because of its ability to generate short sequence reads in massively parallel 
reactions. To utilize this technology, we developed and optimized a novel bowtie-barcode 
pairing strategy for linking two complimentary TCR sequences from individual T cells 
during downstream sequencing. This system is highly modular, and can be easily adapted 
to link the TCRα and TCRβ mRNA from T cell receptor genes or virtually any two 
mRNAs from individual cells by relatively simple changes to the mRNA-capture 
sequences in the bowtie barcode strands. Our design requires that a long ssDNA be 
constructed containing a central 5’-5’ bowtie linkage (pre-synthesized and ordered from 
commercial vendor IDT), allowing for both ends to run 5’à3’ in direction. One side of 
the bowtie linkage contains a specific sequence complimentary to the M13mp18 phage 
ssDNA origami backbone, and both sides contain conserved PCR primer sites for 
downstream amplification, unique barcodes complimentary to one another, and mRNA 
capture sites complimentary to the conserved region of the genes of interest (Figure 
4.2A). This long bowtie mRNA capture strand is then included in the DNA origami 
mastermix and the portion of the bowtie barcode strand complementary to the M13mp18 
sequence allows for self-assembly with the origami nanostructure with the 
complementary mRNA capture portion of the bowtie barcode strands extending off the 
nanostructure template (Figure 4.2B).  
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Figure 4.2: Bowtie barcode design and integration into DNA origami 
nanostructure. [A] Organization of 5’-5’ bowtie barcode mRNA capture probe. 
Various regions of the bowtie barcode strand allow for incorporation into DNA origami 
nanostructures (Origami’), conserved priming sites for downstream PCR amplification (Y 
and X’), barcode pairing (BC and BC’), and TCRα/TCRβ mRNA capture (Cbeta’ and 
Calpha’). [B] Schematic visualization of 5’-5’ bowtie barcode mRNA capture strand 
extending from the surface of an origami nanostructure while annealing with TCRα and 
TCRβ mRNA (note: the length of the 5’-5’ bowtie barcode strand has been exaggerated 
to allow for visualization of the structure).  
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 Oil-emulsion set-up for synthesis of bowtie barcode mRNA capture probes: 
Water-in-oil emulsion droplets are utilized to ensure that complimentary barcodes are 
incorporated onto each side of individual bowtie strands and that a different set of unique 
barcodes is incorporated into each different bowtie strand synthesized. A large aliquot of  
“ssDNA bowtie backbone” strand (including an M13mp18 complimentary sequence and 
2 conserved annealing sites) is procured from a commercial vendor (IDT) (Figure 4.3). 
Additionally, unique barcode-labeled strands consisting of in order 5’à3’: 1) a sequence 
complementary to one side of the 5’-5’ backbone strand whose complement will serve to 
encode the complementary mRNA capture probe for TCRβ (Cbeta), 2) a sequence to 
encode a conserved PCR priming site (x’), 3) a random 12-mer (412 = 16,777,216 unique 
barcode strands) nucleotide barcode (BC’), 4) a second sequence to encode a conserved 
PCR priming site (Y’), and 5) a second sequence complementary to the other side of the 
5’-5’ backbone strand whose complement will serve to encode the complementary 
mRNA capture probe for TCRα (Calpha’) (Figure 4.3). The ssDNA barcode strands 
were converted into dsDNA by a first-strand-synthesis molecular reaction with the E. coli 
DNA Polymerase I Large (Klenow) Fragment [358] as per manufacturer’s 
recommendations (New England Bioscience) resulting in each of the dsDNA strands 
obtaining complimentary barcodes to one another (BC/BC’) (Step 1). The ssDNA bowtie 
backbone and dsDNA barcode strands were then incorporated at a 1:1:1 molecule-to-
molecule-to-droplet ratio in an oil-water emulsion droplet system using the alternative  
protocol from Williams et al. [359] using ABIL EM90 surfactant (Evonik Industries)  
centrifuging the emulsions (Step 2).  
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Figure 4.3: Set-up of oil-water emulsion elongation system. Construction of 
the 5’-5’ bowtie barcode mRNA capture probes containing complimentary barcode 
sequences requires input of two commercially acquired ssDNA oligos. Step 1) First 
strands synthesis of ssDNA barcode strands using a primer complimentary to the Calpha’ 
sequence on the 3’ end of the ssDNA barcode strand creates dsDNA barcode strands. 
Step 2) Using a 1:1 stoichiometric ratio, the dsDNA barcode strands and ssDNA bowtie 
backbone strands are incorporated into individual droplets ensuring that both sides of 
each bowtie backbone strand will incorporate complimentary barcodes and that each 
bowtie barcode strand synthesized will have a unique set of barcodes. 
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 Overlap extension elongation and purification of bowtie barcode strands: As 
the aqueous phase of the emulsion droplets will comprise the necessary enzyme, 
nucleotides, buffer, and other reagents necessary for common PCR, standard denaturation 
(90°C-30s), annealing (55°C-30s), and elongation (72°C-30s) steps were carried out in 
each droplet (Figure 4.4). Following dissociation, the hybridization between individual 
strands of the dsDNA barcode with their complementary annealing sequences on either 
end of the ssDNA bowtie strand (Step 1) acts as a primer and template system for overlap 
extension elongation, incorporating the conserved priming PCR priming sites, 
complimentary 12-mer barcodes, and TCRα/β capture sites on either end of the 5’-5’ 
bowtie linkage (Step 2). While this system does not serve as an exponential PCR 
amplification, multiple (20) cycles were utilized to ensure that both ends of each 5’-5’ 
backbone strand were elongated, minimizing single-sided elongation products. Overlap 
extension products were then extracted from the oil-water emulsion system using a 
standard organic solvent ether/ethyl acetate extraction protocol [359], and ssDNA bowtie 
barcode mRNA capture probes were then purified from remaining nucleic acids by 
standard denaturing PAGE gels. Final products at this point contained (in order from 5’-
5’ central bowtie linkage extending towards both 3’ ends) the following: an (one side 
only) M13mp18 complimentary sequence (Origami’), the annealing sites for oil-water 
emulsion hybridizations (Calpha/Cbeta), internal conserved PCR priming sites (Y/X’), 
complementary 12-mer barcodes (BC/BC’), external conserved PCR priming sites 
(X/Y’), and mRNA capture sequences complementary to conserved regions of TCRα and 
TCRβ mRNAs (Cbeta’/Calpha’) (Step 3).  
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Figure 4.4: Overlap extension and purification of complete bowtie 
barcode strands. Each droplet formed during the oil-emulsion contains a single 
dsDNA barcode strand and a single ssDNA bowtie strand. Step1) Following 95°C 
denaturation, each of the dsDNA barcode strands will hybridize (55°C) with their 
respective complementary sequences on either side of the ssDNA bowtie strand 
(Calpha’/Calpha and Cbeta’/Cbeta). Step 2) Once hybridized, overlap extension 
elongation is carried out (72°C) on both ends of the ssDNA bowtie strand to incorporate 
internal conserved PCR priming sites (Y’ and X), complementary barcodes (BC and 
BC’), external conserved PCR priming sites (X’ and Y), and TCRβ and TCRα 
complementary mRNA capture sequences (Cbeta’ and Calpha’). Step 3) Following 20 
cycles of the denature/anneal/elongate protocol, standard organic solvent extraction and 
denaturing PAGE purification yields purified bowtie barcode strands suitable for 
incorporation into DNA origami nanostructures.  
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 Synthesis of DNA origami with bowtie barcode mRNA capture strand: 
Synthesis of the DNA origami nanostructures follows the same protocol as that outlined 
in chapter 3. While standard staples are mixed in excess, the bowtie barcode mRNA 
capture strands and biotin-tagged staples were PAGE-purified and quantified (by 
measuring absorbance at 260 nm) prior to being included in the origami folding reaction. 
Scaffold M13mp18 ssDNA, staple DNA, and functionalized staples (including the bowtie 
barcode strand) were then mixed in a fixed 1:5:3 ratio (50 nM scaffold, 250 nM staples, 
150 nM bowtie barcode/biotinylated tags/fluorophore tags) in aqueous buffer (1x TAE 
with 12 mM Mg2+), followed by thermal denaturation (90°C) and gradual annealing (to 
20°C) over 12 hours. Final concentration was measured by A260/A280 absorbance and 
standardized to either 20 or 50 nM depending on the downstream application.  
 Mice: 6-8 week old female C57Bl/6J mice were purchased from Jackson 
laboratories (Bar Harbor, Maine). P14 transgenic mice, in which CD8 T cells express 
TCR specific for the DbGP33-41 epitope of LCMV, were obtained from Dr. Rafi Ahmed 
and bred in our animal facilities. All studies were conducted according to animal protocol 
12-1229R under the approval and guidance of the Arizona State University Institute for 
Animal Care and Use Committee. 
 DNA origami transfection into primary T cells: Cell sorting and transfections 
were carried out following the protocol outlined in chapter 3.  
 Intracellular TCR mRNA binding, cell lysis, and origami purification: Cell 
lysis and column purification were performed as outlined in chapter 3 with one alteration.  
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As the nanostructures purified from cell lysate and unbound mRNA was not eluted from 
the purification columns for imaging as it as directly used for reverse transcription of 
captured TCRα/β mRNA, streptavidin conjugated resin was used for purification rather 
than monomeric avidin. Monomeric avidin is mainly designed for use in simple affinity 
chromatography purifications of proteins, antibodies and other molecules with a biotin 
tag. The advantage of monomeric avidin over native avidin, a tetrameric molecule, and 
streptavidin (also tetrameric) is that monomeric avidin has a much lower biotin binding 
affinity, Kd=10-7 as opposed to native avidin/streptavidin Kd=10-15 [360]. The decreased 
binding affinity of monomeric avidin allows more efficient elution of molecules with 
mild elution buffers (2mM Biotin in 1X PBS), as opposed to the strong denaturing 
buffers (8M Guanidine-HCl, pH 1.5) required for the higher affinity avidin/streptavidin 
column elution. 
 Reverse transcription and TCR chain CDR3 amplicon generation: Reverse 
transcription reactions were again performed directly in the streptavidin purification 
columns using the protocol outlined in chapter 3. The TCRα/β capture sequences on the 
ends of the bowtie barcode strands perform identically to the mRNA capture probes 
outlined in chapter 3 in terms of acting as suitable reverse transcription (RT) primers, 
again eliminating the need for [primer:mRNA] optimization. Once mRNA-bound origami 
was purified from cell lysate in the streptavidin columns, reverse transcription (RT) was 
performed directly in the columns. Using the 5’à3’ TCRα and TCRβ capture regions on 
the bowtie barcode strands as RT primers, elongation was achieved by simply adding 40 
µL of the RT mastermix (Omniscript, Qiagen) directly into the purification column, and 
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incubating for 1 hr in a 37°C heat block. The RNA was then removed by addition of 2 µL 
of an RNaseH cocktail (NEB), and barcoded TCRα/TCRβ CDR3 cDNA can be 
dissociated from the origami nanostructures by heating the columns to 95°C via heat 
block for 10 min (dissociating the nanostructure DNA strands), and centrifuging at 
10,000 rpm for 1 min to collect the bowtie barcode strand containing TCRα and TCRβ 
CDR3 sequence information.  
 To validate this approach, initial transfections were conducted using TCR-
transgenic P14 CD8+ T cells. As these cells express only a single TCRα and TCRβ chain, 
comparing captured sequences to the known P14 sequences allowed for confirmation of 
successful mRNA capture, RT, amplification, and sequencing. Amplification products 
were achieved using standard PCR (Phire kit, Thermo Scientific) protocols with two 
primer sets, one for amplification of P14 TCRα CDR3 sequence information and the 
other for P14 TCRβ CDR3 sequence information (see below).  
  
RESULTS: 
 The use of an Oil-emulsion droplet PCR technique created individualized 
PCR reaction vessels. One of the most novel parts of the bowtie barcode synthesis 
system is the utilization of oil emulsion droplets as individual vesicles for bowtie 
elongations. Controlling the stoichiometry between the number of droplets and input of 
bowtie strands vs dsBC strands ensures that both sides of each bowtie strand will be 
elongated by only a single dsBC strand (ensuring complementary barcodes on each 
bowtie strand). We first evaluated time and temperature of oil emulsion set ups to try and 
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establish the most uniform droplet distribution we could containing sufficient numbers of 
droplets to meet the synthesis needs. It was determined that a speed of 2000 rpm for 5 
min at 4°C yields repeatable emulsions with droplets of fairly uniform size at a high 
enough count to satisfy our production needs [Figure 4.5]. Slower spinning and different 
aqueous:oil volumetric ratios have previously been reported to generate ~109 PCR-
competent compartments per milliliter of emulsion [359], we estimate that our system 
can generate an even greater number of droplets >1010 droplets/mL (based on droplet size 
comparisons), which is sufficient for our input of 1.2 x 108 backbone bowtie molecules 
per emulsion. 
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Figure 4.5: Oil-emulsion droplet size and count depends on 
centrifugation speed and duration of spin. Uniform droplet sizes at sufficient 
quantity were obtained by centrifugations at 2000 rpm, for 5 min, at 4°C (right). Slower 
centrifugation speeds yielded emulsions with droplet sizes varying wildly in diameter 
(left and center). Furthermore, oil-emulsions established at RT did not produce repeatable 
results (not shown).  
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 Optimization of [bowtie backbone strand]:[dsBC strand] yields high 
efficiency of double-sided elongation products. Water-in-oil emulsion droplets are 
utilized to incorporate a different set of complimentary barcodes on each bowtie linker 
strand synthesized. To obtain dsDNA barcode strands for input into the emulsions, first 
strand synthesis reactions were performed and optimized to produce individual dsDNA 
barcode strands containing complementary 12mer barcodes on each strand. Synthesis 
reactions were performed with the Large (KLENOW) fragment of the E. coli DNA 
polymerase I enzyme (NEB) per manufacturer’s protocol with slight changes to 
incubation times and input concentrations. Incubation times of 30 minutes were 
determined sufficient for optimal dsDNA barcode synthesis [Figure 4.6A], and a 1:1 
ratio of ssDNA barcode strand to primer at 5 µM each [Figure 4.6B]. 
 Following synthesis of the dsDNA barcode strands, oil-emulsion strand 
elongation of the ssDNA bowtie backbone was performed and optimized revealing a 10:1 
ssDNA backbone bowtie strand:dsDNA barcode strand (5.0 µM:0.5 µM) per droplet ratio 
[Figure 4.7]. While this system is not an exponential PCR amplification, multiple cycles 
(up to 30) were evaluated to determine the minimum number of cycles optimal for 
ensuring that both ends of each backbone bowtie strand were elongated. It was 
determined that 20 cycles are necessary for highly efficient double-sided elongation as 
determined by a lack of non-elongated product remaining in the sample [Figure 4.8].  
 Finally, to evaluate whether or not different dsDNA barcode strands were being 
elongated on either side of a single ssDNA backbone bowtie strand (thus yielding non-
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complementary barcodes on a given bowtie strand), we designed a system including two 
dsDNA barcode strands of different lengths (short = 70 bp and long = 95 bp), included 
equal concentrations (0.25M) of both strands in the oil-emulsion system. Products from 
systems including only the short dsDNA barcode strand yielded 150 bp elongation 
products, while products from systems including only the long dsDNA barcode yielded 
only 200 bp products. When emulsions were carried out using both short and long 
dsDNA barcode input, no detectable hybrid structures (>150 bp < 200 bp) were observed 
[Figure 4.9], indicating that the vast majority of synthesized bowtie barcode strands were 
elongation products from the same dsDNA barcode strand, and therefore the barcodes 
contained on either end of a compete bowtie barcode strand should be complementary to 
one another for bioinformatically linking captured TCRα and TCRβ CDR3 information 
from the same cell back to one another.  
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Figure 4.6: First strand synthesis of dsDNA barcode strand. [A] Time trial 
of E. coli large (KLENOW) fragment elongation reaction demonstrates efficient 
synthesis of dsDNA after 30 min elongation at 37°C. [B] A titration of input ssDNA 
barcode strand vs primer was conducted to determine optimal [ssDNA]:[primer] ratio for 
synthesis of dsDNA. It was determined that a 1:1 ratio of input material (5µM each) 
yielded the most efficient production of dsDNA. 
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Figure 4.7: Evaluation of DNA input concentrations for optimization of 
bowtie barcode mRNA capture strand synthesis. Titrations of ssDNA bowtie 
strand and dsDNA barcode strand were assessed to evaluate the optimal ratio of input 
material. Complete (double-sided) elongation products are 210bp in length, while single-
sided elongation products are 160bp. The dsDNA barcode strand is 110bp. Lanes 1-4: A 
10:1 ratio (5.0 µM:0.5 µM) of ssDNA bowtie strand vs dsDNA barcode strand yielded 
the most efficient production of complete (double-sided) elongation product. Lanes 6-9: 
Increasing the dilution to 100:1 (5.0 µM: 0.05µM) of ssDNA bowtie strand vs dsDNA 
barcode strand greatly reduced the synthesis efficiency of complete (double-sided) 
elongation product. Lanes 11-14: Further dilution to 1000:1 (5.0 µM: 0.005 µM) yielded 
virtually no complete (double-sided) elongation product.  
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Figure 4.8: Optimization of strand dissociation, annealing, and 
elongation cycle number. To assess the minimum number of cycles necessary for 
efficient (double-side) elongation of ssDNA bowtie backbone strands, aliquots of 
emulsion were run for 5 (lanes 2-4), 10 (lanes 4-7), 20 (lanes 8-10), and 30 (lanes 11-13) 
cycles and products analyzed by denaturing PAGE. It was determined that 20 cycles 
(lanes 8-10) are sufficient for dual-sided elongation (a lack of band corresponding to un-
elongated ssDNA bowtie at 80 bp).  
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Figure 4.9: Oil-emulsions and limiting dsDNA barcode concentrations 
ensure complementary barcodes on both ends of bowtie strands. To 
assess whether ssDNA barcode strands were being elongated by different dsDNA 
barcode strands (and thus resulting in non-complementary barcodes being incorporated), 
two dsDNA barcodes of different lengths were included in the same oil-emulsion 
elongation reaction. Lane 2 demonstrates the elongation product from the short dsDNA 
barcode strand only (160bp). Lane 3 demonstrates the elongation product from the long 
dsDNA barcode strand only (200bp). Lane 4 represents the emulsion containing both the 
short and long dsDNA barcode strands. While products identical to those from the short 
and long dsDNA barcode only emulsions are present, no hybrid length products 
(>160bp<200bp) are readily visible, indicating no detectable cross annealing between 
different dsDNA barcode strands on the same bowtie backbone strand. 
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 DNA origami nanostructures incorporate bowtie barcode mRNA capture 
strands: Synthesis of the DNA origami nanostructures followed the same protocol as that 
outlined in chapter 3 with Scaffold M13mp18 ssDNA, staple DNA, and functionalized 
staples (including the bowtie barcode strand) mixed in a fixed 1:5:3 ratio (50 nM 
scaffold, 250 nM staples, 150 nM bowtie barcode strand/biotinylated staples/fluorophore 
conjugated staples) in aqueous buffer (1x TAE with 12 mM Mg2+), followed by thermal 
denaturation (90°C) and gradual annealing (to 20°C) over 12 hours. Final concentration 
was measured by A260/A280 absorbance and standardized to either 20 or 50 nM depending 
on the downstream application. Successfully annealed origami nanostructure products 
were visualized by AFM to confirm incorporation of the bowtie barcode mRNA capture 
strand. 
 Sequencing confirms that purification of DNA origami nanostructures with 
bound TCR mRNA from transfected P14 CD8+ T cells provides suitable input 
material for RT-PCR, and yields barcoded TCRα  and TCRβ  CDR3 sequence 
information. As a proof of principle experiment to validate the bowtie barcode system 
was capable of capturing, protecting, and being reisolated with both TCRα and TCRβ 
mRNA, transfections of sorted CD8+ T cells from splenocyte populations from the 
transgenic TCR P14 mouse were performed. Since the P14 mouse expresses a single 
known TCRα and TCRβ chain, simple RT-PCR and Sanger sequencing was used to 
validate sequence capture. Following transfections, nanostructures with bound mRNAs 
were purified from cell lysate using streptavidin primed purification columns. After  
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rinsing the columns to remove unbound mRNA and cellular debris, RT reactions were 
performed directly in the columns using 40 µL of RT mastermix (Omniscript Kit – 
Qiagen) per manufacturer’s protocol with 1 hr incubations in a 37°C heat block. 
Following RT, the elongated bowtie barcode strands were dissociated from the 
nanostructures by heating to 95°C for 10 min in a heating block and centrifuging at 10k 
rpm for 1 min to collect the elongated bowtie barcodes. Standard PCR reactions (Phire kit 
– Thermo Scientific) were performed using 2 µL of the eluted bowtie barcode. Primers 
for amplification of the TCRα CDR3 region included a forward primer containing a 
sequence of the P14 TCRαV14 gene and a reverse primer with the conserved “X” 
sequence. Amplification of the TCRβ CDR3 region utilized a forward primer for the 
TCRβV13 gene and a reverse primer with the conserved “Y” sequence. Positive controls 
consisted of standard gene-specific RT-PCR using extracted P14 CD8+ T cell mRNA and 
Cα and Cβ RT primers with the same sequence as the bowtie barcode mRNA capture 
sequences, followed by PCR with the same Vα and Vβ primers described above, but 
using the Cα and Cβ primers from the RT step (as there was no bowtie barcode in these 
reactions the use of the X’ and Y primers would not have been possible). Additional 
positive controls using origami with bowtie as RT primers followed by X/Vα14 and 
Y/Vβ13 PCR were also performed. Negative controls consisted of mock transfections 
using origami synthesized without bowtie barcodes followed by X/Vα14 and Y/Vβ13 
PCR. Positive control samples yielded bands of appropriate length based on gel 
electrophoresis and were confirmed to be correct based on comparison to known P14  
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TCRα and TCRβ sequences by standard Sanger sequencing [Figure 4.10A, Lanes 4-5 
and 7-8]. Both amplifications (TCRα and TCRβ) from RT product eluted from purified 
origami synthesized with bowtie barcodes yielded products comparable to positive 
controls as determined by gel electrophoresis [Figure 4.10A, Lanes 6 and 9] and were 
further confirmed to be correct by comparison to known P14 TCRα and TCRβ sequences 
as evaluated by standard Sanger sequencing [Figure 4.10B-C]. Negative controls yielded 
no detectable RT-PCR product as determined by gel electrophoresis [Figure 4.10A, 
Lanes 1-2], indicating that no detectable non-specific amplifications were occurring. 
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Figure 4.10: RT-PCR and sequencing confirm capture, amplification, 
and barcoding of TCRα  and TCRβ  mRNA suitable for downstream 
genetic analysis. [A] Agarose gel electrophoresis of RT-PCR products from origami-
transfected P14 CD8 T cells. Lanes 1-2: Negative control RT-PCRs (TCRα and TCRβ 
respectively) from mock-transfected cells. Lane 3: Ladder. Lanes 4/7: Positive control 
P14 RNA RT-PCRs using Cα/Cβ RT primers followed by Cα-Vα14/Cβ-Vβ13 PCR 
primers, respectively. Lanes 5/8: Positive control P14 RNA RT-PCRs using origami as 
RT primer followed by X-Vα14/Y-Vβ13 PCR primers, respectively. Lanes 6/9: Origami 
transfected samples with X-Vα14/Y-Vβ13 PCR primers, respectively. [B] Sequencing 
trace of excised band from Lane 6 with corresponding TCRα gene/bowtie sequence 
aligned above. [C] Sequencing trace of excised band from Lane 9 with corresponding 
TCRβ gene/bowtie sequence aligned above. 
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DISCUSSION 
 While the aim of this thesis was to demonstrate the ability of bowtie incorporated 
DNA origami nanostructures to capture, barcode, and thus link TCR mRNAs from 
individual cells, future experiments will seek to evaluate the use of the DNA origami 
nanostructure bowtie barcode approach to pair thousands or even millions of TCR gene 
sequences from wild type (wt) individuals in a single experiment. Following transfections 
of wt C57BL/6 CD8+ T cells, cell lysis, and RT, a multiplex PCR will be performed 
using a single primer for both of the conserved priming sequences on either end of the 
mRNA capture probes (Y and X) and the well-established multiplex primer system [202] 
for the 23 functional murine TCRα V-families and the 19 functional TCRβ V-families 
(Table 4.2, Figure 4.11) using manufacturer’s protocols of a commercially available 
multiplex PCR kit (Multiplex Kit – Qiagen) to generate a pool of barcoded amplicons 
with corresponding TCRα and TCRβ CDR3 sequences within the resulting PCR 
products. Obtained amplicons should be roughly 350 bp in length and will be 
immediately suitable for use in standard Illumina paired-end sequencing (to be performed 
under standard Illumina protocols [240]). Reads will first be subjected to a series of 
quality control steps for quantifying biases at any given base, and will then be parsed into 
independent FASTQ files for alignment using BWA-MEM for accurate split-read 
alignment of the unique CDR3 sequences. Using the well-practiced standard for immune 
receptor gene calling strategy, each sequence will be required to have a 12 nucleotide 
match to one of the Vα or Vβ gene segments, corresponding to the CASS consensus 
amino acid sequence from the second conserved cysteine at the 3’ end of the V segment, 
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as well as a 6 nucleotide match to the J segment corresponding to the conserved 
phenylalanine [192, 232, 236, 246, 266, 272]. The total number of nucleotides between 
these codons determines the length and therefore the reading frame of the CDR3 region. 
Processed sequence data will then deposited in the ASU secure relational database 
management system, which allows a WebApp front end through JasperSoft Server as 
well as a secure MongoDB instance allowing Ad Hoc querying. Pairing of TCRα and 
TCRβ sequences form individual cells will be conducted by a simple “if-then” algorithm, 
searching for complementary base pairing at the 12-mer-barcode-sequence stretch of each 
aligned read. 
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Table 4.2: Multiplex PCR system for amplification of C57BL/6 mouse 
TCR genes. TRAV AND TRBV primer sequences were obtained from the 
ImmunoGenetics TRAV/TRBV primer database [202]. 
 
Primer Sequence Primer Sequence 
TRAV1 CTCCACATTCCTGAGCC TRBV1 GTATCCCTGGATGAGCTG  
TRAV2 ACTCTGAGCCTGCCCT TRBV2  GGACAATCAGACTGCCTC  
TRAV3 GCCCTCCTCACCTGAG TRBV3  GATATGGGGCAGATGGTG  
TRAV4 AGGAACAAAGGAGAAT TRBV4  CAGGTGGGAAATGAAGTG  
TRAV5 GGAGAAGGTCCACAGCTC TRBV5  GCCAGAGCTCATGTTTCTC  
TRAV6A GGAGAAGGTCCACAGCTC TRBV12  CCAGCAGATTCTCAGTCC  
TRAV6B CAACTGCCAACAACAAGG TRBV13  GTACTGGTATCGGCAGGAC  
TRAV6C GTTCTGGTATGTGCAGTATCC TRBV14  GGTATCAGCAGCCCAGAG  
TRAV6D TCCTTCCACTTGCAGAAAG TRBV15  GTGTGAGCCAGTTTCAGG  
TRAV7 CAGCAGAGCCCAGAATC TRBV16  GAAGCAACTCTGTGGTGTG  
TRAV8 AGAGCCACCCTTGACAC TRBV17  GAACAGGGAAGCTGACAC  
TRAV9 CCAGTGGTTCAAGGAGTG TRBV19  GGTACCGACAGGATTCAG  
TRAV10 CTACACTGAGTGTTCGAGAGG TRBV20  GCTTGGTATCGTCAATCG  
TRAV11 AACAGGACACAGGCAAAG TRBV23  GCCAGGAAGCAGAGATG  
TRAV12 TGACCCAGACAGAAGGC TRBV24  GCACACTGCCTTTTACTGG  
TRAV13 TCCTTGGTTCTGCAGG TRBV26  GAGGTGTATCCCTGAAAAGG  
TRAV14 CTCTGACAGTCTGGGAAGG TRBV29  GTACTGGTATCGACAAGACCC  
TRAV15 TTAGTGGAGAGATGG TRBV30  GGACATCTGTCAAAGTGGC  
TRAV16 ATTATTCTCTGAACTTTCAGAAGC TRBV31  CTGTTGGCCAGGTAGAGTC  
TRAV17 CAGTCCGTGGACCAGC Y GGACAGCAAAGACAGCACCT 
TRAV18 CAAGATTTCACCGCACG   
TRAV19 GCTGACTGTTCAAGAGGGA   
TRAV21 AATAGTATGGCTTTCCTGGC   
X’ CAAGGGCTATTTCCCTGAGC   
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Figure 4.11: Confirmation of C57BL/6 TCRα /β  multiplex primer 
system. Each individual forward primer from the TCRα multiplex pool (23 primers) 
and TCRβ multiplex pool (19 primers) was subjected to PCR testing using RT products 
from total cellular CD8+ mRNA RT reactions. (Top) The forward TCRα primers were 
paired with a single Cα-specific reverse primer and (Bottom) the forward TCRβ primers 
were paired with a single Cβ-specific reverse primer. Multiple products were observed 
for many of the primer pairs as wild type mice will express numerous reorganizations for 
each Vα/Vβ gene selected. 
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 The recent advancements in NGS technologies have profoundly increased the 
ability of researchers to study and evaluate immune repertoires. The sheer amount of raw 
data alone of which NGS-based approaches allow for acquisition would have been 
unheard of merely ten years ago. With improvements on the efficiency and streamlining 
of methodology of not only our protocol, but all future immune repertoire analysis 
approaches, the rate limiting step will eventually fall on data management and analysis 
rather than the actual wet-lab bench work. As proposed by many researchers in the field 
of immune repertoire analysis, the establishment of communal databases, improvements 
in computational algorithms and software for analyzing massive repertoire data sets will 
be paramount in the continued advancement of the study of immunology [340, 347, 361].  
 Up to this point most robust immune repertoire sequencing approaches have been 
focused on high-throughput single-chain analysis (i.e. TCRβ) or low-throughput single-
cell analysis of both chains (TCRα/β or IgH/L). Single chain approaches do not take into 
account the cognate pairing of alpha chains and beta chains (or heavy and light chains), 
and therefore do not provide the true identity of the antigen receptor as they only shed 
light on ‘half the story’. Single-cell sorting approaches only allow for the analysis of 
hundreds of cells from a given experiment and therefore do not provide a representative 
sample of any meaningful data set. In order to identify TCRs (or BCRs/antibodies) for 
therapeutic use, functional analysis, or vaccine efficacy, sequence information from both 
TCRα and TCRβ chains (or heavy and light chains) must be identified as a pair. Single-
celled approaches for pairing TCR chains up to this point have relied on numerous 
different approaches. Some rely on isolating individual lymphocytes and physically 
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linking the chains by bridge amplification PCR before sequencing. Alternatively, some 
groups have investigated approaches for uniquely barcoding the chains from individual 
cells. These approaches however have proven limited both by cell throughput and 
efficiency and furthermore require fabrication and operation of highly complicated 
microfluidic devices [262, 357]. Advancements in oil-emulsion PCR systems led other 
groups to investigate the use of cell encapsulation, lysis, and RT-PCR all within 
individual oil emulsion droplets, linking the TCR chains by overlap extension PCR. The 
published work however only demonstrated this approach for a single TCRβV gene 
subset of cells (TCRβV7) and extremely poor efficiency (~700 TCRα/β pairs from 8x106 
input cells) [262]. Improvements on the oil-emulsion approach led another group to 
investigate the use of bead capture of individual B cell mRNA followed by linkage PCR 
in emulsion droplets containing one bead each, again however modest paired sequence 
yields and low efficiency was observed [261].  
 Here we present a novel approach at high-throughput paired-chain analysis that 
requires neither initial stage single-cell sorting, nor the need for single-cell/bead oil 
emulsion droplet capture, the limiting factors in the experiments described above. Our 
overall goal was to develop a robust method for sequence analysis of linked genes from 
individual cells without the need for single-cell sorting or specialized equipment that is 
not only cost-effective and has the capacity for analysis of large cell populations, but was 
also easily adaptable for probing sequence diversity of paired genes from other 
heterogeneous cell populations. To such end we have developed novel DNA origami 
nanostructures that are able to capture and protect mRNA from transfected cells and by 
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inclusion of novel complementary bowtie barcodes, link cDNA sequences obtained via 
sequencing. We have developed the DNA origami nanostructures and optimized 
processes for transfection, mRNA capture and recovery of TCRα and TCRβ mRNA from 
antigen-specific T cells. We analyzed the sequences captured by this method and 
demonstrated the ability to barcode captured TCR sequences from transfected cells. We 
validated our nanotechnology approach to obtain linked sequence information for both 
TCR chains from individual cells by utilizing transgenic mice expressing a single known 
TCR. Finally, we have begun the process of adapting this technology to identify 
heterogeneous TCR expressed by wild type mice.  
 The proposed DNA origami nanostructure system for linking paired genes from 
single cells can be applied to a myriad of other biological questions, including current 
applications for the assessment of heterodimeric B cell receptors, characterization of the 
sequence mutation history of cancer cells or identification of rare cancer stem cells, and 
has the potential to revolutionize our understanding of the evolution of both immunity 
and disease. 
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